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Abstract 
Osteoporosis is a chronic disease causing a huge disease and economic burden to the society. 
Many screening and treatment interventions are effective at preventing osteoporotic fractures, 
while implementation of such interventions incur substantial costs. Health economics 
modelling plays a critical role in evaluations that aim at identifying interventions representing 
the best value for money. This thesis presents the construction and validation of a new state of 
the art osteoporosis health economics model, and key important examples of its application in 
the health economic evaluation of screening for osteoporosis and fracture prevention. 
Chapter 1 presents a general introduction to osteoporosis and health economics. 
Chapter 2 presents a systematic review of all osteoporosis health economic models and the 
evolution of modelling in the field of osteoporosis over the past decades. Osteoporosis health 
economic models have improved with the development of more sophisticated modelling 
techniques. In addition, medication persistence and adherence have become increasingly 
recognized as important factors influencing the long-term cost-effectiveness of osteoporosis 
treatments and have been increasingly incorporated in recent models. This review then guided 
the development of a state of the art model that built on the strengths and overcame the 
deficiencies identified. 
One of the key issues in the cost-effectiveness analysis is to assign the health related-utility 
values (HSUVs) to different disease states. Chapter 3 presents the development of a standard 
set of HSUVs for osteoporosis-related conditions using a systematic review and meta-analysis 
approach. Fracture events have great impacts on HSUVs, particularly for patients with hip and 
clinical vertebral fractures, but multiple studies have produced a range of values for the impact 
of fractures on HSUVs. A systematic review and meta-analysis is performed in order to provide 
summary measures of HSUVs before and after fractures, to be used in future health economics 
models. HSUVs improve with time after fracture events, but still remain lower when compared 
with pre-fracture HSUVs. 
Chapter 4 is the key to this thesis, and documents the development and validation of a new 
state of the art osteoporosis health economics model. The model is a state-transition 
microsimulation model incorporating major clinical outcomes of osteoporosis. It is validated 
in the Chinese population but is flexible to be adapted to other populations, and demonstrates 
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good face, internal and external validities. 
Chapter 5 to 7 are three key examples of the model application in cost-of-illness and cost-
effectiveness studies. Chapter 5 presents the first example of the application of the new 
osteoporosis health economics model to estimate the absolute risks of osteoporotic fractures in 
the Chinese population. More than 40% of Chinese women and approximately 10% of Chinese 
men aged 50 years are expected to have the first osteoporotic fracture in their remaining 
lifetimes. Compared to the rest of the world, Chinese women have higher age-matched risks of 
osteoporotic fractures. 
Chapter 6 presents the second example of the model’s application: a cost-of-illness study, 
which quantifies the magnitude of the cost of osteoporosis fractures in China. Annual fracture 
numbers and costs are estimated for the entire Chinese population. Additionally, projections of 
the number and costs of fractures through to the year of 2050 are performed. Approximately 
2.33 (95% CI: 2.08, 2.58) million osteoporotic fractures are estimated to occur in 2010, costing 
USD 9.45 (95% CI: 8.78, 10.11) billion. The number and costs of fracture are estimated to 
double by 2035 if no action is taken. 
Chapter 7 presents the third example of the model’s application. While Chapter 6 informs us 
of the size of the problem, Chapter 7 identifies possible strategies to address the problem. A 
cost-effectiveness analysis of different osteoporosis screening and treatment strategies is 
conducted using the osteoporosis health economics model. Pre-screening with quantitative 
ultrasound (QUS) with subsequent dual energy X-ray absorptiometry (DXA) screening if the 
QUS T-score≤-0.5 with a 2-year rescreening interval in the Chinese women starting at age 55 
is the most cost-effective. Moreover, screening and treatment strategies are cost saving if the 
screening initiation age is 65 years. 
This thesis presents a range of health economic modelling studies with its construction, 
validation and application in health economic evaluations. This work will be useful in the 
scientific community and healthcare decision making in osteoporosis. Further, the model will 
be adapted to other populations to support the pharmaceutical submissions and identifications 
of osteoporotic fracture preventions that present best value for money.  
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Chapter 1: General introduction and outline 
1.1  Introduction of osteoporosis  
The word osteoporosis comes from the Greek term for “porous bones”, where “osteo” is for 
bones and “porosis” denotes porous. Osteoporosis is characterised by low bone mineral density 
(BMD) and micro-architectural deterioration of bone tissue [1]. Patients with osteoporosis have 
increased risks of fracture. While the definition of osteoporosis takes both density and quality 
of bone into account, bone quality is hard to measure in clinical practice. A number of factors 
contribute to bone quality such as bone turnover, geometry, components of the bone minerals 
and micro-architecture [2]. The diagnosis of osteoporosis is, therefore focused on bone density 
[3]. 
1.1.1 Diagnosis of osteoporosis 
Threshold values are critical in the diagnosis of osteoporosis, where thresholds denote cut-off 
values for BMD. The threshold value is the number of standard deviations (SDs) of the BMD 
measurement above or below that of the reference population [3]. When the reference is the 
young adult population, the threshold value is called a T-score. Alternatively, when the 
population of the same ages is used as the reference, the threshold value is called a Z-score. 
The reason for using the difference in SDs of BMD rather than the actual values arose from the 
distribution of the BMD in young healthy adults: BMD was found to remain constant until 
about age 50 years, and it fitted a normalised Gaussian distribution [3, 4]. The criteria for the 
diagnosis of osteoporosis in women by the World Health Organisation was suggested as “hip 
BMD by dual energy X-ray absorptiometry (DXA) 2.5 SD or more below the young adult 
female mean, i.e. T-score≤-2.5” [2, 3, 5]. It was acknowledged that suitable diagnostic BMD 
threshold values in men were less well defined compared with that in women, “a similar cutoff 
value for hip BMD that is used in women can be used in the diagnosis of osteoporosis in men-
namely, a value for BMD 2.5 SDs or more below the average for women” [3, 6]. 
In addition to the diagnostic criteria for osteoporosis, three other categories of osteoporosis-
related conditions had been proposed by the WHO and revised by the International 
Osteoporosis Foundation (IOF) [2, 3, 5]. 
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 Normal: hip BMD greater than 1 SD below the young adult reference mean (T score 
≤–1). 
 Low bone mass (osteopenia): hip BMD greater than 1 SD below the young adult mean, 
but less than 2.5 SD below this value (T score < –1 and > –2·5). 
 Severe osteoporosis (established osteoporosis): hip BMD 2.5 SDs or more below the 
young adult mean in the presence of one or more fragility fractures. 
BMD measured at the hip is used in the diagnosis criteria of osteoporosis, because hip BMD is 
the most precise predictor of a hip fracture which is the most severe complication of 
osteoporosis in terms of mortality increase and quality-of-life (QoL) reduction [7, 8]. BMDs 
measured at other sites are also critical in terms of fracture risk assessment rather than 
diagnosis. 
1.1.2  Prevalence of osteoporosis 
As osteoporosis is defined based on BMD levels, given ethnic differences in BMD [9], it is not 
surprising to observe different prevalence rates of osteoporosis worldwide. In an American 
study comprised 197,848 postmenopausal women from five ethnic groups, Black women had 
the highest BMD, followed by Caucasians and Asians. Based on WHO criteria of diagnosing 
osteoporosis, 4.2%, 7.2% and 10% of Black, Caucasian and Asian women were osteoporotic 
[9]. In Europe, more than 27.6 million people were estimated to live with osteoporosis in 2010 
[10]. Compared with American women, the prevalence of osteoporosis in a European 
Caucasian population was more than twice as high: the prevalence of osteoporosis in Swedish 
women aged 50-84 years was 21% [10]. Prevalence of osteoporosis in Australian women was 
estimated at 23% which was close to that in European women [11]. In Chinese women aged 
over 50 years, the prevalence of osteoporosis was estimated at 12.5% which was relatively low 
compared with the Caucasian population [12]. Irrespective of ethnic groups, prevalence rates 
of osteoporosis were 2-4 times those in men [9-12]. Generally, prevalence rates of osteoporosis 
detected by BMD scan are higher than the self-reported estimates [11]. It reflects the fact that 
osteoporosis is still underdiagnosed due to the absence of overt symptoms [13].  
1.1.3 Fractures and osteoporosis 
Patients with osteoporosis have higher risks of fractures [14-17] and fractures can occur at 
various sites in the skeletal system. The most common osteoporotic fractures occur at the hip, 
vertebrae and distal forearm (wrist) [18]. 
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Osteoporotic hip fractures are typically caused by a fall or low energy trauma, such as bumping 
into a sharp corner. Femoral neck fractures and intertrochanteric hip fractures are the most 
common hip fractures (Figure 1.1) [19]. Femoral neck fractures occur in the narrow section of 
the bone between the main shaft of the femur and the ball, while intertrochanteric hip fractures 
occur just below the femoral neck. Hip fractures might also occur at the shaft of the femur, i.e. 
subtrochanteric fractures, but they are less common. 
Figure 1.1 Bones of the hip and sites of hip fractures. Source: AIHW (2008) Arthritis and 
osteoporosis in Australia 2008. Arthritis series no 8 Cat no PHE 106 AIHW, Canberra [19]. 
Vertebral fractures related to osteoporosis also commonly lead to bone deformities. The 
vertebral column consists 33 vertebrae [20], they are stacked and are separated from each other 
by intervertebral discs. There are three types of vertebral compression fractures: wedge 
fractures, biconcave fractures and crush fractures. The most common vertebral fractures are 
wedge fractures [21]. The vertebrae form a wedge shape but do not move out of place and the 
spinal cord is rarely affected in wedge fractures, patients with a number of wedge fractures 
often present a hunched posture and a reduced height [22-25]. Biconcave fractures refer to 
collapse of the central portion of both vertebral body endplates (Figure 1.2) [26]. While crush 
fractures refer to collapse of entire vertebral body. Approximately three in four patients with 
compression fractures remain asymptomatic, they normally remain underdiagnosed and 
undertreated until more severe clinical consequences occur [27, 28].  
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Figure 1.2 Lateral radiograph of the spine and a biconcave fracture in the L2 vertebrae. Source: 
Ensrud KE, Schousboe JT (2011) Vertebral Fractures. New England Journal of Medicine 
364:1634-1642.  
Wrist fractures often occur when patients with osteoporosis fall on a hard surface, the most 
common wrist fracture is called Colles’ fracture which occurs at the lower end of the radius 
(Figure 1.3). In addition to fractures at hip, vertebrae and wrist, fractures can occur at any 
bones that are weight bearing (such as pelvis and ankle), or stress taking when the patients fall 
(such as forearms, upper arms and shoulder) [19, 29, 30].  
 
 
Biconcave 
fracture in the 
L2 vertebrae 
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Figure 1.3 Colles’ fracture on X-ray.  
Source: https://commons.wikimedia.org/wiki/File:Collesfracture.jpg [31] 
1.1.4 Clinical risk factors for osteoporosis and osteoporotic fractures 
Numerous clinical risk factors (CRFs) have been identified for osteoporosis and osteoporotic 
fractures including: low BMD [32], female sex [33], premature menopause [34], age [35], 
increased rate of falls [36], primary or secondary amenorrhoea [37], primary and secondary 
hypogonadism in males [38], Asian or white ethnicities [33, 39], previous osteoporotic 
fractures [40, 41], glucocorticoid use [42], high bone turnover [43], family history of 
osteoporosis or osteoporotic fractures [40, 44], low body-mass index (BMI) [45, 46], 
neuromuscular disorders [47], smoking [48, 49], excessive alcohol consumption [50], low 
dietary calcium intake [51, 52] and vitamin D deficiency [48].  
Colles’ fracture 
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T-score derived from BMD is a critical indicator used in the definition of osteoporosis. Low 
BMD was found to be associated with higher fracture risks, with a 2- to 3-fold increase in 
fracture incidence for one SD reduction in BMD [32]. However, assessment of osteoporotic 
fracture risk should not solely based on BMD, as other CRFs such as older age, smoking and 
family history of fracture were found to increase with fracture risks independent of BMD [44, 
49, 53].  
1.1.5 Assessment of fracture risk  
As CRFs play an important role in the assessment of fracture risk, they have been incorporated 
in many widely used individualised fracture risk assessment tools, rather than the use of BMD 
alone, for a more precise estimation of future fracture risk. For example, the FRAX® tool which 
has been developed by the WHO incorporated 10 CRFs (age, sex, BMI, previous fracture, 
parent hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis 
and excessive alcohol consumption) with or without BMD results [54]. The Garvan Fracture 
Risk Calculator has incorporated 4 CRFs (history of prior fracture, history of fall during the 
past 12 months, age and BMD) [55].  
The overall accuracy of different risk assessment tools is satisfactory [56]. The 10-year or 5-
year fracture risks assessed from the risk assessment tools may help inform clinicians to decide 
whether or not their patients should receive treatment to prevent future fractures.  
1.1.6 Clinical consequences of osteoporotic fractures 
Patients with an osteoporotic fracture have a higher risk of subsequent fractures [7, 57], 
increased risk of mortality [7] and loss of QoL [58]. 
The Dubbo Osteoporosis Epidemiology Study has shown that the relative risk (RR) of 
subsequent fractures was generally more than 2-fold independent of BMD levels: the RR of 
subsequent fractures ranged from 2.0 (95% confidence interval, CI: 1.2, 3.3) for women with 
normal BMD to 3.2 (95% CI: 2.7, 3.9) for those with diagnosed osteoporosis [7]. The RR of 
subsequent fractures highly dependent on the site of previous fracture: the RR after a hip 
fracture was 9.97 (95% CI: 1.38, 71.98), and that following a clinical vertebral fracture was as 
high as 15.12 (95% CI: 6.06, 37.69) in younger men [57]. Moreover, the Dubbo study has 
demonstrated higher RR of mortality, particularly in those with low BMD: the standardised 
mortality ratio was 1.3 (95% CI: 1.1, 1.7) for women with osteopenia and 1.7 (95% CI: 1.5, 
2.0) for women with osteoporosis [5].  
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Quality of life is the general wellbeing and health of individuals across physical, mental and 
social aspects. Health related health utility values (HSUVs) are cardinal values that represent 
the patients’ preferences on health [59]. In a recent meta-analysis on HSUVs for osteoporosis-
related conditions, patients with osteoporotic fractures were shown to have lower HSUVs 
compared with pre-fracture condition: a 25%, 22% and 5% deduction of HSUVs were found 
for a hip, clinical vertebral and wrist fracture respectively [8]. Time after fracture was 
associated with the change of HSUVs: HSUVs declined immediately after a fracture, but 
improve with time [8, 58, 60]. 
1.1.7 Osteoporotic fracture prevention 
Osteoporotic fracture prevention can be categorised into primary and secondary prevention, 
where primary prevention targets high risk population of osteoporotic fractures and secondary 
prevention refers to prevention strategies for those who have had osteoporotic fractures. 
To date, there are a number of pharmaceuticals available to prevent fractures. According to 
different mechanisms in the bone remodelling cycle, osteoporosis drugs can be categorised into 
either antiresorptive medications or anabolic medications. Antiresorptive medications slow the 
bone loss, and include bisphosphonates, calcitonin, denosumab, estrogen and estrogen 
agonists. Anabolic medications increase the rate of bone formation such as teriparatide. 
Clinical efficacies of osteoporosis medications varied in primary and secondary prevention, in 
addition, clinical efficacies were different in fracture sites. For example, alendronate was 
shown to be both effective in the primary and secondary prevention of vertebral fractures with 
both RR reductions of 45% in postmenopausal women. However, it was only effective in the 
secondary prevention of non-vertebral fractures with a RR reduction of 22% [61].  
In addition to medication treatments, addressing other clinical factors is also important. For 
example, patients with osteoporosis are encouraged to exercise especially some weight-bearing 
activities to improve the balance and muscle strength and ultimately prevent falls [62]. Good 
nutrition and dietary supplements of calcium and vitamin D is also beneficial in osteoporotic 
fracture prevention [63]. In addition, patients with osteoporosis or osteoporotic fractures should 
quit smoking and limit alcohol consumption. In case of a fall, hip protectors have been shown 
to be effective in preventing hip fractures [64]. 
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1.2 Introduction to health economics 
1.2.1 Definition of health economics 
In 1963, Kenneth Arrow published an article entitled “Uncertainty and the welfare economics 
of medical care” in The American Economic Review [65]. This paper has been recognised as 
not only one of the most cited articles in health economics, but also as a creation of this 
discipline [66]. In Arrow’s paper, he has identified factors that distinguished health from other 
goods including extensive government interventions, intractable uncertainties, asymmetric 
information, barriers to entry, externalities and the presence of a third party agent [67]. These 
factors make health economics unique to classic economics, however, the scarcity of resources 
is the common factor in all sub-disciplines of economics and health economics is no exception. 
The World Bank has defined health economics as 
“the study of how scarce resources are allocated among alternative uses for the care of 
sickness and the promotion, maintenance and improvement of health, including the study 
of how healthcare and health-related services, their costs and benefits, and health itself are 
distributed among individuals and groups in society.” 
In summary, it is a study of allocation of scarce healthcare resources. There are generally two 
issues that should be considered: efficiency and equity. Efficiency is satisfied when the 
allocation of scarce resources maximises the achievement of aims [68], i.e. the best use of 
scarce resources. The concept of efficiency is derived from Pareto efficiency which describes 
a state of allocation of resources in which it is not possible to make any individual better off 
without making other individuals worse off [69]. There are three types of efficiencies: 
technical, economic and social efficiency. 
Technical efficiency is a concept that is used in considering how outputs, e.g. health, are 
produced from inputs, e.g. healthcare resources [70]. Technical efficiency is achieved when 
the most number of outputs are produced with the least number of inputs. Rather than using 
the number of inputs to evaluate technical efficiency, economic efficiency is interested in the 
costs of inputs. Economic efficiency is achieved when the most outputs are produced with the 
least/given costs [70]. Social efficiency is a much broader concept compared with the first two 
efficiencies, it is the same as the Pareto efficiency in which both the utilities of suppliers and 
consumers are achieved [70].  
Different from the concept of efficiency, equity is “the absence of avoidable or remediable 
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differences among groups of people, whether those groups are defined socially, economically, 
demographically, or geographically [71].” Equity is closely attached to the concepts of needs 
and social justice, in the egalitarian theory, equity is achieved when everybody in the society 
have the same opportunities to obtain benefits even if the outcomes are different [72]. However, 
in the utilitarian theory, equity equals to equality where equal benefits are distributed across 
the population [70]. In health, we should differentiate equity from equality because health is a 
fundamental human right.  
In this thesis, we focus on the issue of efficiently allocate scarce healthcare resources in 
osteoporosis. The explicit criteria for making choices in resource allocation is economic 
evaluation. 
1.2.2 Health economic evaluation 
Economic evaluation can be defined as the comparative analysis of alternative courses of action 
in terms of both their costs and consequences [73]. There are different types of health economic 
evaluations according to the type of comparison of the costs and consequences: cost-
minimisation analysis (CMA), cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) 
and cost-utility analysis (CUA). 
There were debates around whether to include CMA as a form of economic evaluation, 
however, it is still used in the pharmaceutical submissions in some countries including 
Australia [74]. The premise of CMA is that the effectiveness or efficacies across different 
interventions should be identical, then cheapest intervention is the choice of interest. In CMA, 
the fact of equivalent outcomes in different interventions must be presented transparently and 
comprehensibly. CMA was recommended for economic evaluations in Drummond et al. (1997 
edition) because of its simplicity and ease of analysis and interpretations [75]. However, Briggs 
and O’Brien declared the “death of CMA” in 2001 [76] and in 2013 Dakin and Wordsworth 
suggested “CMA is not only dead but should also be buried” [77], and Drummond et al. have 
no longer considered CMA as a form of full economic evaluation and regarded it as 
inappropriate in most situations [73]. The reasons for excluding CMA include, first, the 
parameter uncertainties fail to be fully addressed in CMA [76]; second, quality-adjusted life 
years may differ between treatment in after-trial period even if equivalence is demonstrated in 
the clinical trial period [76]. Nevertheless, continued use of CMA within a trial-based economic 
evaluation is still acceptable only in trials with non-inferiority or equivalence outcomes [77]. 
CBA assesses whether the benefits in the monetary value of an intervention outstrip its costs 
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using measures such as the benefit-cost ratio (BCR) and net present value (NPV) [78]. The 
BCR calculates the ratio of discounted total benefits and discounted total costs: 
BCR =
𝑃𝑉𝑏𝑒𝑛𝑒𝑓𝑖𝑡𝑠
𝑃𝑉𝑐𝑜𝑠𝑡𝑠
 
where PVbenefit denotes the present value of benefits and PVcosts denotes the present value of 
costs. 
NPV is the difference between discounted benefits and discounted costs as they occur over 
time: 
NVP =∑
(𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠 − 𝐶𝑜𝑠𝑡𝑠)𝑡
(1 + 𝑟)𝑡
𝑛
𝑡=0
 
where r denotes the discount rate, t represents the year and n denotes the analytic horizon. 
A program with a positive NPV or a BCR greater than one indicates the benefits exceed its 
costs and implementing this program will generate a net benefit to society. As CBA 
incorporates benefits in monetary terms, it is useful in economic evaluations not only within 
the healthcare sector but across other sectors in the economy [73]. 
However, placing a monetary value to human life creates challenges to social justice and 
methods in calculating the cost of life. Alternatively, CEA and CUA measure the benefits of 
the intervention in health units and therefore have been extensively used the health sector [79]. 
CUA measures health outcomes in generic terms, such as quality-adjusted life years (QALYs) 
and disability-adjusted life years (DALYs), to allow comparisons between health interventions 
in different disease fields, it is a special form of CEA. The terms of CUA and CBA are often 
interchangeably used in health economic evaluation studies, we will use CEA as a generic term 
for both CEA and CUA to avoid confusions [73]. 
In CEA, two interventions are compared by the incremental cost-effectiveness ratio (ICER) 
which is calculated by the difference in costs divided by the difference in their effectiveness. 
ICER represents the incremental costs associated with one additional unit of measure of 
effectiveness gained. The effectiveness is measure by natural units such as fractures averted, 
change in systolic or diastolic blood pressure, deaths prevented, adverse events averted and so 
on. When ICER is calculated, it is compared with a ceiling ratio, λ, to evaluate whether the 
intervention is cost-effective. The ceiling ratio is called willingness-to-pay (WTP) threshold. 
An important way to visualise the possible results of ICER is called “cost-effectiveness plane” 
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which was developed by Black in 1990 [80]. 
1.2.3 Cost-effectiveness plane 
Cost-effectiveness plane is a two-dimensional space where the x axis represents the difference 
in effectiveness and y axis represents the difference in costs, the comparator is placed at the 
origin and an intervention of interest can be placed anywhere in the cost-effectiveness plane 
based on its incremental costs and effectiveness compared with the comparator. The cost-
effectiveness plane is given in Figure 1.2.  
If an intervention has a higher effectiveness and lower costs, it is placed in the south-east 
quadrant. The intervention dominates the comparator and it is cost-saving. On the contrary, if 
the intervention is more costly but has lower effectiveness compared with the comparator, it is 
placed in the north-west quadrant. In this case, it is dominated by the comparator and should 
not be considered as cost-effective. In most cases, the intervention is placed in the north-east 
quadrant which means it is more costly but also creates more effectiveness compared with the 
comparator. In this case, there is a trade-off between the costs and effectiveness: whether or 
not this intervention is cost-effective depends on a willingness-to-pay (WTP) ceiling for an 
additional effectiveness gained. This ceiling is called WTP threshold [81], it is illustrated as 
the solid red line in Figure 1.2. If the intervention is placed under the WTP threshold, it is 
considered cost-effective. Similar theory can be applied to interventions in the south-west 
quadrant, in which interventions create lower effectiveness but also incur lower costs. The 
trade-off in this quadrant refers to the saving on costs and effectiveness forgone, similarly, 
interventions below the WTP threshold are considered as cost-effective.  
WTP thresholds vary in countries. In the UK, a range between £20,000 to £30,000 per QALY 
gained has been used by the National Institute for Health and Care Excellence (NICE) [82], 
although a recent study suggested this widely used threshold may be too high [83]. In the US, 
the threshold of US$50,000 per QALY gained is often used in the cost-effectiveness studies 
[84]. In Australia, the Australian Pharmaceutical Benefit Advisory Committee was unlikely to 
recommend a drug for listing on the Pharmaceutical Benefit Scheme if the ICER is higher than 
AU$76,000 [85]. For countries that do not have a predetermined WTP threshold, the WHO 
recommended 1 to 3 times per capita gross domestic product (GDP) as the WTP threshold and 
this recommendation was used in China [86, 87]. 
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Figure 1.2. The cost-effectiveness plane, adapted from Black 1990 [80]. Given the difference 
in costs and effectiveness compared to the comparator (C), the new intervention (A) can be 
placed in any of the four quadrants in the cost-effectiveness plane: the north-east (NE), south-
east (SE), south-west (SW) and north-west (NW). The slope of the line between A and C 
(dotted line) denotes the difference in costs over the difference in effects, i.e. the incremental 
cost-effectiveness ratio (ICER). The solid red line denotes the willingness-to-pay (WTP) 
threshold which demonstrates the maximum acceptable value to be paid for one unit of 
additional effects gained.  
1.2.4 Methods of conducting a health economic evaluation 
Generally, a health economic evaluation can be undertaken alongside a clinical trial or through 
economic modelling. Clinical trials have been recognized as the best vehicle for economic 
evaluations, because trials are able to provide the best interval validity [88]. In addition, 
economic evaluation alongside trials enables economists analyse individual-level data using 
statistical and econometric techniques at an early opportunity [73, 89]. Furthermore, the 
collection of economic data only adds modest marginal cost to the clinical trials where large 
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proportion of the trial budget are spent on collecting clinical data [30].  
While there are several advantages of conducting a health economic evaluation alongside 
clinical trials, health economic evaluations solely based on data collected from clinical trials 
are rare due to the following reasons.  
First, the rationale of choosing included therapies is different from the clinical trial and 
economic evaluation perspective. Clinical trials are the most rigorous way to determine the 
causal relationship between treatment and outcome, the treatment included in the intervention 
group is a new treatment of interest and the placebo group is the comparator [90]. In economic 
evaluation study, the choice of included therapies should depend on whether the new treatment 
is intended as an adjunctive therapy or as a substitute for an existing treatment [73]. In addition, 
there are normally more than one interventions included in an economic evaluation while in 
clinical trials the intervention group normally incorporate only one therapy [91].  
Second, health economic evaluations normally require numbers of parameters that might not 
be fully captured in a single clinical trial [81]. Furthermore, clinical effectiveness of an 
intervention shown in the real world might differ from clinical efficacy from trials [92]. In a 
trial, clinical efficacy is generated under ideal circumstances with strict inclusion criteria of 
study population including patient characteristics, conditions under investigation, drug 
regimens and co-morbidities. However, effectiveness research takes into account patient-, 
provider-, and system-level factors that may affect an intervention’s effectiveness [93]. In the 
context of economic evaluation studies, where the interventions are given to the communities, 
effectiveness research can be more relevant to healthcare decision making. 
Finally, some clinical trials use surrogate endpoints and the duration of the trials might not 
enough to capture all relevant outcomes of the intervention [94]. However, economic 
evaluations including cost-effectiveness analysis use clinically meaningful endpoints such as 
mortality, which might not be captured in the short duration of clinical trials. Furthermore, 
evidence has shown a legacy effect even after the cessation of clinical trials [95].  
In summary, a well-designed health economic evaluation study might not be based on a single 
clinical trial. Alternatively, health economic modelling is an approach to overcome the 
limitations of conducting an economic evaluation alongside a clinical trial. This thesis 
documents a health economic study in osteoporosis using modelling approach, with its 
construction, validation and several applications in the cost-of-illness and cost-effectiveness 
studies.  
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1.3  Structure of this thesis 
Chapter 1 presents a general introduction to osteoporosis and health economics. In Chapter 2, 
a systematic review of all osteoporosis health economic models and the evolution of modelling 
in this field is presented. Chapter 3 details a systematic review and meta-analysis of HSUVs 
for osteoporosis-related conditions. A standard set of HSUVs is derived for future modellers 
use in health economic evaluations in osteoporosis. 
Chapter 4 describes the documentation and validation of the new osteoporosis health 
economics model that was developed as a major part of the PhD. Chapter 5 presents the first 
example of the application of the osteoporosis health economics model. Residual lifetime and 
10-years fracture risks for Chinese men and women are estimated using the model. 
Additionally, international comparisons of residual lifetime fracture risks are discussed. 
Chapter 6 describes the second example of model application. Annual fracture numbers and 
costs are estimated for the Chinese population. Additionally, projection of number and costs of 
fractures are discussed through to the year of 2050. 
Chapter 7 presents the third example of model application: a cost-effectiveness analysis of 
different osteoporosis screening and treatment strategies. The most cost-effective osteoporosis 
screening and treatment strategy is recommended. 
Finally, Chapter 8 discusses and summarizes the material presented in this thesis. 
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Chapter 2: A systematic review of models used in cost-
effectiveness analyses of preventing osteoporotic 
fractures 
2.1  Preface 
This chapter provides a systematic review of models used in the health economic evaluations 
of osteoporotic fracture preventions over the past 40 years. This systematic review 
summarises the evolution of health economic models used in evaluations of clinical 
approaches aimed at preventing osteoporotic fractures. It demonstrates that models have 
improved, with medical continuance becoming increasingly recognized as a contributor to 
health and economic outcomes, as well as advancements in epidemiological data. Lessons 
learned from the review are implemented in the design of the model developed in Chapter 4. 
This chapter has been published in Osteoporosis International (Appendix 2A). 
Impact factor: 4.17. 
Si L, Winzenberg TM, Palmer AJ. A systematic review of models used in cost-
effectiveness analyses of preventing osteoporotic fractures. Osteoporosis International, 
Jan 2014; 25(1): 50-60. 
The published article of this 
chapter appears in an appendix to 
the chapter. It has been removed 
for copyright or proprietary 
reasons.
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2.2  Abstract 
Purpose: Model-based health economic evaluation studies are increasingly used to 
investigate the cost-effectiveness of osteoporotic fracture preventions and treatments. The 
objective of this study was to carry out a systematic review of the evolution of health 
economic models used in the evaluation of osteoporotic fracture preventions.  
Methods: Electronic searches within MEDLINE and EMBASE were carried out using a 
predefined search strategy. Inclusion and exclusion criteria were used to select relevant 
studies. References listed of included studies were searched to identify any potential study 
that was not captured in our electronic search. Data on country, interventions, type of fracture 
prevention, evaluation perspective, type of model, time horizon, fracture sites, expressed 
costs, types of costs included and effectiveness measurement were extracted.  
Results: Seventy-four models were described in 104 publications, of which 69% were 
European. Earlier models focused mainly on hip, vertebral and wrist fracture, but later 
models included multiple fracture sites (humerus, pelvis, tibia and other fractures). Modelling 
techniques have evolved from simple decision trees, through deterministic Markov processes 
to individual patient simulation models accounting for uncertainty in multiple parameters. 
Treatment continuance has been increasingly taken into account in the models in the last 
decade.   
Conclusions: Models have evolved in their complexity and emphasis, with medical 
continuance becoming increasing recognized as a contributor to health and economic 
outcomes. This evolution may be driven in part by the desire to capture all the important 
differentiating characteristics of medications under scrutiny, as well as the advancement in 
epidemiological data relevant to osteoporosis fractures. 
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2.3  Introduction 
Osteoporosis is a major health concern especially in developed countries and countries with 
an ageing population, with low bone mass and structural deterioration of bone tissue resulting 
in increased fragility and risk of fractures [1]. It was estimated that 1.9 million Australians 
had doctor-diagnosed osteoporosis in 2001, and the number was set to grow dramatically 
over the next two decades to 3 million osteoporosis cases, approximately 13% of the total 
population in 2021 [2]. Costs of osteoporosis and osteoporotic fractures are one of the major 
burdens on the healthcare system: 304.3 million Australian dollars were spent on direct health 
expenditure for osteoporosis in 2004-2005 in Australia, most of which spent on prescribed 
pharmaceuticals [2, 3]. USA and European Union experienced even higher annual costs of 
osteoporotic fractures [4-6]. 
Aside from the financial costs of osteoporosis and osteoporotic fractures, mortality and 
comorbidity have a major impact in terms of patients’ quality of life (QoL). Although 
osteoporosis does not directly cause death, osteoporotic fractures are associated with excess 
mortality, both immediately following a fracture and longer term [7, 8]. While hip fractures 
were estimated to be responsible for most of the burden of osteoporosis-related fractures, 
recent studies indicated vertebral fractures also play a major role in adversely affecting QoL 
[8-10].  
Modelling techniques have been widely used in cost effectiveness analyses of preventing 
osteoporotic fractures over the last three decades [11-13]. Models in the healthcare context 
can be categorized as “empirical” models in which model inputs are retrieved from 
epidemiological studies, and “theoretical” models in which model parameters are synthesized 
by statistical techniques, mathematical formulae, or computer simulations [14, 15]. Pure 
empirical models are rare in reality because of the scarcity of data sources from trials or 
observational studies. Randomized controlled trials (RCTs) often do not provide head-to-
head comparisons of relevant population subgroups [16]. In addition, the time horizon of 
RCTs is often not long enough to capture all the possible outcomes beyond the trial duration. 
Therefore, results based on health analytic models give healthcare decision makers useful 
information even before launching an intervention. This is of great significance when 
prioritizing health interventions because the scarcity of healthcare resources means only the 
cost-effective interventions should be subsidized.  
Many studies of the cost-effectiveness of preventing osteoporotic fractures have been carried 
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out over the last three decades. Zethraeus (2002) and colleagues performed a review [17] and 
an updated review (2007) [18] with a “reference model” created. However, since that review, 
modelling studies evaluating the health economic impacts of new pharmaceuticals, for 
instance denosumab [19], have been carried out. Moreover, only studies that defined the 
effectiveness measure in terms of life years or quality adjusted life years (QALYs) were 
included in previous reviews rather than including other effectiveness measurements such as 
fracture averted and life years saved. Therefore, the objective of the study was to carry out an 
updated review of all published model-based studies to illustrate the evolution of modelling 
of prevention of osteoporotic fragility fractures, and to summarize the major structural 
parameters and assumptions within the published models. This review will provide future 
investigators an overview of progression of cost effectiveness models on osteoporosis related 
fractures and information on key parameters that affect the robustness of models.  
2.4  Methods 
This systematic review followed PRISMA guidelines [20]. We performed electronic searches 
of MEDLINE and EMBASE from 1980 to February 2013. In addition, reference listed in 
relevant studies were hand searched to identify papers that were not identified in our 
electronic search.  
2.4.1 Search Strategy 
We searched using the key words osteoporosis, postmenopausal osteoporosis, osteoporotic 
fractures, fractures bone, bone mass, cost benefit analysis, costs and cost analysis, utility, 
quality adjusted life years, life saved, life year saved, life gained, fracture avoided. Details of 
the specific search strategies used for each database were listed in Appendix 2B.1. 
2.4.2 Inclusion criteria 
The inclusion criteria for the structured review were: studies in humans, studies reporting 
models of health economic evaluation on primary and/or secondary prevention of 
osteoporotic fracture, studies that included a cost benefit analysis, cost effectiveness analysis 
or cost utility analysis on osteoporosis or osteoporotic fractures. We included studies in all 
ethnic groups globally and in both sexes.  
2.4.3 Exclusion criteria 
Studies not based on model simulations were excluded as we were looking at the studies that 
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incorporate modelling techniques on treating or preventing osteoporotic fractures, rather than 
the focusing on the cost effectiveness or cost utility ratios generated by the models. Other 
exclusion criteria were 
 Publications in languages other than English  
 Review articles  
 Abstracts with no specified models  
We did not evaluate the quality of included studies, as our review was aiming at illustrating 
and summarizing the evolution of key characteristics of models used in health economic 
evaluation on osteoporotic fractures preventions and treatments, rather than evaluating the 
reliability of cost-effectiveness results generated by the models. 
2.4.4 Data extraction 
Study characteristics, modelling techniques, fracture-related costs as well as health state 
utility values were extracted. Study characteristics included country, type of fracture 
prevention (primary or secondary), time horizon, fracture sites, expressed costs, types of costs 
and effectiveness measurement. To allow comparison of costs between countries and at 
different time points, costs data from each study were converted into 2013 US dollars using a 
web-based currency convertor developed by a joint initiative between The Campbell and 
Cochrane Economics Methods Group (CCEMG) and Evidence for Policy and Practice 
Information and Coordinating Centre (EPPI-Center) [21]. In addition, we chose the 
International Monetary Fund (IMF) based Purchasing Power Parity (PPP) value to adjust the 
exchange rate between countries within the EPPI cost converter [21]. We assumed the year of 
costs as the time of publication for studies that did not specify the year in which the costs 
were expressed.  
There are several definitions to be clarified: medication compliance, persistence, adherence, 
as well as offset time effect. Medication compliance or adherence are defined as below: 
“Medication compliance (synonym: adherence) refers to the act of conforming to the 
recommendations made by the provider with respect to timing, dosage, and frequency of 
medication taking [22]”. Medication persistence refers to “the act of conforming to a 
recommendation of continuing treatment for prescribed length of time” thus can be defined as 
the duration of time from initiation to discontinuation of therapy [22].  Medication offset time 
effect refers to residual medication effect after discontinuation of treatment [23].  
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2.5  Results  
The flow chart of study selection for our review was shown in Figure 2.1. From 2761 studies 
identified from our electronic search, 2619 studies remained after removing duplicates. After 
screening by title and abstract, 109 studies remained. After screening of these full text studies 
a further 11 studies were excluded because they were either review or non-model based 
studies. Ninety-eight studies from 1980 to 2013 were then included. A further 6 other studies 
were identified from the reference lists of included studies, resulting in a final total of 104 
included in our review (see Appendix 2B.2). Model-based health economic evaluations on 
osteoporotic fracture prevention were published exponentially in the last decade (Figure 2.2). 
Six of 104 studies involved multiple country evaluation using the same model therefore there 
were a total of 18 countries with 124 assessments involved by splitting the multi-county 
studies.  
Included studies are detailed in Appendix 2B.3 Table 1. Seventy-four models were used 
within 104 studies. Some studies shared model structure for data analyses, for example 
Johnell (2003) [24] used the same  model structure as Borgstrom (2006) [25] and Strom 
(2007) [26]. Tosteson (2001) [27] used the same model structure as Thompson (2010) [28] 
and Alzahouri (2013) [29]. Eighty-five (69%) of studies identified were based in a European 
setting, followed by the US and Canadian (n=29, 23%), six from Asia (5%) and 4 from 
Australia (3%). Hip fracture was the most frequently included fracture site: 101 studies (97%) 
included hip fracture, 79 studies (76%) included vertebral fracture and 69 (66%) included 
wrist fracture. Furthermore, 44 (42%) of studies included other fractures such as pelvis 
fracture, humerus fracture, and tibia fracture. 
There were 12 studies that incorporated established osteoporotic fractures at baseline and 
were categorised as secondary fracture prevention models. Most of the models were designed 
to simulate the prevention of first and subsequent fractures; i.e.: both primary and secondary 
fracture prevention. 
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Thirty models (29%) used a societal perspective that incorporated all costs including direct 
costs, indirect costs as well as costs of added life years. However, 14 studies stated that the 
societal perspective was taken, but did not take indirect costs into consideration. Sixty-three 
studies (60%) chose narrower perspectives such as third-party payer, patients and healthcare. 
Moreover, there were 11 studies (11%) that did not clearly state the perspective of the 
evaluation.  
Figure 2.1 Flow diagram for study selection 
Ninety-three studies (89%) used Markov models. Thirty five studies applied exact modelling 
time horizon such as 10 years and 15 years, especially in the earlier studies (10 out of 13 
studies between 1980 and 1999), while the remaining studies chose “lifetime” modelling 
11 papers excluded: Review 
studies (n=3) 
Non-modelling studies (n=8) 
Studies retrieved from 
MEDLINE (n=507) 
Studies retrieved from 
EMBASE (n=2,254) 
 Studies for title sifting 
(n=2,619) 
Studies for abstract sifting 
(n=147) 
Full articles assessed after 
abstracts rejection (n=109) 
Studies included in the 
review (n=104) 
Duplicates (n=142) 
Paper rejected at title stage: 
(n=2,472) 
Paper rejected at abstract 
stage: (n=38) 
6 papers included from 
reference follow-up 
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horizon, running the model until all simulated patients had died to capture all possible costs 
and patient outcomes associated with the target intervention. 
 
Figure 2.2 Number of publications of modelling studies from 1980-2012 
Early studies typically performed univariate sensitivity analyses to assess the robustness of 
their findings. The first study identified that used probabilistic sensitivity analysis (PSA), 
sampling from distributions to deal with uncertainties around multiple parameters, was 
Fleurence (2004) [30]. PSA was increasingly used thereafter (Table 2.1).  
Appendix 2B.3 Table 2 summarized the costs of fracture categorized by country and specified 
by fracture sites. In line with the fracture sites in Appendix 2B.3 Table 1, the costs of fracture 
were also divided into hip fracture costs, vertebral fracture costs, wrist fracture costs and 
other fracture costs. Age-specific costs were frequently used for the first year costs after hip 
and vertebral fractures [12, 31, 32]. Second year costs of hip fracture depended on residential 
status, fractures resulting in nursing home admissions in particular tended to have higher 
costs [12, 33]. For example, Nayak and colleagues [34] assumed 60% of the patients with hip 
fracture would be admitted to nursing home and annual cost for nursing home was 74,846 US 
dollars in 2010 values. 
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The most frequently (88%) used effectiveness measurements were QALYs that incorporated 
both length and quality of life; the remaining studies used health effects such as life years 
saved, fractures averted or years free from fracture (Appendix 2B.3 Table 1). A detailed 
description of utility values is given in Appendix 2B.3 Table 3. Utility values were generally 
divided into those in the first year after fracture and those in the second-plus years after 
fracture; exact utility values were frequently assigned in most of studies prior to 2000 whilst 
utility multipliers were frequently used after 2000 to calculate the QALY relative to healthy 
population in the same age group. Clinical vertebral fractures were shown to have higher 
impact compared with hip fractures in terms of health utility. Wrist fractures were 
consistently reported as having little/no impact on health utility from the second year 
following initial fractures. The impacts of multiple fractures firstly addressed by Tosteson 
and colleagues in 2001[35], when they found that women with both hip and vertebral fracture 
Table 2.1. Evolution of modelling characteristics from 1980 to 2013 
 1980-1985 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011- 2013 
Fracture included 
in the models        
 Hip fracture 1 (100%) a 2 (100%) 7 (100%) 4 (80%) 21 (95%) 46 (98%) 20 (100%) 
 Vertebral fracture 0 (0%) 0 (0%) 3 (43%) 2 (40%) 19 (86%) 39 (83%) 16 (80%) 
 Wrist fracture 1 (0%) 0 (0%) 4 (57%) 1 (20%) 16 (73%) 33 (70%) 14 (70%) 
 Other fracture 0 (0%) 0 (0%) 2 (29%) 1 (20%) 8 (36%) 24 (51%) 9 (45%) 
Model type 
       
 Simple decision 
tree model 
0 (0%) 0 (0%) 4 (57%) 0 (0%) 2 (9%) 3 (6%) 1 (5%) 
 Memoryless 
Markov model b 
0 (0%) 1 (50%) 3 (43%) 5 (100%) 17 (77%) 30 (64%) 11 (55%) 
 Markov model 
with memory c 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (9%) 14 (30%) 8 (40%) 
Medicine 
Continuance d 
0 (0%) 0 (0%) 2 (29%) 2 (40%) 2 (9%) 17 (36%) 9 (45%) 
Offset time effect e 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (23%) 13 (28%) 5 (25%) 
PSA f 0 (0%) 0 (0%) 0 (0%) 0 (0%) 8 (36%) 27 (57%) 9 (45%) 
Total 1 2 7 5 22 47 20 
a Number of studies and the percentage of that period. b Markov cohort models which the subsequent state was 
independent from the previous state. c Markov cohort models that incorporated tunnel technique or tracker, or 
individual state-transit model. d medicine compliance and persistence. e residual medication effect after discontinuation 
of treatment. f PSA Probabilistic sensitivity analysis. 
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had the lowest utility value. This contradicted with previous studies that recognized hip 
fracture as the “worst” situation and influenced later researchers [36-38]. However, there 
were other ways to adapt utilities for multiple fractures. Wasserfallen and colleagues [39] 
used higher disutility when patients got subsequent fractures. Hiligsmann and colleagues [40, 
41] used additive utility, which was the sum of impacts related to each of the fracture, for 
multiple fractures impact evaluation. Murphy and colleagues [42] used multiplicative utility 
for multiple fractures utility evaluation: for example, the utility value for a patient with both 
hip and vertebral fracture equaled to utility value for hip fracture multiplied by utility value 
for vertebral fracture. For a second fracture in the same site as the initial fracture, Hiligsmann 
and colleagues [40, 41] discounted the impact of second fracture as 50% of that of initial 
fracture.  
Twenty-four studies took “extraskeletal effects” due to treatments into account. Excess 
mortality after fractures was accounted for in 59 out of 104 reviewed studies, expressed as 
mortality rate or mortality relative risk to that of general population or population free from 
fractures. It was argued that not all the excess mortality was associated with fracture events, 
therefore in many studies a discounted excess mortality was used to adjust the mortality 
directly related to fracture events. For instance, 25% was assumed as the percentage of the 
excess mortality that directly caused by fractures [43-45].  
Higher relative risk of second fracture following first fracture was assumed in studies of 
secondary fracture prevention. However, the reviewed studies reported a wide range of 
relative risks of different fracture sites, and even varied within the same fracture site [13, 46]. 
In addition, relative risk of second fracture in younger age was assumed to be higher 
comparing with that in older population. For example, relative risk of second hip fracture 
following an initial hip fracture was 7.14 for age younger than 70 years old whilst for 
population aged older than 70 years that relative risk of second hip fracture was 2.24 [37].  
The effects of many pharmaceutical interventions were assumed not to cease immediately 
after discontinuation of therapy and the residual effects, or so-called offset time effects, 
conversely enhance the cost effectiveness in many of the more recent models, particularly 
those in which bisphosphonates were assessed. Studies constantly assumed the offset time 
effect declined in a linear manner after the discontinuation of treatments for an additional 5 
years [32, 39, 43, 47-51]. Offset time effect of treatment was widely considered in models 
after 2000 (Table 2.1) and was discussed in sensitivity analyses. Offset times ranged from 
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one year to five years depended on the assessed pharmaceuticals and declined in a linear 
manner until no residual effect of treatment was assumed after the discontinuation of the 
treatment [31, 43, 51, 52].  
Medical compliance and persistence were also included in some recent models as a critical 
parameter affecting the cost effectiveness of an intervention. Consequently, patients with 
poor persistence and compliance were assumed to have higher risk of fracture comparing 
with that of full persistence and compliance. Effect of compliance was first applied, to our 
knowledge, in Daly and colleagues’ model in 1992 [53] and then sporadically included 
thereafter (Table 2.1). Studies generally included medication compliance after Kanis and 
colleagues’ Health Technology Assessment report in 2002 [11]. Whilst medical compliance 
and persistence were widely discussed, there were some conflicts in terms of definitions [29, 
39, 45]. The value of compliance and persistence also depends on the assessed treatment; it 
was assumed almost half of patients dropped out from bisphosphonates use within the first 6 
months [28, 38, 40]. Hiligsmann and colleagues found the QALY gains with real world 
adherence only represented 30.2%, 32.1% and 34.2% of the episodes estimated with full 
alendronate compliance for the patients aged 55, 65 and 75 years [54]. 
2.6  Discussion 
New and potentially costly pharmaceuticals for prevention of osteoporosis-related fractures 
are being introduced. Due to health care budget constraint, reimbursement agencies should 
only subsidize interventions that represent good value for money; i.e. are cost-effective. Due 
to the relative short term of nature of clinical trials, modelling has been used as a 
complementary decision analysis tool in the assessment of cost effectiveness of prevention of 
osteoporotic fractures in past decades. Models have evolved in their complexity and emphasis, 
with medical continuance becoming increasing recognized as a contributor to health and 
economic outcomes. Good quality models that incorporate uncertainties around the models 
simulate the treatment or prevention outcomes more precisely. This review provides an 
outline in terms of the evolution of modelling in preventing osteoporotic fractures with a 
recommendation of what parameters should be incorporated in model-based health economic 
evaluations.   
Cost and utility data in model-based cost effectiveness analyses were often retrieved from 
clinical trials, specifically, categories of costs included in the model should be in line with the 
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evaluation perspective. Studies on a societal perspective should incorporate all costs 
including direct and indirect cost from the disease. Studies from a healthcare perspective, 
however, do not necessarily include indirect costs. In osteoporotic fractures context, it was 
necessary to divide the costs of fracture into first year cost after fracture and second year cost. 
In addition, costs were highly depended on severity of fractures. Nursing home hip fractures 
incurred higher costs in the second and following years than the first year costs that were 
basically costs of treatment. Fractures that in older age incurred higher costs than that in 
younger age. Similarly, utilities should split into first year utility and second year utility after 
fractures by utility decrements or utility multiplier relative to the utility of population free 
from fractures. As most of the patients healed from acute fracture events and treatment 
improve the utility on subsequent years following fractures.  
Studies had shown that the white women have higher osteoporotic fracture risks than other 
ethnic women groups [55, 56]; this is in line with our review as most of the reviewed studies 
were targeted on the Caucasian women. Hip, vertebral (including clinical vertebral and 
morphometric) and wrist fractures were the most popular studied fracture sites as they were 
the most commonly osteoporotic fractures, representing 82% of all osteoporotic fracture 
events [6]. However, other fracture sites such as proximal humerus, proximal tibia, distal 
femur and pelvis were also investigated in models [49, 57].  
The use of models that evaluated cost effectiveness of medical interventions has continued in 
health economics in the past decades. Structures of the model should reflect the health 
condition or clinical pathway of assessed diseases [58-60], decision tree model and Markov 
model are commonly used structures in health economics. A decision tree model simulates 
the prognosis of a patient following the choice of a management strategy; it is simple to be 
understood but sophisticated enough to cover the essentials of the problem. Markov models 
are useful when a decision problem involves risk that is continuous over time [61], and when 
important events repeat over time. Therefore, Markov models are particularly useful in 
evaluations involving chronic diseases [62]. This was proven in our review as the majority of 
the reviewed studies chose Markov model. There are three ways to evaluate Markov model: 
matrix algebra, cohort simulation and Monte Carlo simulation [61]. Most of our reviewed 
studies either chose cohort simulation or Monte Carlo simulation. In Markov cohort model, a 
whole cohort of patients through the model simultaneously, the subsequent state is 
independent from the previous state, which is known as “memoryless” nature, or “Markovian 
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assumption”, of Markov cohort [63]. Osteoporotic fracture probability as well as osteoporotic 
fracture related mortality, however, is assumed to be highly dependent on the previous health 
state [7]. Therefore, tunnel technique [32, 51] or tracker [41] was manipulated in many of the 
reviewed studies to overcome this flaw. Another way to overcome the memorylessness is 
individual (or Monte Carlo) simulation, whereas a large number of patients through the 
model individually and the transit probability at the chance node depends on the previous 
state. There were numbers of examples [13, 33, 34, 64] using individual simulation in our 
review. To our knowledge, there was no study looking at the difference in terms of cost 
effectiveness results using Markov cohort simulation comparing with Monte Carlo simulation. 
We noted that some studies [65, 66] in our review claimed a societal perspective but did not 
consider indirect costs. Furthermore, around 11% of studies did not describe the perspective 
of the evaluation. The scope or perspective of a decision analytic model should be clearly 
stated and in line with the study objective [67]. A societal perspective that “considers 
everyone affected by the intervention and counts all significant health outcomes and costs 
that flow from it, regardless of who experiences the outcomes or costs” [68] should 
incorporate all relevant costs, which are direct costs, indirect costs and costs on added life 
years and this, has been recommended in many country-specific economic guidelines [59, 69], 
but not all [70]. Categories of costs in the model should be in line with the evaluation 
perspective and indirect cost should be considered in health economic studies on osteoporotic 
fracture prevention at least in working population. It could be argued this is not necessary in 
older populations (not of working age) where no productivity loss be assumed [71]. Failure to 
incorporate indirect costs may result in biased estimates of cost effectiveness as found in 
recent studies where indirect costs contribute 29.2% [72] and 34% [5] of total costs under a 
societal perspective.   
The defined modelling time horizon should be specified [73] and long enough to encapsulate 
all significant clinical and economic outcomes [59]. A lifetime modelling horizon potentially 
captures all the necessary differences in long-term costs and effects between the treatments 
especially in chronic diseases. Specifically, the analyst should make distinction between the 
treatment continuance and the time horizon of the model [74]. Though it was argued time 
horizon should take the clinical prognosis in consideration [59] and match that of the actual 
process [75], lifetime modelling time horizon is highly recommended in numbers of 
guidelines [68, 70]. 
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Subsequent fractures may occur within the modelling time horizon therefore relative risks of 
second and subsequent fractures need to be accounted for. Klotzbuecher and colleagues 
(2000) [76] review on relative risk of future fractures following initial fracture had been cited 
and used in the National Institute for Health and Care Excellence (NICE) model [12], which 
indicated that an initial fracture greatly increased the risk of subsequent fracture, at the same 
as well as other fracture sites, independently of bone mass density. Johnell and colleagues 
(2004) [77] carried out a study aiming at examining the pattern of fracture risk after an initial 
osteoporotic fracture; their results indicated fracture rates following an initial fracture were 
substantially increased in the immediate post-fracture period. Their findings were used by 
many cost effectiveness studies base on Swedish setting [78, 79].  Given the clinical 
significance of fracture status, a population specific relative risk of fracture should be fitted in 
model included second and subsequent fractures.  
Adverse events, or “extraskeletal” effects included in models influenced cost-effectiveness 
outcomes, especially in early studies on hormone replacement therapies. Breast cancer, 
endometrial cancer, cardiovascular diseases and thromboembolism events were the most 
mentioned extraskeletal effects [53, 80-86]. However, extraskeletal effects were rarely 
discussed after the cessation of hormone replacement therapy (HRT) for long-term 
osteoporotic fractures prevention [87] as HRT treatment involved in higher risk for coronary 
heart disease, pulmonary embolism, stroke and invasive breast cancer though it was a 
protection for colorectal cancer and hip fracture. The reasons behind this phenomenon were 
two-fold: paucity of evidence to prove the evaluated medication had adverse effect on human, 
for example, osteosarcomas cases were found in rats given parathyroid hormone, but no 
human case was found in Neer’s study [88]; or side effects were mild and could be easily 
averted [89]. Extraskeletal effects were recommended in modelling: firstly, costs as well as 
effectiveness from adverse events would affect the cost effectiveness. Woo and colleagues 
[90] argued the degree of risk of osteonecrosis for patients taking oral bisphosphonate was 
uncertain thus warrants careful monitoring, hence costs of monitoring were encouraged to be 
added for studies evaluating bisphosphonates. Secondly, extraskeletal events in some cases 
prompt the discontinuation of therapies [91, 92] that causally decreased the efficacy of 
medication.  
Mortality after osteoporotic fractures was estimated to be higher than the fracture-free 
population, especially for immediate mortalities after hip, vertebral and shoulder fractures 
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[93], but not following forearm fractures [8]. Excess mortality was estimated not only related 
to fracture events, but also the comorbidity factors of osteoporotic fracture patients [94]. 
Numbers of the reviewed studies were in line with the published findings, causal mortality of 
osteoporotic fracture patients were estimated ranged from 23% to 30% [39, 51, 54].  
Persistence, compliance and adherence with medications was widely discussed in reviewed 
studies, particularly after 2002, and proven to affect the cost effectiveness of assessed 
interventions to a substantially [95]. These factors play an important role in modelling on 
osteoporotic fracture prevention, as patients tend to be not fully adherent or persistent with 
medicines [44] as well as non-pharmaceutical interventions such as hip protectors [96]. As a 
consequence, there may be complex interactions between continuing effectiveness of an 
intervention and the impact of medical continuation on costs. 
2.7  Conclusions  
A good modelling study should be in line with the criteria of critical appraisals, such as BMJ 
checklist [97] and CHEERS statement [98]. In addition, a number of points are particularly 
important in cost effectiveness modelling of osteoporotic fracture prevention: Markov 
individual state-transition model that overcomes the memorylessness nature of Markov 
cohort model is preferred in order to capture all the interactions between events and changed 
risks of future fractures and mortality. When a Markov cohort model is implemented, tracker 
variables, tunnel states or other methods for building in memory are required. Modelling time 
horizon should be long enough to capture all possible costs and effectiveness; hence lifetime 
horizon is preferable. Extraskeletal effects of treatment should be considered in the analysis 
as evidence suggests that adverse events strongly affect costs, treatment continuance and 
quality of life. The possibility of more than one fracture should be considered in long time 
horizon modelling. Furthermore, mortality risk following fractures should be based on 
evidence from the population assessed. It is important to take medicine continuance into 
account, and it should be tested in sensitivity analysis. Offset time effects needs to be 
considered for non-adherent or non-persistent patients. Cost and effectiveness data should be 
divided into at least first year and subsequent year costs and utilities.  
Modelling will consistently play an important role in health economic evaluations of 
osteoporotic fracture prevention. It complements the clinical trials to capture long-term costs 
and effectiveness and by comparing different treatment alternatives to inform the policy 
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makers funding the treatment that best worth the value. Therefore, an osteoporosis-related-
fractures model should be transparent to reviewers as well as to policy makers, built by 
independent researchers to minimize the risk of bias, and be constructed in line with health 
economic guidelines. 
2.8 Postscript 
In this chapter, the evolution of health economic modelling in the field of osteoporosis has 
been summarized. In addition, recommendations for future models are provided and have 
been incorporated in the new osteoporosis health economics model that was subsequently 
developed and is documented in Chapter 4: 
 Evolving patient characteristics are important when determining the transition
probabilities and therefore should be recorded using modelling techniques such as tracker 
variables and tunnel states. Tracker variables were subsequently used in the model, for 
example, “number of fractures” was used to determine whether the patient has a fracture 
history and the number of fracture that the patient has sustained; “time after last fracture” 
was used to determine the time elapsed from last fracture. Consequently, microsimulation 
was used to account for the tracker variables to calculate the cost, effectiveness and cost-
effectiveness. 
 Lifetime horizon was adopted in our analyses to capture long term costs, effectiveness
of different treatments and prevention strategies. In addition, costs and health state utility 
values for fractured patients were differentiated in first-year and subsequent years after 
fracture. 
 Impact of medication persistent, adherence and offset time effect was fully
incorporated in the subsequent development of the osteoporosis model. In addition, the 
effect of changes in these parameters on cost, effectiveness and cost-effectiveness were 
tested.  
 In addition to the above considerations, a Bayesian approach was implemented to
account for the prior and posterior probabilities for the osteoporosis screening health 
economics model. This is the first application of Bayesian revision in an osteoporosis 
health economics model. 
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Appendix 2B.1 Search strategy in MEDLINE and EMBASE 
For MEDLINE:   
1. osteoporosis, postmenopausal
2. osteoporosis OR osteoporotic fractures OR fractures, bone OR bone mass
3. cost-benefit analysis OR costs and cost analysis OR utility OR quality-adjusted life years
OR life saved OR life year saved OR life gained OR life years gained OR fractures avoided 
4. #1 AND #2 AND #3
For EMBASE: 
1. 'osteoporosis'/exp OR 'postmenopause osteoporosis'/exp
2. 'osteoporosis'/de OR 'fragility fracture'/de OR 'bone mass'/de OR 'wrist fracture'/de OR
'cervical spine fracture'/de OR 'colles fracture'/de OR 'forearm fracture'/de OR 'spine 
fracture'/de OR 'hip fracture'/de 
3. 'cost effectiveness analysis'/exp OR 'cost utility analysis'/exp OR 'cost'/exp
4. #1 AND #2 AND #3
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Weinstein 
1980 
USA HRT Y Y societal 
cost 
effectiveness 
model 
10 yrs Y N Y N USD Y N 
LYs gained and 
QALE 
Tosteson 
1990 
USA 
screening and 
HRT 
Y Y societal 
Markov 
model 
15 yrs Y N N N 
1987 
USD 
Y N 
Life expectancy 
and QALE 
Weinstein 
1990 
USA HRT Y Y societal NA 
5 and 
15 yrs 
Y N N N 
1988 
USD 
Y N 
quality adjusted 
life expectancy 
(QALE) 
Tosteson 
1991 
USA HRT Y Y patients 
Markov 
model 
10 and 
15 yrs 
Y N N N 
1990 
USD 
Y N 
LYs saved and 
quality adjusted 
LYs saved 
Cheung 
1992 
Australia HRT Y Y Health care 
cost 
effectiveness 
model 
lifetime Y N Y N 
1988 
AUD 
Y N QALY 
Daly 1992 UK HRT Y Y 
National 
Health 
Service 
computer 
model 
10 yrs Y Y Y Y 
1989/19
90 
Pound 
Y Y 
LYs gained and 
QALY 
Torgerson 
1993 
UK 
 HRT and 
calcium 
Y Y Health care 
cost 
effectiveness 
model 
10 yrs Y N N N Pound Y N fractures averted 
Chrischilles 
1994 
USA not specified Y Y societal 
Markov 
model 
life 
time 
Y Y Y N 
1992 
USD 
Y N 
life expectancy 
increased 
Geelhoed 
1994 
Australia 
HRT and 
lifestyle 
intervention 
Y Y Health care 
Markov 
model 
50 yrs Y N N N 
1991 
AUD 
Y N QALY 
Jonsson 
1995 
Denmark not specified Y Y societal 
decision tree 
model 
5 yrs Y Y Y Y SEK Y N 
percentage 
reduction in 
annual fracture 
rate, LYs gained 
and QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs  Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Ankjaer-
Jensen 1996 
Denmark 
calcium , 
etidronate, 
calcitonin and 
HRT 
Y Y societal 
simulation 
model 
life 
time 
Y Y Y N DKK Y Y 
reduction in 
number of hip 
fractures 
Torgerson 
1996  
UK 
Vitamin D, 
thiazide 
diuretics, HRT, 
calcium, 
calcitonin 
Y Y NA 
computer 
model 
5 yrs Y N N N Pound Y N Fx reduction 
Rosner 1998  Canada 
bisphosphonate
s, OHT, 
calcium  
Y Y societal 
decision tree 
model 
3 yrs N Y N N 
1998 
CAD 
Y Y 
vertebral Fx 
averted and 
QALY 
Sendi 2000 
Switzerla
nd 
No intervention  Y Y NA 
Markov 
model 
life 
time 
Y N N N CHF Y N 
expected 
survival and 
distribution of 
residual 
lifetimes 
Solomon 
2000 
USA 
screening, 
alendronate, 
ERT, etidronate 
Y Y societal 
Markov 
model 
life 
time 
Y N N Y 
1998 
USD 
Y N QALY 
                
Willis 2001 Sweden tibolone Y Y 
national 
health 
system 
Markov 
model 
25 yrs Y Y Y N 
1998 
SEK 
Y N 
reduction of Fx 
and QALY 
Grima 2002 USA 
resedronate, 
alendronate 
Y Y NA 
Markov 
state-
transition 
model 
life 
time 
Y Y N N 
2000 
USD 
Y N 
fracture averted 
and QALY 
gained 
Iglesias 
2002 
UK risedronate Y Y NA 
Markov 
state-
transition 
model 
life 
time 
Y Y Y N 
1999 
Pound 
Y N QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Kanis 2002 UK 
pharmaceutical 
agents 
Y Y 
NHS and 
social care 
Markov 
model 
lifetime Y Y Y Y Pound Y N QALY 
Nagata-
Kobayashi 
2002 
Japan HRT Y Y societal 
Markov 
state-
transition 
model 
30 yrs Y N N N 
2000 
Yen 
Y N QALY 
Willis 2002 Sweden 
calcium and 
vitamin D3 
Y Y 
national 
healthcare 
and social 
welfare 
system 
Markov 
model 
until 90 
yrs old 
had 
been 
reached 
Y N N N 
2000 
SEK 
Y N 
QALY and LYs 
gained 
Brecht 2003 Germany risedronate N Y 
German 
social 
insurance 
Markov 
state-
transition 
model 
10 yrs Y Y Y Y 
2000 
Euro 
Y N QALY 
Buckley 
2003 
USA 
calcium and 
vitamin D, 
etidronate and 
alendronate 
Y Y societal 
decision 
analytic 
model 
10 yrs 
and life 
time 
N Y N N 
2000 
USD 
Y Y Fx avoided 
Johnell 2003 Sweden alendronate N Y 
Health 
policy 
Markov 
model 
5 yrs 
treatme
nt+5 
yrs fall 
time 
Y Y Y N 
2000 
SEK 
Y N QALY 
Borgstrom 
2004 
Sweden raloxifene Y Y 
healthcare 
and societal 
Markov 
model 
lifetime Y Y Y N 
2001 
SEK 
Y Y 
QALY and LYs 
gained 
Brecht 2004 Germany 
risedronate, 
alendronate and 
raloxifene 
Y Y 
health 
payer 
Markov 
state-
transition 
model 
10 yrs Y Y N N Euro Y N QALY 
Fleurence 
2004 
UK 
VD and 
calcium and hip 
protectors 
Y Y 
National 
Health 
Service 
Markov 
model 
life 
time 
Y Y Y N 
2000 
USD 
Y N QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Kanis 2004 UK risedronate Y Y Health care 
Markov 
model 
life 
time 
Y Y Y N 
2000/01 
Pound 
Y N 
QALY and LYs 
gained 
Singh 2004 Canada hip protectors Y Y societal 
decision 
analytic 
model 
lifetime Y N N N 
2001 
CAD 
Y N QALY 
Stevenson 
2004 
UK 
alendronate, 
calcitonin, HRT 
and raloxifene 
Y Y NA 
Gaussian 
process 
model 
10 yrs Y Y Y Y 
2002 
Pound 
Y N 
QALY and LYs 
gained 
Christensen 
2005 
Denmark alendronate Y Y 
health-care 
sector 
Markov 
cohort 
simulation 
model 
life 
time 
Y Y Y N 
2002 
DKK 
Y N 
QALY gained, 
LYs gained,  Fx 
avoided 
Kanis 2005 UK raloxifene Y Y Health care 
Markov 
model 
Y Y Y N 
2002 
Pound 
Y N 
QALY and LYs 
gained 
Schousboe 
2005 
USA alendronate Y Y societal 
Markov 
model 
life 
time 
Y Y Y Y 
2001 
USD 
Y Y QALY 
Schousboe 
2005 
USA alendronate Y Y societal 
Markov 
model 
life 
time 
Y Y Y Y 
2001 
USD 
Y N QALY 
Schousboe 
2005 
USA alendronate Y Y societal 
Markov 
model 
life 
time 
Y Y Y Y 
2001 
USD 
Y Y QALY 
Stevenson 
2005 
UK 
bisphosphonate
s, raloxifene, 
oestrogen 
Y Y Health care 
Individual 
state 
transition 
model 
10 yrs Y Y Y Y 
2001/20
02 
Pound 
Y N QALY 
Zethraeus 
2005 
Sweden HRT Y Y societal 
Individual 
state 
transition 
model 
50 yrs Y Y Y Y 
2003 
SEK 
Y Y QALY 
Borgstrom 
2006 
Sweden, 
Finland, 
Belgium, 
Spain 
risedronate Y Y Health care 
Markov 
cohort 
model 
life 
time 
Y Y Y Y 
2003/04 
Euro 
Y N 
LYs gained and 
QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs  Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Borgstrom 
2006 
Australia
,German
y, Japan, 
Sweden, 
Spain 
and UK 
bisphosphonate Y Y societal 
Markov 
cohort 
model 
life 
time 
Y N N N 
2004 
USD 
Y Y QALY 
Borgstrom 
2006 
Sweden 
Strontium 
ranelate 
Y Y societal 
Markov 
cohort 
model 
life 
time 
Y Y Y Y 
2004 
SEK 
Y Y QALY 
Goeree 2006 Canada 
alendronate, 
etidronate, 
risedronate and 
raloxifene 
Y Y 
Provincial 
Governmen
t 
Markov 
model 
30 yrs Y Y N N 
2005 
CAD 
Y N LYs and QALY 
Liu 2006 USA 
Teriparatide, 
alendronate 
Y Y societal 
Microsimula
tion 
life 
time 
Y Y Y N 
2003 
USD 
Y Y QALY 
Lundkvist 
2006 
Sweden 
teriparatide in 
addition to 
vitamin D and 
calcium 
Y Y societal 
Microsimula
tion 
life 
time 
Y Y Y Y 
2003 
Euro 
Y N QALY 
Mobley 
2006 
USA 
HRT, 
raloxifene, 
alendronate 
Y Y 
medical 
care 
Markov 
model 
life 
time 
Y Y N N 
2002 
USD 
Y N 
Fx avoided, LYs 
saved and 
QALY 
Panichkul 
2006 
Thailand screening Y Y individual decision tree 5 yrs Y N N N 
2004 
THB 
Y Y 
numbers of 
perimenopausal 
women free 
from fracture 
Pfister 2006 USA 
calcitonin, 
raloxifene, 
bisphosphonate
s and PTH 
Y Y 
health 
payer 
decision tree 5 yrs Y Y N Y 
2000 
USD 
Y N QALY 
Earnshaw 
2007 
USA 
bisphosphonate
s 
Y Y 
third party 
payer 
Markov 
model 
life 
time 
Y Y Y N 
2006 
USD 
Y N LYs and QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs  Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Schott 2007 France screening Y Y 
health care 
system 
Markov 
state-
transition 
model 
10 yrs Y N N N Euro Y N 
number of years 
without a hip Fx 
gained 
Schwenkgle
nks 2007 
Switzerla
nd 
alendronate Y Y 
health care 
system 
Markov 
state-
transition 
model 
life 
time 
Y Y Y N 
2006 
CHF 
Y N QALY 
Stevenson 
2007 
UK 
Strontium 
ranelate 
Y Y societal 
state 
transition 
model 
10 yrs Y Y Y Y 
2003/04 
Pound 
Y N QALY 
Strom 2007 
Belgium, 
Denmark
, France, 
Germany
, Italy, 
Norway, 
Spain, 
Sweden, 
UK 
alendronate Y Y Health care 
Markov 
cohort 
model 
lifetime Y Y Y N 
2004 
Euro 
Y N QALY 
van Staa 
2007 
UK 
bisphosphonate
s 
Y Y NA 
individual 
patient-
based model 
10 yrs Y Y Y Y Pound Y N QALY 
Ding 2008 Japan risedronate Y Y NA 
state 
transition 
model 
3 yrs N Y N Y USD Y N QALY 
Gandjour 
2008 
Germany hip protectors Y Y 
societal and 
statutory 
health 
insurance 
Markov 
cohort 
model 
17 yrs Y N N N 
2004 
Euro 
Y N QALY 
Grima 2008 Canada 
risedronate and 
alendronate 
Y Y 
provincial 
Ministry of 
Health 
State-
transition 
model 
5 yrs Y N N N 
2006 
CAD 
Y N QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Hiligsmann 
2008 
Belgium 
prescreening 
using 
quantitative 
ultrasonometry 
Y Y health care 
Markov 
microsimul-
ation model 
life 
time 
Y Y Y Y 
2006 
Euro 
Y Y QALY 
Jansen 2008 
UK and 
the 
Netherla
nds 
alendronate and 
cholecalciferol 
Y Y 
healthcare 
payer 
Markov 
model 
10 yrs Y Y Y Y 
2004 
Pound 
Y N QALY 
Johansson 
2008 
Sweden 
non-
pharmaceutical 
prevention 
Y N societal 
Markov 
model 
lifetime Y N N N 
2004 
SEK 
Y N QALY 
Kanis 2008 UK bisphosphonate Y Y health care 
Markov 
cohort 
model 
lifetime Y Y Y Y Pound Y N QALY 
Kreck 2008 Germany ibandronate Y Y societal 
Markov 
model 
10 yrs Y Y Y N 
2004 
Euro 
Y Y QALY 
Lekander 
2008 
Sweden, 
UK and 
US 
Hormone 
therapy 
Y Y societal 
state 
transition 
model 
lifetime Y Y Y N 
2006 
USD 
Y Y QALY 
Mueller 
2008 
Germany screening Y Y 
statutory 
health 
system 
Markov 
model 
life 
time 
Y Y Y N 
2006 
Euro 
Y N QALY 
Mueller 
2008 
Germany 
screening, 
bisphosphonate
s 
Y Y 
statutory 
health 
system 
Markov 
state-
transition 
model 
life 
time 
Y Y Y N 
2006 
Euro 
Y N QALY 
Tosteson 
2008 
USA 
risedronate 
compared with 
alendronate, 
ibandronate, 
and teriparatide 
N Y 
Health 
policy 
Markov 
state-
transition 
model 
10 yrs Y Y N N 
2005 
USD 
Y N QALY 
Tosteson 
2008 
USA bisphosphonate Y Y NA 
State-
transition 
model 
lifetime Y Y Y Y 
2005 
USD 
Y N 
QALY and hip 
Fx averted 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs  Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Wasserfallen 
2008 
Switzerla
nd 
risedronate N Y Health care 
Markov 
model 
lifetime Y Y Y N 
2005 
Euro 
Y N QALY 
Danese 2009 USA 
bisphosphonate
s 
N Y NA 
Monte Carlo 
simulation 
model 
lifetime Y Y Y N 
2008 
USD 
Y N 
lifetime number 
of fx averted 
Hiligsmann 
2009 
Belgium bisphosphonate Y Y 
direct 
health-care 
cost  
Markov 
microsimul-
ation model 
lifetime Y Y Y Y 
2006 
Euro 
Y N QALY 
Majumdar 
2009 
Canada alendronate N Y 
third party 
payer 
Markov 
dedision-
analytic 
model 
lifetime Y Y Y N 
2006 
CAD 
Y N QALY 
Mueller 
2009 
Germany screening Y Y 
statutory 
health 
system 
Markov 
model 
lifetime Y Y Y N 
2006 
Euro 
Y N QALY 
Berto 2010 Italy 
risedronate and 
alendronate 
N Y 
Italian 
National 
Healthcare 
System 
Markov 
state-
transition 
model 
6 yrs Y N N Y Euro Y N QALY 
Borgstrom 
2010 
UK 
strontium 
ranelate 
Y Y 
health care 
perspective 
Markov 
cohort 
model 
lifetime Y Y Y Y 
2006 
Pound 
Y N QALY 
Borgstrom 
2010 
UK risedronate Y Y 
health care 
perspective 
Markov 
cohort 
model 
lifetime Y Y Y Y 
2006 
Pound 
Y N QALY 
Borgstrom 
2010 
Sweden 
parathyroid 
hormone 
Y Y societal 
Markov 
model 
lifetime Y Y Y Y 
2007 
Euro 
Y Y QALY 
Fardellone 
2010 
France 
zoledronic acid, 
bisphosphonate
s, raloxifene, 
strontium 
ranelate and 
teriparatide 
Y Y societal 
decision tree 
model 
3 yrs Y Y N Y 
2009 
Euro 
Y N 
absolute Fx 
probability 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Hiligsmann 
2010 
Belgium 
strontium 
ranelate 
Y Y 
Belgian 
healthcare 
cost 
Markov 
microsimul-
ation model 
lifetime Y Y Y Y 
2006 
Euro 
Y N QALY 
Hiligsmann 
2010 
Belgium 
strontium 
ranelate 
Y Y healthcare 
Markov 
microsimul-
ation model 
lifetime Y Y Y Y 
2006 
Euro 
Y N QALY 
Hiligsmann 
2010 
Belgium 
screen and treat 
with 
alendronate 
Y Y healthcare 
Markov 
microsimul-
ation model 
lifetime Y Y Y Y 
2006 
Euro 
Y N QALY 
Hiligsmann 
2010 
Belgium bisphosphonate Y Y payer 
Markov 
microsimul-
ation model 
lifetime Y Y Y Y 
2006 
Euro 
Y N QALY 
Hiligsmann 
2010 
Belgium bisphosphonate Y Y healthcare 
Markov 
microsimul-
ation model 
lifetime Y Y Y Y 
2006 
Euro 
Y N QALY 
Hiligsmann 
2010 
Belgium denosumab Y Y healthcare 
Markov 
microsimul-
ation model 
lifetime Y Y Y N 
2009 
Euro 
Y N QALY 
Logman 
2010 
UK zoledronic acid Y Y 
National 
Health 
Service 
Markov 
model 
lifetime Y Y Y Y 
2007 
Pound 
Y N QALY 
Strom 2010 Sweden bazedoxifene Y Y societal 
Markov 
model with 
tunnel 
techniques 
lifetime Y Y Y Y Euro Y Y QALY 
Thompson 
2010 
Germany 
risedronate and 
alendronate 
Y Y 
German 
statutory 
health 
insurance 
Markov 
state-
transition 
model 
5 yrs Y N N N 
2008 
Euro 
Y N QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs  Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Akehurst 
2011 
Finland, 
Norway 
and the 
Netherla
nds 
zoledronic acid N Y healthcare 
individual 
simulation 
model 
lifetime Y Y Y Y 
2006 
Euro 
for 
Finland, 
2006 
NOK 
for 
Norway 
and 
2007 
Euro 
for the 
Netherl
ands 
Y N QALY 
Borgstrom 
2011 
Europe bazedoxifene Y Y healthcare 
Markov 
cohort 
simulation 
model 
lifetime Y Y Y Y 
2008 
Euro 
Y N QALY 
Cotte 2011 France 
bisphosphonate
s 
Y Y NA 
Markov 
state-
transition 
model 
10 yrs Y Y Y N 
2010 
Euro 
Y N Fx occurred 
Gauthier 
2011 
UK no intervention  Y Y 
no 
perspective 
Markov 
model 
50 yrs Y Y N Y NA Y N Fx occurred 
Hiligsmann 
2011 
Belgium denosumab Y Y healthcare 
Markov 
microsimul-
ation model 
lifetime Y Y Y Y 
2009 
Euro 
Y N QALY 
Jonsson 
2011 
Sweden denosumab Y Y societal 
Markov 
cohort 
model 
lifetime Y Y Y Y 
2008 
Euro 
Y N QALY 
Majumdar 
2011 
Canada 
multifaceted 
intervention 
N Y healthcare 
Markov 
decision-
analytic 
model 
lifetime Y Y Y N 
2006 
CAD 
Y N QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
McLellan 
2011 
UK 
Fracture liaison 
services 
N Y 
National 
Health 
Service 
Markov 
cohort 
model 
lifetime Y N Y Y 
2009 
Pound 
Y N QALY 
Mueller 
2011 
Germany 
diagnosis of 
osteoporosis 
and treat with 
alendronate 
Y Y 
German 
statutory 
health 
insurance 
Markov 
model 
lifetime Y Y Y N 
2010 
Euro 
Y N QALY 
Nayak 2011 USA screening Y Y payer 
Individual 
state 
transition 
model 
lifetime Y Y Y N 
2010 
USD 
Y N QALY 
Pham 2011 USA bisphosphonate Y Y societal 
Markov 
model 
lifetime Y Y N Y 
2008 
USD 
Y Y QALY 
Chau 2012 Canada 
denosumab, 
alendronate, 
raloxifene, 
risedronate 
Y Y payer 
Markov 
model 
lifetime Y Y Y Y 
2010 
CAD 
Y N QALY 
Cooper 2012 Australia 
Minimal 
Trauma 
Fracture 
Liaison 
N Y 
universal 
health care 
insurance 
Markov 
model 
10 yrs Y N Y Y 
2010 
AUD 
Y N QALY 
Hiligsmann 
2012 
Ireland 
oral 
bisphosphonate 
Y Y healthcare 
Markov 
microsimul-
ation model 
(tracker 
technique 
was 
incorporated
) 
lifetime Y Y Y N 
2008 
Euro 
Y N QALY 
Kingkaew 
2012 
Thailand 
screening and 
treatment 
Y Y societal 
Markov 
model 
lifetime Y Y N N 
2007 
THB 
Y N QALY 
Murphy 
2012 
Sweden 
teriparatide,oral 
bisphosphonate 
N Y NA 
Markov 
microsimul-
ation model 
lifetime Y Y Y N 
2011 
Euro 
Y N QALY 
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Study Country 
Assessed 
intervention 
Type of 
fracture 
prevention 
Evaluation 
perspective 
Type of 
model 
Time 
horizon 
Fracture sites Costs 
unit 
Costs Effectiveness 
measurement 
P S Hip Vertebral Wrist Other D I 
Pueyo 2012 Spain alendronate Y Y societal 
decision 
analytic 
model 
10 and 
20 yrs 
Y N N N 
2009 
Euro 
Y Y QALY 
Alzahouri 
2013 
France 
branded 
alendronate 
Y Y 
French 
healthcare 
system 
Markov 
state-
transition 
model 
lifetime Y N N N 
2011 
Euro 
Y N QALY 
Moriwaki 
2013 
Japan alendronate Y Y 
health care 
system 
Individual 
state 
transition 
model 
5 yrs Y Y N N 
2012 
USD 
Y N QALY 
Nshimyumu-
kiza 2013 
Canada 
calcium and 
vitamin D, 
physical 
activity, 
bisphosphonate
s 
Y Y 
Ministry of 
Health and 
Public 
Medical 
Insurance 
individual 
Markov 
decision 
model 
lifetime Y Y Y N 
2007-
2008 
CAD 
Y N QALY 
Abbreviations: P: primary, S: secondary, D: direct, I: indirect, QALY: quality-adjusted life years, QALE: quality-adjusted life expectancy, Fx: fracture, LY: life year, USD: 
US dollar, SEK: Swedish krona, CAD: Canadian dollar, CHF: Swiss franc, DKK: Danish krona, THB: Thai Baht, NA: not applicable, Y: yes, N: no. 
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Appendix 2B.3 Table 2: Costs* of fracture in studies included in the systematic review 
First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
USA  
Weinstein 1980 NA NA NA NA NA NA NA NA 
Tosteson 1990  18,460-21,792 NA NA NA NA NA NA NA 
Weinstein 1990 17,847-21,068 NA NA NA 65,357 NA NA NA 
Tosteson 1990 20,695 (50-59y) NA NA NA NA NA NA NA 
24,435(80-89y) 
Chrischilles 
1994 
NA NA NA NA NA NA NA NA 
Solomon 2000 18,345 NA NA 1,256 NA NA NA NA 
Grima 2002 48,505 2,474 NA NA 5,042 93 NA NA 
Buckley 2003 NA 1,105 NA NA NA NA NA NA 
Schousboe 2005 20,737 8,624 4,794 7,155 8,100 NA NA NA 
Schousboe 2005 20,737 8,624 4,794 7,155 8,100 NA NA NA 
Schousboe 2005 20,737 8,624 4,794 7,155 8,100 NA NA NA 
Borgstrom 2006 15,889 NA NA NA 81,527 NA NA NA 
Liu 2006 21,520 8,801 4,778 NA NA NA NA NA 
Mobley 2006 37,324 2,110 NA NA 5,055 196 NA NA 
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First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
Pfister 2006 33,329(65-69y) 3,968(65-69y) NA 6,954(65-69y) NA NA NA NA 
35,291(70-74y) 3,884(70-74y) 7,118(70-74y) 
31,973(75-79y) 3,814(75-79y) 7,720(75-79y) 
31,982(80-84y) 3,630(80-84y) 7,951(80-84y) 
25,137(85y+) 3,489(85y+) 8,951(85y+) 
Earnshaw 2007 40,232 2,255 2,109 NA 5,556 242 NA NA 
Danese 2009 35,625 9,460 7,356 7,356 35,625 9,460 7,356 7,356 
Lekander 2008 15,402 6,300 3,420 NA NA 0 0 NA 
Tosteson 2008 46,177(65-74y) 3,780(65-74y) NA NA 5,494 254 NA NA 
47,397(75-84y) 3,608(75-84y) 
Tosteson 2008 34,379 9,791 4,897 13,220 8,354 NA NA NA 
Nayak 2011 23,694 9,691 5,262 NA 
78,721(60% of hip fx 
patients ended up 
with NH) 
NA NA NA 
Pham 2011 26,050 8,008 NA 15,987 9,144 258 NA 0 
UK  
Daly 1992 NA NA NA NA NA NA NA NA 
Torgerson 1993 NA NA NA NA NA NA NA NA 
Torgerson 1996 NA NA NA NA NA NA NA NA 
Iglesias 2002 NA NA NA NA NA NA NA NA 
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First year after fracture   Second year after fracture 
Hip Vertebral Wrist  Others   Hip Vertebral Wrist  Others 
Fleurence 2004 25,461 1,005 982 2,809 
 
NA NA NA NA 
Kanis 2004 25,082 991 968 2,768 
 
16,165(10% of hip fx 
ended up with NH) 
314 0 NA 
Stevenson 2004 25,082 991 968 2,768 
 
43,186 for NH 407 0 NA 
Borgstrom 2006 11,128(50-59y) NA NA NA 
 
36,600 NA NA NA 
 
13,536(60-69y) 
        
 
16,498(70-79y) 
        
 
24,690(80-89y) 
        
 
27,628(90y +) 
        
Stevenson 2007 
9,503(50-54y, 
not NH) 
879(50-54y) 662(50-54y) NA 
 
43,419(50-54y, NH) 409(50-54y) 0 NA 
 
9,503(60-64y, 
not NH) 
879(60-64y) 662(60-64y) 
  
43,419(60-64y, NH) 409(60-64y) 
  
 
11,954(70-74y, 
not NH) 
993(70-74y) 662(70-74y) 
  
44,668(70-74y, NH) 409(70-74y) 
  
 
15733(80-84y, 
not NH) 
1,071(80-84y) 1,078(80-84y) 
  
46,726(80-84y, NH) 409(80-84y) 
  
 
57,676(50-54y) 
        
Stevenson 2007 
57,676(60-64y, 
NH)         
 
60,084(70-74y, 
NH)         
 
63,858 (80-84y, 
NH)         
Strom 2007 22,897(50-64y) 3,723(50-64y) 629(50-64y) NA 
 
3,900 NA NA NA 
 
23,135(65-74y) 3,365(65-74y) 629(65-74y) 
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First year after fracture   Second year after fracture 
Hip Vertebral Wrist  Others   Hip Vertebral Wrist  Others 
 
27,029(75-84y) 2,791(75-84y) 1,020(75-84y) 
      
 
28,562(85y +) 1,342(85y +) 3,201(85y +) 
      
van Staa 2007 
9,503(40-69y, 
not NH) 
879(40-69y) 1,752(40-79y) NA 
 
43,419(40-69y, NH) 409(40-69y) NA NA 
 
11,100(70-79y, 
not NH) 
922(70-79y) 1,752(80y +) 
  
43,419(70-79y, NH) 409(70-79y) 
  
 
15,733(80y +, 
not NH) 
1,071(80y +) 
   
46,726(80y +, NH) 409(80y +) 
  
 
53,554(40-69y, 
NH)         
 
55,790(70-79y, 
not NH)         
 
63,858(80y +, 
not NH)         
Kanis 2008 17,868 2,833 875 
22,868 for other 
femoral fx  
NA 0 0 NA 
    
15,337 for pelvic 
fx      
Kanis 2008 
   
244 for rib and 
sternal fx      
    
1,847 for forearm 
fx      
    
6,417 for leg fx 
     
Lekander 2008 16,360-27,566 2,095-3,818 1,098 NA 
 
NA 0 0 NA 
Borgstrom 2010 
by 2 
17,868 2,833 875 
22,868 for other 
femoral fx  
NA 0 0 NA 
    
15,337 for pelvic 
fx      
    
244 for rib and 
sternal fx      
    
1,847 for forearm 
fx      
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First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
6,417 for leg fx NA NA NA NA 
Logman 2010 1,824 2,919 902 NA 1,824 2,919 902 NA 
Borgstrom 2011 13,374(50-69y) 3,334 1,527 2,240-2,729 2,738(50-59y) 590(50-59y) NA NA 
15,594(70-79y) 2,657(60-69y) 518(60-69y) 
24,631(80y +) 4,168(70-79y) 820(70-79y) 
6,007(80y +) 1,719(80y +) 
Gauthier 2011 NA NA NA NA NA NA NA NA 
Scandinavia 
countries 
Jonsson 1995 26,451 2,713 678 NA 
33,911 (10% of the 
hip fx ended in NH) 
0 0 NA 
Ankjaer-Jensen 
1996 
11,148 NA NA NA 24,375 NA NA NA 
Willis 2001 15,306-49,495 622 516 NA 486 for healed hip fx NA NA NA 
3,462 for partial 
healed hip fx 
21,241 for 
permanently disabled 
hip fx 
Willis 2002 14,464-46,772 NA NA NA 3,650 NA NA NA 
Johnel 2003 24,468 2,163 541 NA 5,542 NA NA NA 
Borgstrom 2004 NA 4,119 NA NA NA 676 NA NA 
Christensen 
2005 
NA NA NA NA 
5,353 for severe hip 
fx 
281 1,907 NA 
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First year after fracture   Second year after fracture 
Hip Vertebral Wrist  Others   Hip Vertebral Wrist  Others 
      
402 for moderate hip 
fx    
Zethraeus 2005 8,106 7,863 2,898 NA 
 
9,903 for NH fx NA NA NA 
Borgstrom 2006 12,349(50-64y) 4,681 2,974 NA 
 
7,963 0 0 NA 
 
13,443(65-74y) 
        
 
23,742(75-84y) 
        
 
33,185(85-
100y)         
Borgstrom 2006 15,104(50-64y) NA NA NA 
 
81,241 for NH hip fx NA NA NA 
Borgstrom 2006 15,465(65-74y) 
        
 
16,142(75-84y) 
        
 
22,179(85y +) 
        
Borgstrom 2006 10,967(50-64y) 4,157 2,642 2,742 
 
5,013(50-64y) 566 0 0 
 
11,940(65-74y) 
    
4,903(65-74y) 
   
 
21,086(75-84y) 
    
7,661(75-84y) 
   
 
29,473(85y +) 
    
16,937(85y +) 
   
Lundkvist 2006 12,284(50-64y) 4,419 2,807 NA 
 
7,272 725 NA NA 
 
13,300(65-74y) 
        
 
23,437(75-84y) 
        
 
32,760(85y +) 
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First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
Strom 2007 12,572(50-64y) 4,765 3,028 NA 8,107 NA NA NA 
13,685(64-74y) 
24,169(75-84y) 
33,782(85y +) 
Strom 2007 22,968 1,213 883 NA 7,058 NA NA NA 
Strom 2007 29,282 1,528 1,327 NA 5,369 NA NA NA 
Lekander 2008 13,526-17,146 2,215-13,685 3,072 NA 
based on age specific 
NH status: 6.7%-
22.6% 
0 0 NA 
Borgstrom 2010 11,790-14,567 3,059-9,677 2,752 8,307 
3,934-16,889 for NH 
hip fx 
1,629-5,951 0 0 
153-3,776 for hip fx
Strom 2010 13,521-24,901 2,333-16,194 2,864 4,571-11,709 5,256-11,532 637-1,856 264 0 
Akehurst 2011 11,025 1,398 1,199-2,629 1,320-2,295 53,788 461 NA NA 
Akehurst 2011 14,557 2,512 2,061 2,061 70,202 NA NA NA 
Borgstrom 2011 13,521(50-64y) 2,333(50-59y) 2,864 4571-11709 5,256(50-59y) 637(50-59y) 264 0 
16,405(65-74y) 15,878(60-69y) 5,211(60-69y) 572(60-69y) 
17,121(75-84y) 16,437(70-79y) 8,177(70-79y) 904(70-79y) 
24,901(85y +) 16,194(80y +) 11,532(80y +) 1,856(80y +) 
Jonsson 2011 15,780(50-64y) 2,511(50-64y) 2,944 5,076(50-54y) NA 0 0 0 
16,262(65-74y) 16,729(65-74y) 5,471(55-59y) 
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First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
18,151(75-84y) 17,317(75-84y) 6,513(60-64y) 
24,114(85y +) 17,434(85y +) 10,840(65-69y) 
11,110(70-74y) 
10,489(75-79y) 
Jonsson 2011 9,880(80-84y) 
10,713(85y +) 
Murphy 2012 11,389(50-64y) 4,097 2,603 NA 6,742 672 NA NA 
12,694(65-74y) 
22,369(75-84y) 
30,373(85y +) 
Belgium 
Strom 2007 22,107 4,990 1,350 NA 2,677 NA NA NA 
Hiligsmann 
2008 
21,500-27,432 3,173 2,821 4,668 1,295-5,977 NA NA NA 
Hiligsmann 
2009 
21,500-27,433 3,173 2,821 4,668 
25,895-19,919 for 
NH 
NA NA NA 
Hiligsmann 
2010 by 6 
21,500-27,433 3,173 2,821 4,668 
25,895-19,919 for 
NH 
NA NA NA 
Canada 
Rosner 1998 NA 2,190 NA NA NA NA NA NA 
Singh 2004 
17,397 for acute 
hospital 
treatment 
NA NA NA NA NA NA NA 
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First year after fracture   Second year after fracture 
Hip Vertebral Wrist  Others   Hip Vertebral Wrist  Others 
 
119,907 for NH 
        
Grima 2008 23,207 NA NA NA 
 
4,973(65-74y) NA NA NA 
      
2,614(75-84y) 
   
      
0(85y +) 
   
Majumdar 2009 NA NA NA NA 
 
NA NA NA NA 
Majumdar 2011 27,549 1,893 1,359 NA 
 
44,107 for NH hip fx 
(20%) 
NA NA NA 
Chau 2012 16,560(50-59y) 8,642(50-59y) 1,174(50-59y) NA 
 
3,886 177 NA NA 
 
15,786(60-69y) 11,602(60-69y) 1,664(60-69y) 
      
 
20,805(70-79y) 14,066(70-79y) 4,288(70-79y) 
      
 
22,522(80-89y) 17,910(80-89y) 
10,716(80-
89y)       
 
20,719(90y +) 21,432(90y +) 14,716(90y +) 
      
Nshimyumukiza 
2013 
20,980 NA NA NA 
 
NA NA NA NA 
Germany  
         
Brecht 2003 23,943 6,958(50-64y) NA NA 
 
11,851 NA NA NA 
  
7,637(65-74y) 
       
  
8,528(75-100y) 
       
Brecht 2004 13,265 for SHI 7,037 for SHI  NA NA 
 
NA NA NA NA 
Brecht 2004 9,504 for LTCI 
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First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
22,768 for SHI 
Borgstrom 2006 20,987 NA NA NA 62,349 NA NA NA 
Strom 2007 22,864 6,644(50-64y) 1,396 NA 4,050 NA NA NA 
7,292(65-74y) 
8,144(75-84y) 
8,144(85y +) 
Kreck 2008 18,194(40-49y) 4,262(40-49y) 4,524(40-49y) NA 7,075(65y +) NA NA NA 
18,218(50-59y) 4,279(50-59y) 4,524(50-59y) 
18,476(60-64y) 4,306(60-64y) 4,524(60-64y) 
21,467(65-69y) 2,848(65-69y) 959(65-69y) 
21,624(70-79y) 2,902(70-79y) 1,012(70-79y) 
21,955(80-89y) 2,848(80-89y) 959(80-89y) 
Mueller 2008 by 
3 
NA 5,602 5,373 NA NA NA NA NA 
Thompson 2010 31,303 NA NA NA 15,495 NA NA NA 
Borgstrom 2011 24,099 7,003(50-64y) 1,471 NA 2,904(50-59y) 537(50-59y) NA NA 
7,687(65-74y) 2,817(60-69y) 472(60-69y) 
8,583(75y +) 4,352(70-79y) 748(70-79y) 
7,007(80y +) 1,566(80y +) 
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First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
Mueller 2011 40,625-86,281 5,344 5,126 NA NA NA NA NA 
Japan 
Nagata-
Kobayashi 2002 
18,462 NA NA NA 5,539-21,819 NA NA NA 
Borgstrom 2006 28,016 NA NA NA 44,682 NA NA NA 
Ding 2008 NA NA NA NA NA NA NA NA 
Moriwaki 2013 27,967 9,829 NA NA 
44,339 for nursing 
home fx which took 
13.6% of all hip fx  
NA NA NA 
Australia  
Cheung 1992 10,232 584 NA NA NA NA NA NA 
Geelhoed 1994 8,357 584 NA NA NA NA NA NA 
Borgstrom 2006 14,213 NA NA NA 35,746 NA NA NA 
Cooper 2012 14,630 NA 1,671 3,736 2,994 NA NA NA 
Switzerland  
Sendi 2000 NA NA NA NA NA NA NA NA 
Schwenkglenks 
2007 
NA NA NA NA 4,227 1,476 1,148 NA 
Wasserfallen 
2008 
33,484(50-64y) 25,887(50-64y) 9,157(50-64y) NA 2,131(50-64y, NH) NA NA NA 
52,701(65-74y) 26,385(65-74y) 
10,148(65-
74y) 
4,363(65-74y, NH) 
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First year after fracture Second year after fracture 
Hip Vertebral Wrist Others Hip Vertebral Wrist Others 
57,740(75-84y) 27,399(75-84y) 
13,856(75-
84y) 
6,659(75-84y, NH) 
56,488(85y +) 47,905(85y +) 33,296(85y +) 9,142(85y +, NH) 
Thailand 
Panichkul 2006 1,698 NA NA NA NA NA NA NA 
Kingkaew 2012 5,391 5,157 NA NA NA NA NA NA 
Spain  
Borgstrom 2006 8,882 2,769 543 NA 2,042 NA NA NA 
Borgstrom 2006 10,123 NA NA NA 41,433 NA NA NA 
Borgstrom 2011 16,351 3,617 998 1,687-2,057 4,367(50-59y) 444(50-59y) NA NA 
4,237(60-69y) 391(60-69y) 
Borgstrom 2011 6,648(70-79y) 618(70-79y) 
9,581(80y +) 1,295(80y +) 
Strom 2007 9,096 2,012 556 NA 2,091 NA NA NA 
Pueyo 2012 15,820 NA NA NA 10,616 NA NA NA 
France 
Schott 2007 23,680 NA NA NA NA NA NA NA 
Strom 2007 11,728(50-64y) 4,446 2,825 NA 7,563 NA NA NA 
12,768(65-74y) 
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First year after fracture   Second year after fracture 
Hip Vertebral Wrist  Others   Hip Vertebral Wrist  Others 
 
22,548(75-84y) 
        
 
31,516(85y +) 
        
Fardellone 2010 10,136-10,991 
upper limit of 
7,743 
NA 2,971 
 
NA NA NA NA 
Borgstrom 2011 12,916(50-69y) 3,221 1,475 NA 
 
2,645(50-59y) 569(50-59y) NA NA 
 
15,055(70-79y) 
    
2,566(60-69y) 500(60-69y) 
  
 
23,788(80y +) 
    
4,026(70-79y) 792(70-79y) 
  
      
5,802(80y +) 1,661(80y +) 
  
Alzahouri 2013 17,520 NA NA NA 
 
24,873 for NH hip fx NA NA NA 
Italy  
         
Strom 2007 22,968 5,080 1,402 NA 
 
2,741 NA NA NA 
Berto 2010 14,421 NA NA NA 
 
1,645 NA NA NA 
Borgstrom 2011 24,378 5,392 1,489 NA 
 
4,186(50-59y) 662(50-59y) NA NA 
      
4,061(60-69y) 583(60-69y) 
  
      
6,373(70-79y) 922(70-79y) 
  
      
9,581(80y +) 1,931(80y +) 
  
The 
Netherlands          
Jansen 2008 82,025 (NH) 699 1,189 1,459 
 
60754 (NH) 139 63 177 
Akehurst 2010 20,478 9,938 1,371 1,371 
 
41,565 NA NA NA 
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First year after fracture   Second year after fracture 
Hip Vertebral Wrist  Others   Hip Vertebral Wrist  Others 
Ireland 
         
Hiligsmann 
2012 
14,282-16,734 2,483-2,910 NA NA 
 
5,666-6,119 NA NA  NA  
 
15,350-17,883 2,669-3,110 NA NA  
 
5,760-6,170 NA NA NA 
Abbreviations: NA: not applicable, fx: fracture, NH: nursing home dwelling, SHI: Social Health Insurance, LTCI: statutory long-term care insurance. 
* Costs data were converted into 2013 US dollars using a web-based currency convertor. 
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Chapter 3: A systematic review and meta-analysis of 
utility-based quality of life for osteoporosis-related 
conditions 
3.1  Preface 
This chapter provides a systematic review and meta-analysis of health-state utility values for 
osteoporosis-related conditions. This study statistically combines multiple health state utility 
values (HSUVs) reported in the literature for patients with osteoporosis and osteoporotic 
fractures. Fracture events are associated with decrements in HSUVs which differed between 
fracture sites and time since the occurrence of fractures. In addition, we have provided 
summary values for use in future health economics analyses in osteoporosis, that we later 
implemented in the health economics model described in Chapter 4.  
This chapter has been published in Osteoporosis International (Appendix 3A). 
Impact factor: 4.17. 
Si L., Winzenberg TM, de Graaff B, and Palmer A.J., A systematic review and meta-
analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporosis 
International, Aug 2014, 25(8): 1987-97. 
The published article of this 
chapter appears in an appendix to 
the chapter. It has been removed 
for copyright or proprietary 
reasons.
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3.2  Abstract 
Introduction: Osteoporotic fractures have high financial and health burden. Economic 
evaluations on osteoporotic fracture prevention have been frequently performed in past 
decades. One of the challenges in the economic evaluations was to identify consistent health 
state utility values (HSUVs) to use for osteoporotic fracture related conditions. The objective 
of this study was to determine summary measures of multiple HSUVs reported in the 
literature for patients with osteoporosis and osteoporotic fractures. 
Methods: We performed a systematic review, meta-analysis and meta-regression of 
published literature that reported HSUVs for osteoporotic fracture related conditions.  
Results: There were 62 studies representing 142,477 patients included. In total, 362 HSUVs 
were identified: 106 for pre-fracture; 89 for post-hip fracture; 130 for post-vertebral fracture 
and 37 for post-wrist fracture. The pooled HSUVs, using a random-effects model were 0.76 
(95% CI: 0.75, 0.77, I2=0.99) for pre-fracture; 0.57 (95% CI: 0.52, 0.63, I2=1) for post-hip 
fracture; 0.59 (95% CI: 0.55, 0.62, I2=0.99) for post-vertebral facture and 0.72 (95% CI: 0.67, 
0.78, I2=1) for post-wrist fracture. Heterogeneities were addressed through meta-regression. 
HSUVs immediately following hip, vertebral and wrist fracture were 0.31, 0.44 and 0.61 
respectively. Patients’ HSUVs improved over time following fracture events: HSUVs for the 
first year after hip, vertebral and wrist fracture were 0.59, 0.55 and 0.78 respectively; and 
0.66, 0.66 and 0.81 for subsequent years. 
Conclusions: Fractures were associated with significant decrements in HSUVs. This study 
provides a standard set of HSUVs that can be used in health economic assessments in 
osteoporosis. 
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3.3  Introduction  
Osteoporosis is characterized by reduced bone mass and disruption of bone structure, 
resulting in increased risk of fracture and bone fragility [1]. It was estimated 200 million 
women were affected by osteoporosis and about 9 million fractures occurred globally in 2000 
[2]. Though a downward trend in fracture rates was observed in the past decade regionally [3], 
a recent report suggested the number of men and women with osteoporosis is expected to rise 
from 27.5 million in 2010 to 33.9 million in 2025 across European countries [4].  
Increase in health care expenditure for osteoporosis is driven by the costs of pharmaceutical 
medicines, making up 70% of the total costs [3]. Cost-effectiveness analysis models that 
assess whether medications/interventions provide good value for money, have been 
increasingly used in past decades [5-8]. One of the challenges for modelling osteoporosis 
interventions is estimating a health state utility value (HSUV) to calculate the quality 
adjusted life years (QALYs) [9], because the HSUVs used in decision analytic models can 
have a substantial impact on the cost-effectiveness of the assessed invention [10].  
HSUVs are cardinal values to measure patients’ health preferences, generally ranging 
between 0 and 1, where 1 represents perfect health, 0 represents death, and can be derived 
from direct measurements such as standard gamble (SG), rating scale and time trade off 
(TTO) [11], or alternatively from multi-attribute health state descriptive systems such as EQ-
5D, Quality of Well Being (QWB) [12], Health Utilities Index (HUI) [13], and SF-6D [14]. 
Particularly, EQ-5D HSUV was recommended by National Health Institute for Clinical 
Excellence (NICE) [15] and was substantially used in evaluating HSUVs in osteoporosis 
context [16-18]. The EQ-5D evaluates the health status through 243 distinct health states 
across five dimensions (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) [19], from which HSUVs can be derived based on different population 
norms.  
Evidence on osteoporotic fracture conditions have been previously discussed: Brazier et al. 
[20] and Peasgood et al. [16] conducted systematic reviews up to 2007, providing estimated 
HSUV multipliers based on empirical evidences for osteoporotic fractures. However, there 
were some discrepancies between the two studies: Peasgood’s estimates for hip fractures and 
vertebral fractures were considerably lower than that in Brazier’s review [16, 20]. 
Furthermore, neither of the previous reviews provided the HSUVs for subsequent year after 
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vertebral and wrist fracture because of limited evidence [16]. The aims of this review were 
two-fold: 1) provide summary measures of HSUVs for osteoporosis related conditions, 
including HSUVs for pre-fracture, post-hip, post-vertebral and post-wrist fractures, 
accounting for important parameters like time after fracture, age and sex; and 2) provide 
HSUVs prediction algorithms through meta-regression analyses. 
3.4  Methods 
3.4.1 Literature search 
This systematic review was conducted in line with Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [21]. A systematic search was performed 
in broad electronic database searches including 2 biomedical databases, 3 health economics 
databases, Wiley library database and Cochrane database. Biomedical databases were 
MEDLINE and Embase. Health economics databases were searched in NHS Economic 
Evaluation Database (NHS EED), Database of Abstracts of Reviews of Effects (DARE) and 
Health Technology Assessment Database (HTA).  
3.4.2 Search methods 
Both thesaurus and free-text term searches were performed to identify possible studies. The 
search strategy (Appendix 3B.1) was based on that developed by Brazier and colleagues [22]. 
The sensitive search terms ensured the search returned a wide range of potential studies. 
Furthermore, the references of the retrieved studies were hand-searched to identify any 
studies missed by electronic database searches. 
3.4.3 Study selection 
The search was performed without limitations to year of publication. Studies reporting 
osteoporosis or osteoporotic fracture-related HSUVs were included in our review. We 
included studies in languages other than English if there were sufficient data for meta-
analyses. Abstracts and working papers were also included. Health economic modelling 
studies using secondary HSUV data, i.e. HSUV that had already been reported originally 
from trials, were excluded in our study. Studies that did not provide sufficient data for meta-
analyses were also excluded. Studies reporting quality of life scores without reporting 
HSUVs, or where HSUVs could not be generated by mapping functions, were excluded. In 
addition, systematic reviews or meta-analyses were excluded. 
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3.4.4 Data extraction and management 
Study characteristics and data for meta-analyses were retrieved onto standardized data sheets 
by 2 independent reviewers. Any disagreement was resolved through discussion. The 
reviewers were not blinded to study authors, affiliations, or journal names [23]. Data 
extracted were authors and year of publication, country, number of patients, utility elicitation 
method, mean age, proportion of females and HSUV estimates. Pre-fracture HSUVs referred 
to HSUVs from osteoporosis patients without a fracture or retrospectively from patients with 
fractures evaluating the HSUV for the condition prior to the fracture event. Pre-fracture 
HSUV type was defined in terms of whether the HSUV was retrospective, i.e. recall HSUV 
collected after the fracture event. Additionally, time after fracture and whether the patients 
had fracture history were extracted for post-fracture conditions. 
3.4.5 Data analysis 
The HSUVs were pooled through meta-analyses, using random-effects models that accounted 
for both within-trial variance and between-trial heterogeneity [24]. Heterogeneity was 
assessed by I2 statistic in Cochran’s Q tests [25] which quantifies inconsistency across studies 
and describes the percentage of variability in effect estimates that is due to heterogeneity 
rather than sampling error (chance) [26]. HSUVs were weighted by the inverse of variance 
[27]. Where studies did not report standard deviations, missing data were calculated, where 
possible, using standard error and number of patients [28]. For studies that did not provide 
either the variance or standard error, the standard error was imputed from other studies that 
provided a standard deviation, using multiple imputation [29]. The number of iterations was 
the proportion of missing data [30].  
Significance of subgroups was determined by Wald test [31]. We performed subgroup 
analyses by age, sex, HSUV elicitation method and type, fracture history and country for pre-
fracture condition. For post-fracture condition, factors such as time after fracture, age, sex, 
fracture history and country were included in subgroup analyses to determine whether the 
HSUVs varied by the chosen factors. Point and interval HSUV estimates for the sum of 
coefficients were determined using linear combinations of coefficients [32]. The HSUV 
prediction model was provided using multi-variable meta-regression adjusted for covariates 
[33]. All statistical analyses were performed using STATA (STATA12.1, StataCorp LP, 
College Station, TX, USA) and statistical significance was set as a p-value equal to or less 
than 0.05 (two-tailed). 
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3.5  Results  
3.5.1 Study characteristics 
The flow chart for identifying included studies is given in Figure 3.1. Initially, the electronic 
database searches identified 9,077 tittles after duplicates were removed. There were 362 
articles and abstracts remaining after title screening. After screening by abstract and full text, 
56 articles remained. Six additional studies were identified from reference lists of retrieved 
publications.  
Finally, there were 62 studies included (Appendix 3B.2), representing 142,477 patients. A 
total of 362 HSUVs were identified from the included studies: 106 for pre-fracture, 89 for 
post-hip fractures, 130 for post-vertebral fracture and 37 for post-wrist fracture. A summary 
of characteristics of included studies is given in Appendix 3B.3. Most of the studies used EQ-
5D HSUVs, followed by visual analogue scale (VAS) and only a small number of studies 
used direct measurements. Study characteristics for pre-fracture, post-hip fracture, post-
vertebral fracture and post-wrist fracture are given in Appendix 3B.4 Table 1, 2, 3 and 4 
respectively. 
3.5.2 Imputation of standard deviations 
For the pre-fracture condition, standard deviations were available for 93 (88%) HSUVs (of 
106). The standard deviation imputations ranged from 0.10 to 0.21. For post-hip fracture, 
standard deviations were available for 78 (88%) HSUVs (of 89) and the imputations for 
missing standard deviation ranged from 0.17 to 0.26. For post-vertebral fracture, standard 
deviations were available for 79 (61%) (of 130) and the imputations ranged from 0.18 to 0.31. 
Imputation was not performed for post-wrist fracture HSUVs since there were no missing 
standard deviation data. 
3.5.3 Pooled HSUV estimates 
The pooled HSUV for the pre-fracture condition was estimated to be 0.76 (95% CI: 0.75, 
0.77), the I2 statistic in Cochran’s Q test was 0.99. For post-hip fracture, the HSUV estimate 
was 0.57 (95% CI: 0.52, 0.63, I2=1). For post-vertebral fracture, the HSUV estimate was 0.59 
(95% CI: 0.55, 0.62, I2=0.99). The pooled HSUV for post-wrist fracture was 0.72 (95% CI: 
0.67, 0.78, I2=1). 
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Figure 3.1 Flow diagram for study selection 
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3.5.4 Subgroup analyses 
Pre-fracture 
The country from which HSUVs were retrieved was found to have no influence on HSUVs 
using Wald test (p=0.80). Similarly, patients’ sex and fracture history were found to have no 
significant impact on HSUVs (p=0.11 and p=0.87 respectively) (Table 3.1). 
Table 3.1 Pre-fracture HSUVs meta-regressions 
Analysis Factor 
Coefficient estimates ** 
(95% CI) 
p-value 
HSUV estimates 
(95% CI) 
Age group (subgroup 
difference p=0.02*) 
Intercept 0.84 (0.76, 0.92) <0.001 
 
 
<60 ref. 
 
0.84 (0.76, 0.92) 
 
60-69 -0.07 (-0.15, -0.02) 0.14 0.78 (0.74, 0.81) 
 
70-79 -0.11 (-0.19, -0.02) 0.02 0.74 (0.70, 0.78) 
 
≥80 -0.11 (-0.21, -0.02) 0.02 0.73 (0.67, 0.78) 
HSUV elicitation 
method (subgroup 
difference p<0.001*) 
Intercept 0.78 (0.75, 0.80) <0.001 
 
 
EQ-5D ref. 
 
0.78 (0.75, 0.80) 
 
HUI -0.01 (-0.12, 0.10) 0.89 0.77 (0.66, 0.88) 
 
Rating scale 0.12 (-0.15, 0.26) 0.09 0.90 (0.76, 1.00) 
 
SF-36 -0.06 (-0.24, 0.13) 0.56 0.72 (0.53, 0.91) 
 
SG 0.14 (0.00, 0.28) 0.05 0.92 (0.78, 1.00) 
 
TTO -0.08 (-0.16, 0.01) 0.42 0.71 (0.62, 0.79) 
 
VAS -0.13 (-0.18, -0.08) <0.001 0.65 (0.60, 0.70) 
HSUV type (subgroup 
difference p=0.02*) 
Intercept 0.73 (0.71, 0.76) <0.001 
 
 
Not 
retrospective 
ref. 
 
0.73 (0.71, 0.76) 
 
Retrospective 0.05 (0.01, 0.09) 0.01 0.78 (0.76, 0.82) 
Country (subgroup 
difference p=0.80*) 
Intercept 0.75 (0.69, 0.81) <0.001 
 
 
Asian ref. 
 
0.75 (0.69, 0.81) 
 
Not Asian 0.01(-0.06, 0.07) 0.79 0.75 (0.73, 0.78) 
Patients' sex (subgroup 
difference p=0.11*) 
Intercept 0.74 (0.71, 0.77) <0.001 
 
 
Female ref. 
 
0.74 (0.71, 0.77) 
 
Mixed 0.03(-0.01, 0.07) 0.14 0.77 (0.74, 0.80) 
Fracture history 
(subgroup difference 
p=0.87*) 
Intercept 0.72 (0.53, 0.90) <0.001 
 
 
Not fractured ref. 
 
0.72 (0.53, 0.90) 
 Mixed 0.01(-0.28, 0.29) 0.96 0.72 (0.50, 0.94) 
HSUV, Health state utility value, HUI, Health utility index, SG, Standard gamble, TTO, Time trade-off, VAS, 
Visual analogue scale. 
*Significance of subgroup was determined by Wald test. 
** Mean difference from the reference value. 
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Mean patient age was a significant predictor of HSUVs: patients aged less than 60 years had 
a HSUV of 0.84 (95% CI: 0.76, 0.92), and HSUVs for patients aged 60 to 69 years, 70 to 79 
years and older than 80 years, were all lower than that of the reference group (differences 
were -0.07, -0.11 and -0.11 respectively). 
The HSUV elicited from the EQ-5D using population norm was 0.78 (95% CI: 0.75, 0.80). 
HSUVs derived from the EQ-5D VAS were significantly lower than that of the reference 
group: the difference was -0.13. The retrospective HSUVs were significantly higher than that 
of non-retrospective: the difference was 0.05. 
Post-hip fracture  
Time after fracture influenced HSUV for post-hip fracture condition (p<0.001): HSUV 
immediately after a fracture was estimated to be 0.31 (95% CI: 0.22, 0.39). HSUVs for 1 year 
and subsequent years after fracture were higher than that of the reference group: the 
differences were 0.29 and 0.35 respectively. Patients’ sex and whether the study was of 
patients with prevalent fractures also affected HSUVs (p=0.04 and p<0.001 respectively): 
HSUVs from a mixed population were 0.11 (p=0.04) lower than the female population. A 
population with prevalent fractures had a HSUV 0.31 lower than that of the population free 
from fracture history (p<0.001).  
HSUVs elicitation methods (p=0.10) may potentially influence HSUVs. EQ-5D VAS and 
standard gamble HSUVs were higher than the EQ-5D HSUVs generated from population 
norms, the differences were 0.15 and 0.36 respectively.  
Age group and country, however, were found to have no influence on HSUVs (p=0.32 and 
p=0.11 respectively) (Table 3.2).  
Post-vertebral fracture 
Time after fracture, patient age and patients’ sex influenced the HSUVs for the post-vertebral 
fracture condition (p<0.001, p=0.01 and p=0.001 respectively): The HSUV for immediately 
after vertebral fracture was 0.44 (95% CI: 0.37, 0.51), and HSUVs for the first year and 
subsequent years were 0.11 and 0.22 higher respectively than that of the reference group. The 
patients aged less than 70 years had higher HSUVs than patients aged 70 to 75 years and 
patients aged above 75 years, with differences of -0.14 and -0.13 respectively. The female 
population had a HSUV of 0.69 (95% CI: 0.63, 0.74), which was 0.15 higher than that of the 
mixed gender population. 
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Country and fracture history had no impact on HSUVs (p=0.54 and p=0.10). Utility 
elicitation methods may potentially affect HSUV (p=0.11), this factor was also included in 
subgroup analysis (Table 3.3). 
Post-wrist fracture 
Time after fracture, patients’ sex and fracture history affected the HSUVs for post-wrist 
fracture condition (p=0.001, p=0.03 and p=0.02 respectively): HSUV for immediately after 
fracture was 0.61 (95% CI: 0.54, 0.67), and HSUVs for first year and subsequent years were 
higher than that of the reference group: the differences were 0.17 and 0.20 respectively. The 
mixed population group had a lower HSUV than the female population, with a HSUV 
difference of -0.13. Patients with prevalent fractures were also found to have lower HSUVs 
compared with patients free from fractures (the difference was -0.13). 
HSUV elicitation method and patient age however had no influence on HSUVs (p=0.22 and 
p=0.97) (Table 3.4). 
3.5.5 HSUVs prediction models 
HSUV prediction models were given for pre-fracture, post-hip fracture, post-vertebral 
fracture and post-wrist fracture (Table 3.5) using multivariable meta-regressions. Covariates 
used in pre-fracture models were patients’ age, HSUV elicitation methods and HSUV types. 
Covariates used in post-fracture models were time after fracture, patients’ age, HSUV 
elicitation method, patients’ sex and fracture history. The explanatory powers R2 for pre-
fracture, post-hip, post-vertebral and post-wrist fracture models were 0.31, 0.63, 0.45 and 
0.56 respectively. 
Patients’ age, sex, fracture history, HSUV elicitation method and whether the HSUVs were 
retrospective did not explain heterogeneity seen between studies for all pre- and post-fracture 
HSUVs. Additionally, time after fracture did not explain heterogeneity for post-fracture 
HSUV studies. Residual heterogeneities remained high for all conditions (pre-fracture: 
I2=0.99, post-hip fracture: I2=0.98, post-vertebral fracture: I2=0.98, post-wrist fracture: 
I2=0.99). 
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Table 3.2 Post-hip fracture HSUVs meta-regressions 
Analysis Factor 
Coefficient estimates ** 
(95% CI) 
p-value 
HSUV estimates 
(95% CI) 
Time after fracture 
(subgroup 
difference p<0.001*) 
Intercept 0.31 (0.22, 0.39) <0.001 
 
 
Immediate ref. 
 
0.31 (0.22, 0.39) 
 
First year 0.29 (0.19, 0.39) <0.001 0.59 (0.54, 0.65) 
 
Subsequent years 0.35 (0.25, 0.44) <0.001 0.65 (0.60, 0.70) 
Sex (subgroup 
difference p=0.04*) 
Intercept 0.66 (0.57, 0.76) <0.001 
 
 
Female ref. 
 
0.66 (0.57, 0.76) 
 
Mixed -0.11 (-0.22, -0.01) 0.04 0.55 (0.51, 0.60) 
Fracture history 
(subgroup 
difference p=0.001*) 
Intercept 0.64 (0.61, 0.68) <0.001 
 
 
Not fractured ref. 
 
0.64 (0.61, 0.68) 
 
Mixed -0.31 (-0.39, -0.23) <0.001 0.34 (0.27, 0.40) 
HSUV elicitation 
method (subgroup 
difference p=0.10*) 
Intercept 0.51 (0.47, 0.56) <0.001 
 
 
EQ-5D ref. 
 
0.51 (0.47, 0.56) 
 
HUI 0.17 (-0.04, 0.40) 0.12 0.69 (0.47, 0.90) 
 
QWB 0.10 (-0.27, 0.46) 0.61 0.61 (0.24, 0.98) 
 
SG 0.36 (0.09, 0.63) 0.01 0.88 (0.61, 1.00) 
 
TTO 0.15 (-0.09, 0.38) 0.22 0.66 (0.43, 0.89) 
 
Rating scale 0.22 (-0.05, 0.49) 0.11 0.73 (0.47, 1.00) 
 
VAS 0.15 (0.06, 0.25) 0.002 0.67 (0.58, 0.75) 
Age group 
(subgroup 
difference p=0.32*) 
Intercept 0.50 (0.35, 0.64) <0.001 
 
 
<70 ref. 
 
0.50 (0.35, 0.64) 
 
70-74 0.14(-0.03, 0.30) 0.1 0.64 (0.56, 0.71) 
 
75-79 0.07(-0.09, 0.23) 0.38 0.57 (0.51, 0.63) 
 
≥80 0.02(-0.16, 0.20) 0.81 0.52 (0.42, 0.62) 
Country (subgroup 
difference p=0.11*) 
Intercept 0.73 (0.53, 0.92) <0.001 
 
 
Asian ref. 
 
0.73 (0.53, 0.92) 
  Not Asian -0.16(-0.36, 0.04) 0.13 0.57 (0.52, 0.61) 
HSUV, Health state utility value, HUI, Health utility index, QWB, Quality of well-being, SG, Standard gamble, 
TTO, Time trade-off, VAS, Visual analogue scale. 
*Significance of subgroup was determined by Wald test. ** Mean difference from the reference value.  
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Table 3.3 Post-vertebral fracture HSUVs meta-regressions 
Analysis Factor 
Coefficient estimates ** 
(95% CI) 
p-value
HSUV estimates 
(95% CI) 
Time after fracture 
(subgroup 
difference p<0.001*) 
Intercept 0.44 (0.37, 0.51) <0.001 
Immediate ref. 0.44 (0.37, 0.51) 
First year 0.11 (0.03, 0.20) 0.01 0.55 (0.50, 0.60) 
Subsequent years 0.22 (0.14, 0.31) <0.001 0.66 (0.62, 0.71) 
Age (subgroup 
difference p=0.01*) 
Intercept 0.69 (0.63, 0.76) <0.001 
<70 ref. 0.69 (0.63, 0.76) 
70-74 -0.14 (-0.23, -0.06) <0.001 0.55 (0.50, 0.60) 
≥75 -0.13 (-0.21, -0.04) <0.001 0.56 (0.51, 0.61) 
HSUV elicitation 
method (subgroup 
difference p=0.11*) 
Intercept 0.56 (0.53, 0.60) <0.001 
EQ-5D ref. 0.56 (0.53, 0.60) 
HUI 0.22 (0.01, 0.43) 0.04 0.78 (0.57, 0.99) 
QWB 0.09 (-0.17, 0.34) 0.5 0.65 (0.40, 0.90) 
SG 0.31 (0.05, 0.57) 0.02 0.88 (0.62, 1.00) 
TTO 0.14 (-0.01, 0.30) 0.07 0.71 (0.56, 0.86) 
Rating scale 0.23 (-0.02, 0.49) 0.08 0.80 (0.54, 1.00) 
VAS 0.01 (-0.07, 0.10) 0.74 0.58 (0.50, 0.65) 
Sex (subgroup 
difference p=0.04*) 
Intercept 0.69 (0.63, 0.74) <0.001 
Female ref. 0.69 (0.63, 0.74) 
Mixed -0.15 (-0.21, -0.08) <0.001 0.54 (0.50, 0.58) 
Country (subgroup 
difference p=0.54*) 
Intercept 0.73 (0.53, 0.92) <0.001 
Asian ref. 0.73 (0.53, 0.92) 
Not Asian -0.16(-0.36, 0.04) 0.13 0.58 (0.55, 0.62) 
Fracture history 
(subgroup 
difference p=0.10*) 
Intercept 0.64 (0.61, 0.68) <0.001 
Not fractured ref. 0.64 (0.61, 0.68) 
Mixed -0.06 (-0.12, 0.01) 0.09 0.56 (0.51, 0.60) 
HSUV, Health state utility value, HUI, Health utility index, QWB, Quality of well-being, SG, Standard gamble, 
TTO, Time trade-off, VAS, Visual analogue scale. 
*Significance of subgroup was determined by Wald test.
** Mean difference from the reference value. 
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Table 3.4 Post-wrist fracture HSUVs meta-regressions 
Analysis Factor 
Coefficient estimates ** 
(95% CI) 
p-value
HSUV estimates 
(95% CI) 
Time after fracture 
(subgroup 
difference p=0.001) 
Intercept 0.61 (0.54, 0.67) <0.001 
Immediate ref. 0.61 (0.54, 0.67) 
First year 0.17 (0.08, 0.26) <0.001 0.78 (0.72, 0.84) 
Subsequent years 0.20 (0.08, 0.33) <0.001 0.81 (0.70, 0.92) 
HSUV elicitation 
method (subgroup 
difference p=0.22*) 
Intercept 0.70 (0.65, 0.75) <0.001 
EQ-5D ref. 0.70 (0.65, 0.75) 
HUI 0.16 (-0.05, 0.37) 0.13 0.86 (0.66, 1.00) 
SG 0.17 (-0.05, 0.40) 0.13 0.87 (0.65, 1.00) 
Rating scale 0.14 (-0.07, 0.36) 0.9 0.84 (0.63, 1.00) 
VAS 0.02 (-0.28, 0.31) 0.19 0.72 (0.43, 1.00) 
Sex (subgroup 
difference p=0.03*) 
Intercept 0.81 (0.73, 0.90) <0.001 
Female ref. 0.81 (0.73, 0.90) 
Mixed -0.13 (-0.23, -0.03) 0.01 0.69 (0.63, 0.74) 
Fracture history 
(subgroup 
difference p=0.02*) 
Intercept 0.78 (0.72, 0.84) <0.001 
Not fractured ref. 0.78 (0.72, 0.84) 
Mixed -0.13 (-0.22, -0.04) 0.01 0.65 (0.59, 0.72) 
Age group 
(subgroup 
difference p=0.97*) 
Intercept 0.72 (0.66, 0.79) <0.001 
<70 ref. 0.72 (0.66, 0.79) 
≥70 0.00(-0.10, 0.10) 0.97 0.72 (0.64, 0.81) 
HSUV, Health state utility value, HUI, Health utility index, SG, Standard gamble, VAS, Visual analogue scale. 
*Significance of subgroup was determined by Wald test.
** Mean difference from the reference value. 
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Table 3.5 Multivariable meta-regressions 
Category 
Pre-fracture Post-hip fracture Post-vertebral fracture Post-wrist fracture 
Variable Coef. *** (S.E.) Variable Coef. *** (S.E.) Variable Coef. *** (S.E.) Variable Coef. *** (S.E.) 
Time after fracture Immediate NA Immediate ref. Immediate ref. Immediate ref. 
 
First year NA First year 0.25 (0.04) * First year 0.16 (0.04) * First year 0.20 (0.04) * 
 
Subsequent 
years 
NA 
Subsequent 
years 
0.27 (0.05) * 
Subsequent 
years 
0.21 (0.04) * 
Subsequent 
years 
0.25 (0.06) * 
Age <60 ref.  <70 ref. <70 ref. <70 ref. 
 
60-69 -0.05 (0.05) ** 70-74 0.04 (0.05) ** 70-74 -0.19 (0.04) * ≥70 -0.03 (0.06) ** 
 
70-79 -0.12 (0.05) * 75-79 0.06 (0.05) ** ≥75 -0.18 (0.04) * 
  
 
≥80 -0.12 (0.05) * ≥80 -0.05 (0.06) ** 
    
HSUV elicitation method EQ-5D ref. EQ-5D ref. EQ-5D ref. EQ-5D ref. 
 
VAS -0.11 (0.02) * VAS 0.04 (0.04) ** VAS -0.02 (0.03) ** VAS 0.15 (0.11) ** 
 
others -0.01 (0.02) ** others 0.15 (0.06) * others 0.22 (0.04) * others 0.17 (0.09) ** 
HSUV type 
Not 
retrospective 
ref. 
Not 
retrospective 
NA 
Not 
retrospective 
NA 
Not 
retrospective 
NA 
 
Retrospective 0.06 (0.02) * Retrospective NA Retrospective NA Retrospective NA 
Sex Female NA Female ref. Female ref. Female ref. 
 
Mixed NA Mixed 0.02 (0.12) ** Mixed 0.01 (0.07) ** Mixed 0.15 (0.33) ** 
Fracture history Not fractured  NA Not fractured  ref. Not fractured  ref. Not fractured  ref. 
 
Mixed NA Mixed -0.18 (0.04) * Mixed -0.11 (0.03) * Mixed -0.02 (0.06) ** 
Constant  0.84 (0.05)  0.34 (0.07)  0.58 (0.08)  0.44 (0.29) 
I2  0.99  0.98  0.98  0.99 
R2   0.31   0.63   0.45   0.56 
HSUV, Health state utility value, VAS, Visual analogue scale, S.E. standard error, NA, not applicable in multivariable meta-regression. 
* p<0.05, ** not significant, ***coefficient: the mean difference from Constant statistic. 
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3.6  Discussion 
To date, this is the largest meta-analysis evaluating health-related HSUVs for osteoporosis 
and osteoporotic fracture related conditions. Former reviews have provided more general 
HSUVs for osteoporotic fracture conditions, while we have determined the HSUV point and 
interval estimates, as well as HSUV prediction models for osteoporotic pre-fracture and post-
fracture conditions, which allow cost effectiveness modellers in osteoporosis contexts to 
incorporate HSUV interval estimates in probabilistic sensitivity analyses [34]. This study 
confirmed that the HSUVs for fracture conditions were lower than that for the pre-fracture 
condition [16, 20]. Furthermore, our study expanded the previous work in four ways: first, by 
including more studies, meta-regressions were performed to identify both within study 
variance and between study heterogeneities. Second, the review provides data that were not 
available in previous reviews, such as HSUVs for subsequent years after vertebral fracture; 
third, specific contributors for HSUV heterogeneities such as patient’s age, time after fracture 
and utility elicitation method were addressed through meta-regressions; and finally, HSUV 
prediction models were provided that incorporated significant covariates. 
Previously it has been assumed that there is no HSUV loss for the “osteoporosis without 
fracture” condition versus the general population [16], and our estimates confirmed this when 
comparing the age-specific HSUVs (Table 3.1) with the UK normative dataset of HSUVs for 
the general population [35]. 
Our study has shown that hip fracture had the highest impact on HSUV. However, HSUV for 
post-hip fracture improved significantly with time thereafter (Table 3.2). HSUV for first year 
post-hip fracture was even higher than that of post-vertebral facture (0.59 versus 0.55), but 
still lower than post-wrist fracture (HSUV=0.78). Interestingly, HSUVs for subsequent years 
after hip and vertebral fractures were equivalent and lower than that of post-wrist fracture 
(0.66 versus 0.81).  
A previous study suggested that retrospective HSUV would overestimate the HSUV due to 
recall bias [18]. Our findings supported this: the retrospectively reported HSUV was 0.05 
higher than what was reported at the time of fracture.  
Quality adjusted life years (QALYs) derived from HSUVs were widely used in health 
technology assessments on osteoporotic fracture preventions [5-7, 36]. Whilst different 
instruments provide varied HSUVs, EQ-5D is still preferred by NICE as the instrument for 
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calculating HSUVs for adult populations unless it was unavailable or proved inappropriate 
[37]. Standard gamble provided higher HSUVs compared with EQ-5D for all conditions. 
Similar evidence was found for other diseases such as chronic kidney disease [38] and breast 
cancer [39]. Our result suggested the HSUV elicited from the VAS was greater than that from 
the EQ-5D for the pre-fracture condition, but conversely lower for the post-hip fracture 
condition. This apparent contradiction has been discussed in a previous review [16] and has 
been supported by a number of subsequent studies [40]. Given the discrepancy of HSUVs 
from different elicitation methods evaluating the same health status, there is a need to adopt 
international standard methods, in particular the EQ-5D, to measure the utility-based quality 
of life for osteoporosis related conditions. 
Conventionally, the male study population was expected to have higher HSUVs than the 
female population, with this difference explained by socio-demographic and socio-economic 
status [41]. However, our results suggested the female study population had higher HSUVs 
than mixed population: the mixed population had 0.11, 0.15 and 0.13 lower HSUV 
comparing with that of female population. However, the differences were not significant 
when accounting for other covariates. In our analysis we were unable to perform a 
comparison between female and male HSUV due to the paucity of data on HSUV for male 
populations.  
A number of studies indicated an additional decrement in HSUVs for patients with 
prevalent/pre-existing fractures [10, 18], particularly in vertebral fracture patients [40]. Our 
findings, however, suggested that if a patient had a past history of fracture, there was a more 
dramatic impact of new hip fractures on HSUVs. The HSUV difference between patients 
with prevalent fracture and patients without prevalent fracture was -0.31 (95% CI: -0.39, -
0.23): this difference was still significant after adjusting for time after fracture. This question 
may be addressed further clarified by future analysis of patient-level data from trials such as 
the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) [18]. 
The explanatory power of the pre-fracture HSUV prediction model was weak, with an R-
squared value of 0.31. However, the post-fracture HSUV models performed fairly well, given 
an R-squared value of nearly 0.50 or greater. The reason for the weak prediction for pre-
fracture could be explained by the complexity of the pre-fracture population, since the 
population characteristics were often unknown. Treatment history, fear of falling, bone 
profile and comorbidities were potential contributors to HSUVs [42]. Accounting for these 
parameters was not feasible in aggregated level data, therefore the explanatory power for pre-
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fracture HSUV prediction was weak. 
The strengths of this review were three-fold: first, this review included 362 HSUVs from 
142,477 patients; substantially larger than in size than previous reviews [16, 20]. It completed 
the missing evidence from previous reviews [16, 20] due to the paucity of data. Second, this 
review performed meta-regression analyses that indicated HSUV disparity within the patients’ 
demographic characteristics such as sex, age and history of fracture. And third, HSUVs 
prediction algorithms were provided for pre- and post-fracture conditions. 
There were a number of limitations to this study. It was not feasible to specify the treatment 
that potentially affected patients’ HSUVs. Surgical management of osteoporotic vertebral 
fractures resulted in a higher HSUV than non-surgical management [43].Severity of fractures 
could be a contributor to HSUVs, but it was not possible to ascertain the severity of fractures 
from aggregate data. HSUV for morphometric vertebral fracture was estimated differ from 
that of fractures with clinical diagnosis [16, 44]. Similarly, hip fracture patients ending in 
nursing home tended to have lower HSUV that of patients with independent mobility [44]. 
Accordingly, patients with worse prognoses were expected to have a lower HSUV comparing 
with patients with better prognoses. A number of studies reported HSUVs at multiple time 
points after fractures [17, 18] that tended to be stochastically dependent, as they came from 
the same population. However, the HSUVs were analysed independently in our study 
ignoring the correlation between time points [45]. Finally, meta-regressions performed in this 
study were univariate meta-regressions that explored particular covariates’ contribution to 
between-study heterogeneity [33]. However, the I2 statistic was greater than 0.75 in all 
analyses which indicates considerable heterogeneity remained [26] and a large part of the 
between study variation remained unexplained by the factors we examined. It is likely that 
other variables, such as co-morbidities, severity of the fracture, that potentially affect the 
HSUVs contribute to this heterogeneity, but we were not able to assess this due to the lack of 
availability of aggregated-level data. As the development of the methodology for 
synthesizing HSUVs from multiple studies is at an early stage, the validity of apply 
conventional meta-analytic techniques to HSUV data is not well understood [22]. 
Improvements in synthesizing HSUVs will be achieved with further progress in this area. 
This study is the largest meta-analysis conducted on HSUV on osteoporotic fracture context 
with subgroup analyses performed for the first time through meta-regressions. Furthermore, 
this study provided prediction models that incorporate variables that contributed to HSUVs. 
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This study confirmed that fracture events had substantial impact on osteoporotic patients in 
terms of quality of life. Specifically, HSUVs after hip and vertebral fracture were 
dramatically decreased. Additional decrements of HSUVs were found in hip and vertebral 
fracture patients with prevalent fractures. These findings can be applied in future health 
economic evaluations investigating cost effectiveness of osteoporotic fracture preventions, 
and may also be useful for studies on cost effectiveness of post-fracture interventions aiming 
at improving the quality of life after fracture. 
3.7 Postscript 
Despite a large number of participants included in the meta-analysis, most of the included 
populations were Caucasian and therefore there is a small chance that the results might not be 
applicable to other populations. To address this concern, HSUV multipliers, which quantify 
the proportionate effect of a fracture on the baseline population HSUV were derived from this 
meta-analysis. For example, the HSUV multiplier for the first year after a hip fracture was set 
at 0.776 and this value was combined with the HSUV for the Chinese general population to 
calculate the HSUVs for the first year after a hip fracture. Using the HSUV multipliers 
enables the quantification of the effects of fractures on HSUVs and also accounts for 
Chinese-specific population HSUVs. 
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1. *Osteoporosis/ 45. or/40-44
2. *Bone Disease, Metabolic/ 46. 39 or 45
3. osteoporo$.ti 47. 31 and 46
4. or/1-3 48. 4 or 14 or 47
5. (bone adj6 densit*).ti 49. *Quality of life/
6. *Bone Density/ 50. *QALY/
7. (bone or bones).ti 51. *Health status/
8. *densitometry/ 52. *Health status indicators/
9. *Tomography, X-Ray Computed/ 53. or/49-52
10. densit*.ti 54. (quality of life).tw
11. 9 and 10 55. (life quality).tw
12. 8 or 11 56. hql.tw
13. 7 and 12 57. qol.tw
14. 5 or 6 or 13 58. (euroqol or eq 5d or eq5d).tw
15. *Colles' Fracture/ 59. qaly*.tw
16. *hip fractures/ 60. (quality adjusted life year*).tw
17. *Spinal Fractures/ 61. hye*.tw
18. *Fractures, Shoulder/ 62. (health* year* equivalent*).tw
19. or/ 15-18 63. (health utility*).tw
20. *Fractures, Bone/ 64. (hui or hui1 or hui2 or hui3).tw
21. fractur*.ti 65. (quality of wellbeing*).tw
22. or/19-21 66. (quality of well being).tw
23. colles*.ti 67. qwb.tw
24. (hip or hips).ti 68. (qald* or qale* or qtime*).tw
25. (femur adj6 neck).ti 69. (standard gambl*).tw
26. (femural adj6 neck).ti 70. (time trade off).tw
27. (spine or spinal).ti 71. (time tradeoff).tw
28. vetebra*.ti 72. tto.tw
29. *Lumbar Vertebrae/ 73. (visual analog* scale*).tw
30. or/23-29 74. (discrete choice experiment*).tw
31. 22 and 30 75. (health state* utility*).tw
32. *Estrogen Replacement Therapy/ 76. (health state* value*).tw
33. (estrogen replacement therapy).ti 77. (health state* preference*).tw
34. (oestrogen replacement therapy).ti 78. or/54-77
35. (hormone replacement therapy).ti 79. 78 or 53
36. ert.ti 80. letter.pt
37. ort.ti 81. editorial.pt
38. hrt.ti 82. comment.pt
39. or/32-38 83. or/80-82
40. *menopause/ 84. 79 not 83
41. *Climacteric/ 85. 48 and 84
42. menopaus*.ti
43. postmenopaus*.ti
44. climacteric.ti
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Category 
Pre-fracture Post-hip fracture Post-vertebral fracture Post-wrist fracture 
Variable 
Number of 
HSUVs (%) 
Variable 
Number of 
HSUVs (%) 
Variable 
Number of 
HSUVs (%) 
Variable 
Number of 
HSUVs (%) 
Time after fracture Immediate NA Immediate 14 (16%) Immediate 22 (17%) Immediate 13 (35%) 
 
First year NA First year 34 (38%) First year 45 (35%) First year 19 (51%) 
 
Subsequent years NA Subsequent years 41 (46%) Subsequent years 63 (48%) Subsequent years 5 (14%) 
Age <60 7 (7%) <70 7 (8%) <70 30 (23%) <70 23 (62%) 
 
60-69 38 (36%) 70-74 25 (28%) 70-74 52 (40%) ≥70 14 (38%) 
 
70-79 46 (43%) 75-79 42 (47%) ≥75 48 (37%) 
  
 
≥80 15 (14%) ≥80 15 (17%) 
    
HSUV elicitation 
method 
EQ-5D 73 (72%) EQ-5D 58 (65%) EQ-5D 93 (71%) EQ-5D 30 (81%) 
 
HUI 3 (3%) HUI 3 (4%) HUI 3 (2%) HUI 2 (5%) 
 
Rating scale 2 (2%) QWB 1 (1%) QWB 2 (2%) SG 2 (5%) 
 
SF-36 1 (1%) SG 2 (2%) SG 2 (2%) Rating scale 1 (4%) 
 
SG 2 (2%) TTO 3 (4%) TTO 6 (5%) VAS 2 (5%) 
 
TTO 5 (5%) Rating scale 2 (2%) Rating scale 2 (2%) 
  
 
VAS 17 (16%) VAS 20 (22%) VAS 22 (16%) 
  
HSUV type Not retrospective 60 (43%) Not retrospective NA Not retrospective NA Not retrospective NA 
 
Retrospective 46 (57%) Retrospective NA Retrospective NA Retrospective NA 
Sex Female 52 (49%) Female 17 (19%) Female 39 (30%) Female 11 (30%) 
 
Mixed 54 (51%) Mixed 72 (81%) Mixed 91 (70%) Mixed 26 (70%) 
Fracture history Not fractured 62 (59%) Not fractured 69 (78%) Not fractured 72 (55%) Not fractured 20 (54%) 
 
Mixed 44 (41%) Mixed 20 (22%) Mixed 58 (45%) Mixed 17 (46%) 
Country Asian 10 (9%) Asian 4 (5%) Asian 9 (7%) Asian 0 (0%) 
 
Not Asian 96 (91%) Not Asian 85 (95%) Not Asian 121 (93%) Not Asian 100 (100%) 
Total 
 
106 (100%) 
 
89 (100%) 
 
130 (100%) 
 
37 (100%) 
HSUV, Health state utility value, HUI, Health utility index, QWB, Quality of well-being, SG, Standard gamble, TTO, Time trade-off, VAS, Visual analogue scale 
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Studies Countries Sample size 
HSUV elicitation 
method 
Mean age Female(%) Retrospective HSUV 
Standard deviation 
of HSUV 
Gabriel 1999 US 75 TTO 76.0 100% Y 0.840 0.290 
Gabriel 1999 US 199 TTO 68.0 100% N 0.430 0.400 
Hall 1999 Australia 100 SF-36 74.3 100% N 0.720 0.070 
Oleksik 2000 Europe 302 EQ-5D 66.2 100% N 0.822 0.021 
Salkeld 2000 Australia 203 EQ-5D 83.0 100% N 0.770 NA 
Salkeld 2000 Australia 120 TTO 80.0 100% N 0.700 NA 
Salkeld 2000 Australia 120 TTO >=85 100% N 0.620 NA 
Cranney 2001 Canada 11 Rating scale 56.0 100% N 0.920 0.080 
Cranney 2001 Canada 11 SG 56.0 100% N 0.900 0.110 
Cranney 2001 Canada 11 HUI 56.0 100% N 0.800 0.100 
Cranney 2001 Canada 11 Rating scale 56.0 100% N 0.880 0.120 
Cranney 2001 Canada 11 SG 56.0 100% N 0.930 0.070 
Cranney 2001 Canada 11 HUI 56.0 100% N 0.820 0.070 
Tosteson 2001 US 199 TTO 67.4 100% N 0.910 0.216 
Tidermark 2002 Sweden 89 EQ-5D 79.9 76% Y 0.780 0.210 
Cockerill 2004 Europe 136 EQ-5D 64.1 77% N 0.825 0.160 
Cockerill 2004 Europe 136 VAS 64.1 77% N 0.699 0.215 
Blomfeldt 2005 Sweden 49 EQ-5D 79.2 82% Y 0.800 0.220 
Blomfeldt 2005 Sweden 53 EQ-5D 81.4 79% Y 0.840 0.130 
Dhillon 2005 UK 159 EQ-5D 65.0 96% N 0.650 0.280 
Dhillon 2005 UK 159 VAS 65.0 96% N 0.680 0.200 
Sawka 2005 Canada 421 HUI >65 73% N 0.690 0.270 
van Schoor 2005 
the 
Netherlands 
152 EQ-5D >65 52% N 0.800 NA 
Yoh 2005 Japan 19 EQ-5D >60 100% N 0.750 0.150 
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Studies Countries Sample size 
HSUV elicitation 
method 
Mean age Female(%) Retrospective HSUV 
Standard deviation 
of HSUV 
Borgstrom 2006 Sweden 277 EQ-5D 77.6 78% Y 0.800 0.015 
Borgstrom 2006 Sweden 81 EQ-5D 75.0 81% Y 0.730 0.031 
Borgstrom 2006 Sweden 276 EQ-5D 69.5 91% Y 0.890 0.010 
Soderqvist 2006 Sweden 163 EQ-5D 82.8 82% Y 0.640 0.290 
Salaffi 2007 Italy 244 EQ-5D 68.1 100% N 0.710 0.157 
Salaffi 2007 Italy 244 VAS 68.1 100% N 0.605 0.190 
Cooper 2008 Europe 830 EQ-5D 70.6 100% N 0.530 0.320 
Cooper 2008 Europe 830 EQ-5D 70.6 100% N 0.590 0.280 
Cooper 2008 Europe 830 EQ-5D 70.6 100% N 0.620 0.280 
Cooper 2008 Europe 843 VAS 70.6 100% N 0.559 0.188 
Cooper 2008 Europe 843 VAS 70.6 100% N 0.581 0.183 
Cooper 2008 Europe 843 VAS 70.6 100% N 0.609 0.188 
Sugeno 2008 Japan 50 EQ-5D 77.4 80% Y 0.772 0.235 
Sugeno 2008 Japan 50 VAS 77.4 80% Y 0.626 0.217 
van Schoor 2008 Europe 271 EQ-5D 66.2 100% N 0.820 0.010 
van Schoor 2008 Europe 120 EQ-5D 64.4 79% N 0.820 0.015 
Ekstrom 2009 Sweden 87 EQ-5D 82.5 75% Y 0.730 NA 
van Schoor 2009 Africa 55 EQ-5D 66.8 100% N 0.850 NA 
van Schoor 2009 Asia 37 EQ-5D 65.6 100% N 0.760 NA 
van Schoor 2009 Europe 1034 EQ-5D 65.5 100% N 0.770 NA 
van Schoor 2009 Oceania 38 EQ-5D 66.3 100% N 0.900 NA 
van Schoor 2009 S. America 1477 EQ-5D 65.9 100% N 0.840 NA 
van Schoor 2009 N. America 447 EQ-5D 65.1 100% N 0.820 NA 
Rajzbaum 2009 France 409 EQ-5D 67.0 100% N 0.770 0.200 
Rajzbaum 2009 France 409 VAS 67.0 100% N 0.723 0.143 
Adachi 2010 International 42577 EQ-5D 68.7 100% N 0.790 0.200 
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Studies Countries Sample size 
HSUV elicitation 
method 
Mean age Female(%) Retrospective HSUV 
Standard deviation 
of HSUV 
Bianchi 2010 Italy 59 EQ-5D 81.0 100% Y 0.880 0.020 
Bianchi 2010 Italy 59 VAS 81.0 100% Y 0.800 0.015 
Dennison 2010 UK 2567 EQ-5D 68.4 100% N 0.760 0.230 
Dennison 2010 UK 1512 EQ-5D 70.7 100% N 0.830 0.200 
Dimai 2010 Austria 95 EQ-5D 71.0 80.0% Y 0.800 0.026 
Dimai 2010 Austria 66 EQ-5D 71.0 80.0% Y 0.870 0.036 
Lekander 2010 Russia 184 EQ-5D 65.0 81.0% Y 0.730 0.015 
Lekander 2010 Russia 216 EQ-5D 65.0 81.0% Y 0.900 0.010 
Muraki 2010 Japan 678 EQ-5D 69.7 0.0% N 0.910 0.140 
Thomas 2010 France 42 EQ-5D 72.0 82.0% Y 0.650 0.046 
Thomas 2010 France 85 EQ-5D 72.0 82.0% Y 0.800 0.026 
Togawa 2010 Japn 30 EQ-5D 78.0 87.5% Y 0.907 NA 
Togawa 2010 Japn 10 EQ-5D 78.0 87.5% Y 0.736 NA 
Adami 2011 Italy 34 EQ-5D 72.9 90.5% N 0.610 0.290 
Adami 2011 Italy 37 VAS 72.9 90.5% N 0.545 0.230 
Aloumanis 2011 Greece 301 VAS 69.5 100% N 0.540 0.250 
Aloumanis 2011 Greece 275 VAS 69.5 100% N 0.800 0.190 
Chico 2012  Mexico 452 EQ-5D 71.8 86% Y 0.680 0.310 
Chico 2012  Mexico 452 VAS 71.8 86% Y 0.794 0.185 
Nakamura 2012 Japan 1069 EQ-5D 73.5 100% N 0.706 0.199 
Nakamura 2012 Japan 1069 VAS 73.5 100% N 0.637 0.193 
Nakamura 2012 Japan 1069 EQ-5D 73.5 100% N 0.780 0.189 
Nakamura 2012 Japan 1069 EQ-5D 73.5 100% N 0.804 0.192 
Tadic 2012 Serbia 50 EQ-5D 63.0 100% N 0.580 0.200 
Tadic 2012 Serbia 50 VAS 63.0 100% N 0.505 0.232 
Voigt 2012 Germany 95 VAS 60.9 0% N 0.745 0.178 
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Studies Countries Sample size 
HSUV elicitation 
method 
Mean age Female(%) Retrospective HSUV 
Standard deviation 
of HSUV 
Yoh 2012 Japan 491 EQ-5D 70.7 100% N 0.700 0.170 
Yoh 2012 Japan 389 EQ-5D 70.7 100% N 0.760 0.160 
Yoh 2012 Japan 303 EQ-5D 70.7 100% N 0.770 0.170 
Borgstrom 2013 Austria 266 EQ-5D 76.2 76% Y 0.750 0.015 
Borgstrom 2013 Spain 46 EQ-5D 80.4 78% Y 0.660 0.056 
Borgstrom 2013 France 197 EQ-5D 76.7 78% Y 0.790 0.015 
Borgstrom 2013 Italy 112 EQ-5D 79.4 96% Y 0.850 0.020 
Borgstrom 2013 Lithuania 34 EQ-5D 74.9 79% Y 0.800 0.026 
Borgstrom 2013 Mexico 44 EQ-5D 78.8 82% Y 0.640 0.046 
Borgstrom 2013 Russia 219 EQ-5D 68.9 70% Y 0.710 0.015 
Borgstrom 2013 Sweden 355 EQ-5D 77.5 79% Y 0.800 0.015 
Borgstrom 2013 Austria 113 EQ-5D 67.9 92% Y 0.860 0.015 
Borgstrom 2013 Australia 50 EQ-5D 68.1 86% Y 0.910 0.026 
Borgstrom 2013 France 168 EQ-5D 68.4 90% Y 0.830 0.015 
Borgstrom 2013 Italy 30 EQ-5D 75.0 96% Y 0.940 0.020 
Borgstrom 2013 Russia 202 EQ-5D 62.6 86% Y 0.880 0.010 
Borgstrom 2013 Sweden 390 EQ-5D 69.2 92% Y 0.900 0.010 
Borgstrom 2013 USA 34 EQ-5D 69.3 82% Y 0.870 0.031 
Borgstrom 2013 Austria 71 EQ-5D 72.5 79% Y 0.780 0.036 
Borgstrom 2013 France 76 EQ-5D 72.1 72% Y 0.660 0.041 
Borgstrom 2013 Italy 47 EQ-5D 72.7 98% Y 0.930 0.026 
Borgstrom 2013 Russia 197 EQ-5D 67.8 89% Y 0.790 0.015 
Borgstrom 2013 Sweden 120 EQ-5D 76.5 80% Y 0.740 0.020 
Borgstrom 2013 USA 37 EQ-5D 75.8 73% Y 0.750 0.041 
Buecking 2013 Germany 350 EQ-5D 81.0 27% Y 0.710 0.290 
Buecking 2013 Germany 350 VAS 81.0 27% Y 0.570 0.230 
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Studies Countries Sample size 
HSUV elicitation 
method 
Mean age Female(%) Retrospective HSUV 
Standard deviation 
of HSUV 
Guillemin 2013 International 1143 EQ-5D 45-54 100% N 0.810 0.230 
Guillemin 2013 International 2638 EQ-5D 55-64 100% N 0.780 0.250 
Guillemin 2013 International 2366 EQ-5D 65-74 40.0% N 0.740 0.260 
Guillemin 2013 International 1686 EQ-5D >=75 40.0% N 0.670 0.290 
HSUV, Health state utility value, HUI, Health utility index, SG, Standard gamble, TTO, Time trade-off, VAS, Visual analogue scale 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Cranney 2001 Canada 10 rating scale 79.5 100% 0% 0 0.710 0.110 
Cranney 2001 Canada 10 SG 79.5 100% 0% 0 0.910 0.120 
Cranney 2001 Canada 10 HUI 79.5 100% 0% 0 0.670 0.120 
Borgstrom 2006 Sweden 277 EQ-5D 77.6 78% 23% 0 0.180 0.015 
Sugeno 2008 Japan 50 EQ-5D 77.4 80% 0% 0 0.669 0.205 
Sugeno 2008 Japan 50 VAS 77.4 80% 0% 0 0.641 0.220 
Borgstrom 2013 Austria 266 EQ-5D 76.20 76% 19% 0 0.190 0.250 
Borgstrom 2013 Spain 46 EQ-5D 80.40 78% 33% 0 0.030 0.104 
Borgstrom 2013 France 197 EQ-5D 76.70 78% 19% 0 0.090 0.215 
Borgstrom 2013 Italy 112 EQ-5D 79.40 96% 15% 0 0.040 0.162 
Borgstrom 2013 Lithuania 34 EQ-5D 74.90 79% 9% 0 0.010 0.030 
Borgstrom 2013 Mexico 44 EQ-5D 78.80 82% 9% 0 0.010 0.068 
Borgstrom 2013 Russia 219 EQ-5D 68.90 70% 25% 0 0.030 0.151 
Borgstrom 2013 Sweden 355 EQ-5D 77.50 79% 22% 0 0.180 0.192 
Gabriel 1999 US 37 HUI 76 100% 0% 36 0.680 0.180 
Gabriel 1999 US 37 QWB 76 100% 0% 36 0.610 0.080 
Gabriel 1999 US 37 VAS 76 100% 0% 36 0.720 0.160 
Gabriel 1999 US 37 TTO 76 100% 0% 36 0.700 0.410 
Cranney 2001 Canada 10 rating scale 79.5 100% 0% 2 0.760 0.180 
Cranney 2001 Canada 10 SG 79.5 100% 0% 2 0.840 0.180 
Cranney 2001 Canada 10 HUI 79.5 100% 0% 2 0.710 0.090 
Tosteson 2001 US 35 TTO 80.3 100% 0% 18 0.480 0.483 
Tosteson 2001 US 32 TTO 80.3 100% 0% 24 0.790 0.375 
Tidermark 2002 Sweden 71 EQ-5D 79.90 76% 0% 0.25 0.440 0.330 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Tidermark 2002 Sweden 79 EQ-5D 79.90 76% 0% 4 0.550 0.370 
Tidermark 2002 Sweden 69 EQ-5D 79.90 76% 0% 17 0.510 0.360 
Zethraeus 2002 Sweden 86 EQ-5D 75 62% 0% 0.5 0.420 0.320 
Zethraeus 2002 Sweden 65 EQ-5D 75 62% 0% 6 0.640 0.270 
Zethraeus 2002 Sweden 58 EQ-5D 75 62% 0% 9 0.600 0.310 
Zethraeus 2002 Sweden 46 EQ-5D 75 62% 0% 12 0.580 0.310 
Zethraeus 2002 Sweden 82 VAS 75 62% 0% 0.5 0.540 0.200 
Zethraeus 2002 Sweden 66 VAS 75 62% 0% 6 0.640 0.210 
Zethraeus 2002 Sweden 55 VAS 75 62% 0% 9 0.620 0.230 
Zethraeus 2002 Sweden 44 VAS 75 62% 0% 12 0.640 0.230 
Tidermark 2003 Sweden 10 EQ-5D 73.4 30% 0% 38 0.620 0.264 
Blomfeldt 2005 Sweden 49 EQ-5D 79.20 82% 0% 4 0.730 NA 
Blomfeldt 2005 Sweden 53 EQ-5D 81.40 79% 0% 4 0.600 NA 
Blomfeldt 2005 Sweden 49 EQ-5D 79.20 82% 0% 12 0.730 NA 
Blomfeldt 2005 Sweden 53 EQ-5D 81.40 79% 0% 12 0.630 NA 
Blomfeldt 2005 Sweden 49 EQ-5D 79.20 82% 0% 24 0.700 NA 
Blomfeldt 2005 Sweden 53 EQ-5D 81.40 79% 0% 24 0.640 NA 
Blomfeldt 2005 Sweden 34 EQ-5D 79.20 82% 0% 48 0.620 0.310 
Blomfeldt 2005 Sweden 21 EQ-5D 81.40 79% 0% 48 0.520 0.400 
Borgstrom 2006 Sweden 277 EQ-5D 77.6 78% 23% 4 0.620 0.015 
Borgstrom 2006 Sweden 277 EQ-5D 77.6 78% 23% 12 0.670 0.015 
Jakob 2006 Europe 1309 EQ-5D 71.2 100% 0% 14.5 0.470 0.340 
Jakob 2006 Europe 1309 VAS 71.2 100% 0% 14.5 0.521 0.192 
Jakob 2006 Europe 1005 EQ-5D 69 100% 0% 15.8 0.530 0.320 
Jakob 2006 Europe 1005 VAS 69 100% 0% 15.8 0.563 0.191 
Soderqvist 2006 Sweden 163 EQ-5D 82.80 82% 0% 4 0.430 NA 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Soderqvist 2006 Sweden 163 EQ-5D 82.80 82% 0% 12 0.490 NA 
Sugeno 2008 Japan 50 EQ-5D 77.4 80% 0% 12 0.807 0.166 
Sugeno 2008 Japan 50 VAS 77.4 80% 0% 12 0.796 0.168 
Ekstrom 2009 Sweden 87 EQ-5D 82.50 75% 0% 4 0.530 NA 
Ekstrom 2009 Sweden 87 EQ-5D 82.50 75% 0% 12 0.530 NA 
Ekstrom 2009 Sweden 87 EQ-5D 82.50 75% 0% 24 0.520 NA 
Adachi 2010 International 1074 EQ-5D 68.66 100% 0% 18 0.640 0.300 
Lekander 2010 Russia 184 EQ-5D 65.00 81% 25% 12 0.510 0.026 
Adachi 2011 International 1005 EQ-5D 74.41 76.7% 0.0% 3 0.580 0.317 
Adachi 2011 International 1005 EQ-5D 74.59 75.5% 0.0% 3 0.570 0.317 
Adachi 2011 International 996 VAS 74.41 76.7% 0.0% 3 0.658 0.177 
Adachi 2011 International 1002 VAS 74.59 75.5% 0.0% 3 0.657 0.184 
Adachi 2011 International  808 VAS 74.41 76.7% 0.0% 6 0.715 0.151 
Adachi 2011 International  775 VAS 74.59 75.5% 0.0% 6 0.718 0.150 
Adachi 2011 International  738 VAS 74.41 76.7% 0.0% 12 0.740 0.158 
Adachi 2011 International  711 VAS 74.59 75.5% 0.0% 12 0.733 0.157 
Adachi 2011 International  450 VAS 74.41 76.7% 0.0% 24 0.748 0.168 
Adachi 2011 International  413 VAS 74.59 75.5% 0.0% 24 0.725 0.169 
Adachi 2011 International  101 VAS 74.41 76.7% 0.0% 36 0.716 0.204 
Adachi 2011 International  83 VAS 74.59 75.5% 0.0% 36 0.707 0.189 
Adachi 2011 International  814 EQ-5D 74.41 76.7% 0.0% 6 0.700 0.285 
Adachi 2011 International  781 EQ-5D 74.59 75.5% 0.0% 6 0.690 0.279 
Adachi 2011 International  742 EQ-5D 74.41 76.7% 0.0% 12 0.740 0.272 
Adachi 2011 International  715 EQ-5D 74.59 75.5% 0.0% 12 0.710 0.267 
Adachi 2011 International  457 EQ-5D 74.41 76.7% 0.0% 24 0.730 0.214 
Adachi 2011 International  427 EQ-5D 74.59 75.5% 0.0% 24 0.720 0.207 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Adachi 2011 International 100 EQ-5D 74.41 76.7% 0.0% 36 0.660 0.300 
Adachi 2011 International 83 EQ-5D 74.59 75.5% 0.0% 36 0.690 0.273 
McDonough 2012 US 42 EQ-5D 68.1 72% 0% 36 0.780 0.150 
Borgstrom 2013 Austria 266 EQ-5D 76.20 76% 19% 4 0.650 0.333 
Borgstrom 2013 Spain 46 EQ-5D 80.40 78% 33% 4 0.640 0.208 
Borgstrom 2013 France 197 EQ-5D 76.70 78% 19% 4 0.570 0.286 
Borgstrom 2013 Italy 112 EQ-5D 79.40 96% 15% 4 0.450 0.270 
Borgstrom 2013 Lithuania 34 EQ-5D 74.90 79% 9% 4 0.360 0.268 
Borgstrom 2013 Mexico 44 EQ-5D 78.80 82% 9% 4 0.460 0.305 
Borgstrom 2013 Russia 219 EQ-5D 68.90 70% 25% 4 0.430 0.378 
Borgstrom 2013 Sweden 355 EQ-5D 77.50 79% 22% 4 0.620 0.288 
Buecking 2013 Germany 277 EQ-5D 81 27% 0% 0.5 0.460 0.330 
Buecking 2013 Germany 277 VAS 81 27% 0% 0.5 0.530 0.200 
HSUV, Health state utility value, HUI, Health utility index, QWB, Quality of well-being, SG, Standard gamble, TTO, Time trade-off, VAS, Visual analogue scale 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Cranney 2001 Canada 10 rating scale 79.5 100% 0% 0 0.710 0.110 
Cranney 2001 Canada 10 SG 79.5 100% 0% 0 0.910 0.120 
Cranney 2001 Canada 10 HUI 79.5 100% 0% 0 0.670 0.120 
Borgstrom 2006 Sweden 277 EQ-5D 77.6 78% 23% 0 0.180 0.015 
Sugeno 2008 Japan 50 EQ-5D 77.4 80% 0% 0 0.669 0.205 
Sugeno 2008 Japan 50 VAS 77.4 80% 0% 0 0.641 0.220 
Borgstrom 2013 Austria 266 EQ-5D 76.20 76% 19% 0 0.190 0.250 
Borgstrom 2013 Spain 46 EQ-5D 80.40 78% 33% 0 0.030 0.104 
Borgstrom 2013 France 197 EQ-5D 76.70 78% 19% 0 0.090 0.215 
Borgstrom 2013 Italy 112 EQ-5D 79.40 96% 15% 0 0.040 0.162 
Borgstrom 2013 Lithuania 34 EQ-5D 74.90 79% 9% 0 0.010 0.030 
Borgstrom 2013 Mexico 44 EQ-5D 78.80 82% 9% 0 0.010 0.068 
Borgstrom 2013 Russia 219 EQ-5D 68.90 70% 25% 0 0.030 0.151 
Borgstrom 2013 Sweden 355 EQ-5D 77.50 79% 22% 0 0.180 0.192 
Gabriel 1999 US 37 HUI 76 100% 0% 36 0.680 0.180 
Gabriel 1999 US 37 QWB 76 100% 0% 36 0.610 0.080 
Gabriel 1999 US 37 VAS 76 100% 0% 36 0.720 0.160 
Gabriel 1999 US 37 TTO 76 100% 0% 36 0.700 0.410 
Cranney 2001 Canada 10 rating scale 79.5 100% 0% 2 0.760 0.180 
Cranney 2001 Canada 10 SG 79.5 100% 0% 2 0.840 0.180 
Cranney 2001 Canada 10 HUI 79.5 100% 0% 2 0.710 0.090 
Tosteson 2001 US 35 TTO 80.3 100% 0% 18 0.480 0.483 
Tosteson 2001 US 32 TTO 80.3 100% 0% 24 0.790 0.375 
Tidermark 2002 Sweden 71 EQ-5D 79.90 76% 0% 0.25 0.440 0.330 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Tidermark 2002 Sweden 79 EQ-5D 79.90 76% 0% 4 0.550 0.370 
Tidermark 2002 Sweden 69 EQ-5D 79.90 76% 0% 17 0.510 0.360 
Zethraeus 2002 Sweden 86 EQ-5D 75 62% 0% 0.5 0.420 0.320 
Zethraeus 2002 Sweden 65 EQ-5D 75 62% 0% 6 0.640 0.270 
Zethraeus 2002 Sweden 58 EQ-5D 75 62% 0% 9 0.600 0.310 
Zethraeus 2002 Sweden 46 EQ-5D 75 62% 0% 12 0.580 0.310 
Zethraeus 2002 Sweden 82 VAS 75 62% 0% 0.5 0.540 0.200 
Zethraeus 2002 Sweden 66 VAS 75 62% 0% 6 0.640 0.210 
Zethraeus 2002 Sweden 55 VAS 75 62% 0% 9 0.620 0.230 
Zethraeus 2002 Sweden 44 VAS 75 62% 0% 12 0.640 0.230 
Tidermark 2003 Sweden 10 EQ-5D 73.4 30% 0% 38 0.620 0.264 
Blomfeldt 2005 Sweden 49 EQ-5D 79.20 82% 0% 4 0.730 NA 
Blomfeldt 2005 Sweden 53 EQ-5D 81.40 79% 0% 4 0.600 NA 
Blomfeldt 2005 Sweden 49 EQ-5D 79.20 82% 0% 12 0.730 NA 
Blomfeldt 2005 Sweden 53 EQ-5D 81.40 79% 0% 12 0.630 NA 
Blomfeldt 2005 Sweden 49 EQ-5D 79.20 82% 0% 24 0.700 NA 
Blomfeldt 2005 Sweden 53 EQ-5D 81.40 79% 0% 24 0.640 NA 
Blomfeldt 2005 Sweden 34 EQ-5D 79.20 82% 0% 48 0.620 0.310 
Blomfeldt 2005 Sweden 21 EQ-5D 81.40 79% 0% 48 0.520 0.400 
Borgstrom 2006 Sweden 277 EQ-5D 77.6 78% 23% 4 0.620 0.015 
Borgstrom 2006 Sweden 277 EQ-5D 77.6 78% 23% 12 0.670 0.015 
Jakob 2006 Europe 1309 EQ-5D 71.2 100% 0% 14.5 0.470 0.340 
Jakob 2006 Europe 1309 VAS 71.2 100% 0% 14.5 0.521 0.192 
Jakob 2006 Europe 1005 EQ-5D 69 100% 0% 15.8 0.530 0.320 
Jakob 2006 Europe 1005 VAS 69 100% 0% 15.8 0.563 0.191 
Soderqvist 2006 Sweden 163 EQ-5D 82.80 82% 0% 4 0.430 NA 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Soderqvist 2006 Sweden 163 EQ-5D 82.80 82% 0% 12 0.490 NA 
Sugeno 2008 Japan 50 EQ-5D 77.4 80% 0% 12 0.807 0.166 
Sugeno 2008 Japan 50 VAS 77.4 80% 0% 12 0.796 0.168 
Ekstrom 2009 Sweden 87 EQ-5D 82.50 75% 0% 4 0.530 NA 
Ekstrom 2009 Sweden 87 EQ-5D 82.50 75% 0% 12 0.530 NA 
Ekstrom 2009 Sweden 87 EQ-5D 82.50 75% 0% 24 0.520 NA 
Adachi 2010 International 1074 EQ-5D 68.66 100% 0% 18 0.640 0.300 
Lekander 2010 Russia 184 EQ-5D 65.00 81% 25% 12 0.510 0.026 
Adachi 2011 International 1005 EQ-5D 74.41 76.7% 0.0% 3 0.580 0.317 
Adachi 2011 International 1005 EQ-5D 74.59 75.5% 0.0% 3 0.570 0.317 
Adachi 2011 International 996 VAS 74.41 76.7% 0.0% 3 0.658 0.177 
Adachi 2011 International 1002 VAS 74.59 75.5% 0.0% 3 0.657 0.184 
Adachi 2011 International 808 VAS 74.41 76.7% 0.0% 6 0.715 0.151 
Adachi 2011 International 775 VAS 74.59 75.5% 0.0% 6 0.718 0.150 
Adachi 2011 International 738 VAS 74.41 76.7% 0.0% 12 0.740 0.158 
Adachi 2011 International 711 VAS 74.59 75.5% 0.0% 12 0.733 0.157 
Adachi 2011 International 450 VAS 74.41 76.7% 0.0% 24 0.748 0.168 
Adachi 2011 International 413 VAS 74.59 75.5% 0.0% 24 0.725 0.169 
Adachi 2011 International 101 VAS 74.41 76.7% 0.0% 36 0.716 0.204 
Adachi 2011 International 83 VAS 74.59 75.5% 0.0% 36 0.707 0.189 
Adachi 2011 International 814 EQ-5D 74.41 76.7% 0.0% 6 0.700 0.285 
Adachi 2011 International 781 EQ-5D 74.59 75.5% 0.0% 6 0.690 0.279 
Adachi 2011 International 742 EQ-5D 74.41 76.7% 0.0% 12 0.740 0.272 
Adachi 2011 International 715 EQ-5D 74.59 75.5% 0.0% 12 0.710 0.267 
Adachi 2011 International 457 EQ-5D 74.41 76.7% 0.0% 24 0.730 0.214 
Adachi 2011 International 427 EQ-5D 74.59 75.5% 0.0% 24 0.720 0.207 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard 
deviation of HSUV 
Adachi 2011 International 100 EQ-5D 74.41 76.7% 0.0% 36 0.660 0.300 
Adachi 2011 International 83 EQ-5D 74.59 75.5% 0.0% 36 0.690 0.273 
McDonough 2012 US 42 EQ-5D 68.1 72% 0% 36 0.780 0.150 
Borgstrom 2013 Austria 266 EQ-5D 76.20 76% 19% 4 0.650 0.333 
Borgstrom 2013 Spain 46 EQ-5D 80.40 78% 33% 4 0.640 0.208 
Borgstrom 2013 France 197 EQ-5D 76.70 78% 19% 4 0.570 0.286 
Borgstrom 2013 Italy 112 EQ-5D 79.40 96% 15% 4 0.450 0.270 
Borgstrom 2013 Lithuania 34 EQ-5D 74.90 79% 9% 4 0.360 0.268 
Borgstrom 2013 Mexico 44 EQ-5D 78.80 82% 9% 4 0.460 0.305 
Borgstrom 2013 Russia 219 EQ-5D 68.90 70% 25% 4 0.430 0.378 
Borgstrom 2013 Sweden 355 EQ-5D 77.50 79% 22% 4 0.620 0.288 
Buecking 2013 Germany 277 EQ-5D 81 27% 0% 0.5 0.460 0.330 
Buecking 2013 Germany 277 VAS 81 27% 0% 0.5 0.530 0.200 
HSUV, Health state utility value, HUI, Health utility index, QWB, Quality of well-being, SG, Standard gamble, TTO, Time trade-off, VAS, Visual analogue scale 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard deviation 
of HSUV 
Dolan 1999 UK 50 EQ-5D 71.5 100% 0% 0 0.539 0.162 
Dolan 1999 UK 50 VAS 71.5 100% 0% 0 0.716 0.091 
Cranney 2001 Canada 11 rating scale 68.0 100% 0% 0 0.840 0.110 
Cranney 2001 Canada 11 SG 68.0 100% 0% 0 0.870 0.190 
Cranney 2001 Canada 11 HUI 68.0 100% 0% 0 0.860 0.060 
Borgstrom 2006 Sweden 276 EQ-5D 69.5 91% 14% 0 0.560 0.015 
Borgstrom 2013 Austria 113 EQ-5D 67.9 92% 18% 0 0.490 0.011 
Borgstrom 2013 Australia 50 EQ-5D 68.1 86% 12% 0 0.610 0.011 
Borgstrom 2013 France 168 EQ-5D 68.4 90% 16% 0 0.370 0.008 
Borgstrom 2013 Italy 30 EQ-5D 75.0 96% 7% 0 0.460 0.015 
Borgstrom 2013 Russia 202 EQ-5D 62.6 86% 40% 0 0.450 0.013 
Borgstrom 2013 Sweden 390 EQ-5D 69.2 92% 13% 0 0.560 0.006 
Borgstrom 2013 USA 34 EQ-5D 69.3 82% 44% 0 0.640 0.034 
Dolan 1999 UK 50 EQ-5D 71.5 100% 0% 1.6 0.925 0.097 
Dolan 1999 UK 50 EQ-5D 71.5 100% 0% 1.6 0.908 0.063 
Cranney 2001 Canada 11 rating scale 68.0 100% 0% 2 0.840 0.110 
Cranney 2001 Canada 11 SG 68.0 100% 0% 2 0.870 0.190 
Cranney 2001 Canada 11 HUI 68.0 100% 0% 2 0.860 0.060 
Zethraeus 2002 Sweden 126 EQ-5D 72.0 88% 0% 0.5 0.540 0.270 
Zethraeus 2002 Sweden 103 EQ-5D 72.0 88% 0% 6 0.760 0.220 
Zethraeus 2002 Sweden 92 EQ-5D 72.0 88% 0% 9 0.810 0.210 
Zethraeus 2002 Sweden 80 EQ-5D 72.0 88% 0% 12 0.820 0.200 
Zethraeus 2002 Sweden 132 EQ-5D 72.0 88% 0% 0.5 0.640 0.220 
Zethraeus 2002 Sweden 114 EQ-5D 72.0 88% 0% 6 0.730 0.200 
Zethraeus 2002 Sweden 95 EQ-5D 72.0 88% 0% 9 0.760 0.180 
Zethraeus 2002 Sweden 83 EQ-5D 72.0 88% 0% 12 0.760 0.200 
Borgstrom 2006 Sweden 276 EQ-5D 69.5 91% 14% 4 0.820 0.010 
Borgstrom 2006 Sweden 276 EQ-5D 69.5 91% 14% 12 0.860 0.010 
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Studies Countries 
Sample 
size 
HSUV elicitation 
method 
Mean age Female (%) 
Recurrent 
fractures (%) 
Time after 
fracture (months) 
HSUV 
Standard deviation 
of HSUV 
Adachi 2010 International 4825 EQ-5D 68.7 100% 0% NA 0.730 0.300 
McDonough 2012 US 153 EQ-5D 68.1 72% 0% NA 0.880 0.070 
Borgstrom 2013 Austria 113 EQ-5D 67.9 92% 18% 4 0.760 0.217 
Borgstrom 2013 Australia 50 EQ-5D 68.1 86% 12% 4 0.780 0.216 
Borgstrom 2013 France 168 EQ-5D 68.4 90% 16% 4 0.700 0.198 
Borgstrom 2013 Italy 30 EQ-5D 75.0 96% 7% 4 0.780 0.279 
Borgstrom 2013 Russia 202 EQ-5D 62.6 86% 40% 4 0.810 0.218 
Borgstrom 2013 Sweden 390 EQ-5D 69.2 92% 13% 4 0.830 0.202 
Borgstrom 2013 USA 34 EQ-5D 69.3 82% 44% 4 0.680 0.268 
HSUV, Health state utility value, HUI, Health utility index, SG, Standard gamble, VAS, Visual analogue scale 
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Chapter 4: Screening for and treatment of osteoporosis: 
construction and validation of a state-transition 
microsimulation cost-effectiveness model 
4.1  Preface 
This chapter documents an osteoporosis state-transition microsimulation model of 
osteoporosis-related fractures. Model validity is assessed in three facets: face, internal and 
external validity. This model is validated in the Chinese population, but is flexible enough to 
be adapted to other jurisdictions using country- and population-specific epidemiological and 
health economics data. It will be used as an important tool for researchers and policy makers 
to evaluate the cost-effectiveness of different osteoporosis screening and treatment strategies.  
This chapter has been published in Osteoporosis International (Appendix 4A). 
Impact factor: 4.17. 
Si L, Winzenberg TM, Jiang Q, Palmer AJ. Screening for and treatment of osteoporosis: 
construction and validation of a state-transition microsimulation cost-effectiveness model. 
Osteoporosis international, May 2015. 26(5): 1477-89. 
The published article of this 
chapter appears in an appendix to 
the chapter. It has been removed 
for copyright or proprietary 
reasons.
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4.2  Abstract 
Introduction: The objective of this study was to document and validate a new cost-
effectiveness model of screening for and treatment of osteoporosis. 
Methods: A state-transition microsimulation model using a lifetime horizon was constructed 
with seven Markov states (no history of fractures, hip fracture, vertebral fracture, wrist fracture, 
other fracture, post-fracture state and death) describing the most important clinical outcomes 
of osteoporotic fractures. Tracker variables were used to record patients’ history, such as 
fracture events, duration of treatment, time-since-last-screening. The model was validated for 
Chinese post-menopausal women receiving screening and treatment versus no screening. 
Goodness-of-fit analyses were performed for internal and external validation. External validity 
was tested by comparing life expectancy, osteoporosis prevalence rate, lifetime and 10-year 
fracture risks with published data not used in the model. 
Results: The model represents major clinical facets of osteoporosis-related conditions. Age-
specific hip, vertebral and wrist fracture incidence rates were accurately reproduced (the 
regression line slope was 0.996, R2=0.99). The changes in costs, effectiveness and cost-
effectiveness were consistent with changes in both one-way and probabilistic sensitivity 
analysis. The model predicted life expectancy and 10-year any major osteoporotic fracture risk 
at the age of 65 of 19.01 years and 13.7% respectively. The lifetime hip, clinical vertebral and 
wrist fracture risks at age 50 were 7.9%, 29.8% and 18.7% respectively, all consistent with 
reported data. 
Conclusions: Our model demonstrated good internal and external validity, ensuring it can be 
confidently applied in economic evaluations of osteoporosis screening and treatment strategies. 
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4.3  Introduction 
Osteoporosis and osteoporotic fractures are of significant concern to patients and broadly to 
the society [1-3]. To date, several treatments are effective in preventing osteoporotic fractures 
[1]. However, the costs of osteoporotic fractures are substantial [4]. Osteoporosis challenges 
the sustainability of the healthcare system with rapidly ageing population in much of the world 
[2], making it essential to accurately assess the cost-effectiveness of different approaches to its 
prevention, screening and treatment.  
Health economic evaluations are performed using randomized controlled trial data and/or using 
decision analytic modelling [5]. Evaluation solely based on randomized controlled trial (RCT) 
data is often limited to intermediate clinical endpoints and by short duration of follow-up that 
may not be long enough to capture all relevant health economics outcomes. As an alternative, 
health economic evaluations are performed with decision analytic modelling that extrapolates 
the RCT data to a longer period of follow-up.  
Decision analytic modelling studies have been performed extensively in the field of 
osteoporosis in the past decades [6-13]. The quality of osteoporosis models has improved with 
time [10, 11], but inevitably they were constructed with some limitations due to use of less 
advanced modelling techniques or out-of-date input data [10]. The objective of this study was 
to develop and validate a new osteoporosis decision analytic model for the assessment of cost-
effectiveness of osteoporosis screening and treatment strategies. 
4.4  Methods 
4.4.1 Model structure 
This cost-effectiveness model is an individual-level state-transition model. Cost-effectiveness 
is analysed over a life-time horizon, but may be varied according to perspective. Both costs 
and effectiveness were discounted at 3% annually and were changeable according to country-
specific pharmacoeconomic guidelines. The model had a 1-year cycle length and ran until death 
of simulated subjects. Construction and validation of the model were performed using TreeAge 
Pro Suite 2014 (TreeAge Software, Williamstown, Massachusetts). 
Osteoporosis is a chronic disease with a number of consequences: patients simulated in the 
model are either alive or dead. Alive patients could stay without any fracture for the entire life 
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(represented as “no history of fracture”), or sustain a fracture (represented as “fractured”), or 
stay in post-fracture state (represented as “post-fracture”), or sustain another fracture 
(represented as “fractured”). Therefore a Markov approach was used in our model so as to be 
able to incorporate multiple disease states (Figure 4.1). Most fragility fractures occur in hip 
(proximal femur), vertebrae (spine) and wrist (distal radius), though they can occur in “other” 
sites such as humerus, pelvis, ribs and shoulder [14]. Accordingly, seven Markov states were 
included: no history of fractures, hip fracture, vertebral fracture, wrist fracture, other fracture, 
post-fracture state and death.  
Figure 4.1. Structure of the Markov model. Simulated patients can transit between Markov 
states following the arrow direction, “Fractured” is a temporary state and denotes patients 
sustaining a hip, vertebral, wrist or other osteoporotic fracture. “Death” is an absorbing state 
that indicates all simulated patients will end in that state. 
4.4.2 Model validation 
The model validation procedure followed the recommendation from the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force-7 [15] and three types 
of validities were addressed in our study: face validity, internal validity and external validity. 
Face validity is subjective and determined by clinicians who have an interest in the particular 
disease modelled. They are responsible for evaluating whether the model is constructed in 
accordance with best medical evidence. Internal validity is used to test any unintentional 
computational error and inconsistency with the model’s specifications by comparing predicted 
values with input data. External validation compares the model’s results with key outcomes 
from available published data [15].  
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For the internal validation, we modelled an osteoporosis screening strategy for Chinese post-
menopausal women comparing its cost-effectiveness with that of no screening from the 
Chinese healthcare system perspective. A willingness to pay (WTP) threshold of $20,000 per 
quality-adjusted life year (QALY) gained was set to determine whether the intervention was 
cost-effective [16]. While for this example all the data inputs referred to published Chinese 
data for validation purposes, this can be varied to country- and ethnicity-specific data in future 
applications. The input epidemiological and health economic data are summarized in Table 
4.1. 
4.4.3 Bayes’ revision 
Screening could identify undiagnosed osteoporosis and therefore prevent future fractures by 
early treatment. However, as many screening techniques are not performed with perfect 
accuracy, sensitivity and specificity of the screening strategy were accounted for using Bayes’ 
revision within the model structure. The Bayes’ revision was characterized by Bayes’ theorem 
which incorporates both prior and likelihood probabilities [17]. Revised posterior probabilities 
were adopted in the model using a built-in Bayes revision wizard in TreeAge Pro Suite 2014. 
Detailed calculations of posterior probability are elaborated in Appendix 4B.1. 
4.4.4 Memory integration 
In the model, whether a patient was screened was dependent on whether he/she sustained a 
fracture or was diagnosed with osteoporosis and whether he/she was between the rescreening 
intervals. Fracture risk depended on whether the fracture was the first fracture ever to have 
occurred, or a subsequent fracture following previous fractures. The effectiveness of 
medication (alendronate) depended on whether the patients persisted on treatment and whether 
they fully adhered to the recommended regimen. Subjects’ health-state utility value (HSUV) 
depended on fracture sites and the time since fractures had occurred. 
Tracker variables were used in our model to record patient characteristics. For example, “time 
after previous screening” and “fracture events” were used to determine whether the patient 
required a screening; “time after last fracture” and “time after diagnosis with osteoporosis” 
were used to determine the duration of treatment that contributed to determining medication 
persistence, adherence and offset time; “number of fractures” was used to determine the health-
state utility value and costs for patients with multiple fractures. Individual patient-level 
(microsimulation) using tracker variables was implemented to account for these parameters. 
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Table 4.1 Key parameters in the model 
Parameter Base-case Range for SA Distribution Source 
Osteoporosis prevalence 
50-59 years 0.035 0.028-0.042 a Triangular [28] 
60-69 years 0.142 0.114-0.170 a Triangular [28] 
70-79 years 0.268 0.214-0.322 a Triangular [28] 
  80+ years 0.392 0.314-0.470 a Triangular [28] 
Annual fracture incidence rate Table 4.2 Table 4.2 - 
RR of wrist fracture in Asians 
versus Caucasians 
0.72 0.53-1.00 Beta [32] 
Osteoporosis attribution 
probabilities for hip fractures 
50-64 years 0.75 0.20-0.85 Beta [33] 
65-84 years 0.85 0.50-0.95 Beta [33] 
  85+ years 0.95 0.60-0.95 Beta [33] 
Osteoporosis attribution 
probabilities for vertebral fractures 
50-64 years 0.75 0.40-0.80 Beta [33] 
65-84 years 0.85 0.50-0.95 Beta [33] 
  85+ years 0.95 0.60-0.95 Beta [33] 
Osteoporosis attribution 
probabilities for wrist fractures 
50-64 years 0.60 0.10-0.70 Beta [33] 
65-84 years 0.70 0.35-0.80 Beta [33] 
  85+ years 0.70 0.55-0.90 Beta [33] 
Probability of nursing home 
residency after hip fractures 
60-69 years 0.04 0.032, 0.048 a Triangular [12] 
70-79 years 0.04 0.032, 0.048 a Triangular [12] 
80-89 years 0.12 0.096-0.144 a Triangular [12] 
  90+ years 0.17 0.136-0.204 a Triangular [12] 
1-year mortality rate after hip
fracture in nursing home residence 
60-69 years 0 0-0.02 Beta [12] 
70-79 years 0.13 0.104-0.156 Beta [12] 
80-89 years 0.22 0.176-0.264 Beta [12] 
  90+ years 0.23 0.184-0.276 Beta [12] 
1-year mortality rate after hip
fracture in community-dwelling 
60-69 years 0.04 0.032-0.048 Beta [12] 
70-79 years 0.06 0.048-0.072 Beta [12] 
80-89 years 0.11 0.088-0.132 Beta [12] 
  90+ years 0.16 0.128-0.192 Beta [12] 
RR of death after vertebral fractures 1.82 1.52-2.17 Gamma [39] 
RR of death after wrist fractures 1.42 1.19-1.70 Gamma [39]
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Parameter Base-case Range for SA Distribution Source 
RR of subsequent fracture 
following a prior fracture  
    
  Hip fracture 2.0 1.9-2.2 Gamma [12] 
  Vertebral fracture 2.0 1.6- 2.4 Gamma [12] 
  Wrist fracture 1.9 1.6- 2.2 Gamma [12] 
RR of osteoporotic fracture with 
alendronate treatment 
    
  Hip fracture without prior fracture 0.44 0.31-0.57 Beta [36] 
  Hip fracture with prior fracture 0.49 0.34-0.64 Beta [35] 
  Vertebral fracture without prior 
fracture 
0.50 0.35-0.65 Beta [36] 
  Vertebral fracture with prior 
fracture 
0.53 0.37-0.69 Beta [35] 
  Wrist fracture without prior 
fracture 
0.88 0.62-1.00 Beta [36] 
  Wrist fracture with prior fracture 0.52 0.36-0.68 Beta [35] 
Medication persistence      
  First year after treatment onset 0.519 0.26-0.78 b Triangular [26] 
  Fifth year after treatment onset 0.182 0.09-0.27 b  Triangular [6] 
Treatment duration, years 5 2, 10 - Assumption 
Probability of being high adherent 
to alendronate c 
    
  First year after treatment onset 0.619 0.31-0.93 b Triangular [27] 
  Third year after treatment onset 0.479 0.24-0.72 b Triangular [27] 
Costs d     
 Average direct costs of the first 
year after fractures e 
    
  Hip fracture 6,462 3,231-9,693 b Triangular [41] 
  Vertebral fracture 4,884 2,442-7,326 b Triangular [41] 
  Wrist fracture 1,980 990-2,970 b Triangular [41] 
 Annual medication cost f 1,190 595-1,785 b Triangular [40] 
 DEXA scan  70 35-104b Triangular [40] 
 Annual nursing home  4,395 3,767-5,023 b Triangular [42,43] 
HSUVs     
  Healthy/Osteoporotic population 
without fractures g 
    
    60-64 years 0.728 0.582-0.874 a Triangular [45] 
    65-69 years 0.702 0.562-0.842 a Triangular [45] 
    70-74 years 0.685 0.548-0.822 a Triangular [45] 
    75-79 years 0.669 0.535-0.803 a Triangular [45] 
    80-84 years 0.655 0.524-0.786 a Triangular [45] 
    85+ years 0.643 0.514-0.772 a Triangular [45] 
  Hip fracture, first year h  0.776 0.720-0.844 Beta [46] 
  Hip fracture, subsequent years h 0.855 0.800-0.909 Beta [46] 
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Parameter Base-case Range for SA Distribution Source 
  Vertebral fracture, first year h 0.724 0.667-0.779 Beta [46] 
  Vertebral fracture, subsequent 
years h 
0.868 0.827-0.922 Beta [46] 
  Wrist fracture, first year h 1.000 0.960-1.000 Triangular [46] 
  Wrist fracture, subsequent years h 1.000 0.930-1.000 Triangular [46] 
  Nursing home dwelling 0.400 0.320-0.480 Triangular [12] 
Annual discount rate 
  Costs 0.03 0, 0.05 - [16]
  Effectiveness 0.03 0, 0.05 - [16]
DEXA= dual-energy x-ray absorptiometry, RR = relative risk, SA = sensitivity analysis, HSUV = health-state
utility value. 
a One-way sensitivity analysis values ±20% of base-case value. 
b One-way sensitivity analysis values  ±50% of base-case value. 
c Medication adherence is measured by medication possession ration MPR; MPR≥0.8 was defined as high 
compliance. 
d Costs are presented in 2013 US dollars. 
e Direct costs include costs of outpatient consultations, inpatient care, investigations, medication, rehabilitation 
after fracture events, physical therapy, transportation, homecare, preventive care foods and specific equipment. 
f Annual costs of oral alendronate (70 mg per week) is $1,100, annual cost of calcium (600mg per tablet) and 
vitamin D3 (125 IU per tablet) is $90. 
g Visual analogue scale (VAS) HSUVs.  
h  Multipliers for the proportionate effects of fractures on HSUVs, calculated from Si. et al. [46].  
4.4.5 Screening strategy 
Screening with dual-energy X-ray absorptiometry (DEXA) and treatment with alendronate has 
been shown to be cost-effective in Caucasian contexts [7-9], therefore this was selected as the 
screening and treatment strategy in this study. In the “screening” arm, post-menopausal 
Chinese women aged 65 years without fracture history were assumed to be screened with 
DEXA. Diagnosis of osteoporosis was determined in accordance with World Health 
Organization (WHO) standards: i.e. hip (femoral neck) bone mineral density (BMD) 2.5 
standard deviation (SD) or more below the young adult female mean (i.e. T-score ≤-2.5) [18]. 
Because DEXA scan at the femoral neck is currently regarded as the gold standard for 
osteoporosis diagnosis, we assumed a test sensitivity and specificity of 100% in the base-case 
analysis, with these values varied in extensive one-way sensitivity analysis [19]. It is 
recommended that follow-up bone densitometry should be performed at intervals greater than 
2 years [20], therefore the rescreening time interval was set at 5-years for the base-case. A 
conceptual diagram of screening strategy versus no screening is illustrated in Figure 4.2. 
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4.4.6 Treatment 
Oral alendronate, a cost-effective medication in the United Kingdom [21], was selected as the 
treatment option for patients identified has having osteoporosis in the screening arm, with the 
dosage of 70 mg per week with a combination of calcium and vitamin D3. Those patients in the 
no screening arm were assumed to not receive alendronate treatment following a fracture. In 
the screening arm, patients with no osteoporosis were assumed to not receive any alendronate 
after a fracture. For patients identified as having osteoporosis in the screening arm received 
alendronate, and were assumed to continue on alendronate after a fracture occurred. The 
relative risks of fractures on alendronate therapy are shown in Table 4.1. Imperfect medication 
adherence and persistence affect cost-effectiveness of interventions [6], and their impact has 
been increasingly recognized in more recent osteoporosis health economics models [10]. 
Additionally, the residual effect on fracture risk for those who discontinue treatment was 
considered, known as offset-time effect [22, 23]. 
We used the definitions of medication adherence and persistence from ISPOR [24]. Medication 
compliance (synonym: adherence) refers to “the extent to which a patient acts in accordance 
with the prescribed interval and dose of a dosing regimen” [24]. Percentage of doses taken as 
prescribed, known as medication possession ratio (MPR), was used to define the level of 
medication compliance [24]. An MRP ≥80% was defined as high compliance [25]. Medication 
persistence refers to “the duration of time from initiation to discontinuation of the therapy” 
[24]. 
Alendronate persistence data was not available for Asian populations so this was derived from 
Caucasian studies: 51.9% of those who commenced oral alendronate were assumed to 
discontinue in the first year [26], with the discontinuation rate assumed to decline linearly to 
18.2% in the fifth year [6]. For those who stayed in treatment, we used medication adherence 
data from an Asian study. The probability of having high compliance was 61.9% at 12 months 
and decreased to 47.9% in the third year after treatment onset [27]. We assumed the residual 
effect would decline to “no effect” in a linear manner over 5 years after alendronate treatment 
discontinuation [9].  
4.4.7 Osteoporosis prevalence 
Age-specific prevalence rates of osteoporosis for the Chinese population was obtained from a 
recent meta-analysis [28], from which the initial distribution of the simulated patient population 
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was determined (e.g. at age 65, 85.8% no osteoporosis, 14.2% osteoporosis). After the initial 
stage, we calculated the probability of developing osteoporosis in people not having 
osteoporosis from the differences in prevalence of osteoporosis plus the mortality rate for that 
age band [28, 29]. The calculated risks of developing osteoporosis were 0.011, 0.014, 0.018 
and 0.033 for ages 50-59, 60-69 70-79 and 80+ years respectively. We validated our calculation 
by comparing the model predicted age-specific osteoporosis prevalence rates against that from 
literature using cohort analysis. Similarly, the initial probability of simulated patients being 
osteoporotic in the “screening” arm was based on the prevalence rate, the probability of testing 
positive for those who were tested negative in the last screening was calculated from the 
prevalence rate, test sensitivity and mortality rate for that age band. Accordingly, the calculated 
risks of testing positive for individuals who did not have osteoporosis at the prior screening 
were 0.061, 0.084, 0.098 and 0.102 for ages 55-64, 65-74, 75-84, and 85+ years respectively. 
4.4.8 Fracture rates and mortality 
Annual fracture incidence rates were based on data from Chinese studies wherever available 
[30-32]. In the Chinese setting, there was limited data on “other” fracture incidence, therefore 
only hip, vertebral (clinical) and wrist fractures were included in the external validation 
analyses: annual age-specific hip fracture incidence rates were derived from the Hefei 
osteoporosis project [30], annual vertebral fracture incidence rates were taken from the Hong 
Kong Osteoporosis Study [31], annual wrist fracture incidence rates were taken from a 
Norwegian study and calibrated for Asian populations [32]. Fracture rates for patients with and 
without osteoporosis were adjusted from the age- and fracture site-specific proportion of 
osteoporosis attributed fractures, based on Melton’s osteoporosis attributed rates approach 
[33]. Fracture site and age-specific annual incidence rates and adjusted annual osteoporotic 
fracture rates are presented in Table 4.2. 
Patients in the model were allowed to sustain multiple fractures at different sites in different 
years of the simulation. The risk of subsequent fractures was higher for those with a fracture 
history [12, 34]. Accordingly, the efficacy of alendronate for both primary and secondary 
fracture prevention in osteoporotic patients was used, dependent on patient fracture history [35, 
36]. The risk of hip fracture among poorly compliant patients was 35% higher than that in 
highly compliant patients [37], and there was a 17% increase for non-hip fracture in poorly 
compliant patients [38]. 
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Age-specific mortality rates for the general population were obtained from the China Public 
Health Statistical Yearbook 2012 [29]. Mortality for the first year after hip fracture increased 
with age [12]. In the base-case analysis, patients who survived the first year after hip fracture 
were assumed either to reside in a nursing home post-fracture, remaining there for the rest of 
their life [12], or to normal community dwelling, dependent on the age at which the fracture 
was sustained. Patients were also assumed to have higher mortality rates following vertebral 
or wrist fracture events: the standardized mortality ratio (SMR) after vertebral fracture was 
1.82 (95% CI: 1.52, 2.17) and SMR after wrist fracture was 1.42 (95% CI: 1.19, 1.70) [39]. 
4.4.9 Costs 
Direct costs of screening tests, medical treatment, fracture inpatient costs and nursing home 
costs were based on published Chinese data [40-43]. All costs were converted to 2013 USD 
using a web-based currency converter [44]. As a Chinese healthcare system perspective was 
adopted in this model validation study, only direct costs after fractures were incorporated. We 
used data from a recent Chinese study on the economic burden of fractured patients with 
osteoporosis. Costs of outpatient consultation, inpatient, investigation, medication, 
rehabilitation after fracture events and physical therapy were included for direct medical costs 
[41]. Direct non-medical costs included costs of transportation, homecare, preventive care 
foods and specific equipment [41]. Average costs in the first year after hip, vertebral and wrist 
fracture were set at $6,462, $4,884 and $1,980 respectively [41]. Costs of treatment for those 
who tested positive were $1,190 ($1,100 for alendronate and $90 for calcium combined with 
vitamin D3, 1000 mg calcium plus 125 IU vitamin D3 per tablet) annually [40]. Costs of nursing 
home care varied between levels and geographical locations, and were assumed to be $4,395 
per annum in the base-case analysis [42, 43]. No medication costs were assumed for patients 
who discontinued treatment, and a 30% reduction in medication costs was assumed for patients 
with poor adherence in the base-case analysis [6]. 
4.4.10 Health-state utility values (HSUVs) 
The age-specific HSUVs for the female general population were retrieved from the National 
Health Services Survey 2008 [45]. HSUVs for women with osteoporosis but no history of 
fractures have been shown to be no different from those of the general population [46]. 
Subsequently, we defined HSUVs for osteoporotic women without fractures to be the same as 
those of the female general population. Hip and clinical vertebral fractures were associated 
with a decrease in HSUV, and the proportionate effect of a fracture on HSUV in the first and 
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subsequent year was calculated from a recent meta-analysis (Table 4.1) [46]. A HSUV 
multiplier of 0.4 was used for those residing in nursing homes after fractures [12]. 
4.4.11 Statistical methodology in internal and external validation 
In the base-case analysis, distributions were sampled 100 times. After each sample, 2000 trials 
(patients) were run through the model using the values drawn from each sample. The mean 
costs and effectiveness following the 2,000 trials were then calculated. This process was 
repeated for each of the 100 samples, and the mean costs and effectiveness were calculated 
across each of the 100 samples x 2,000 trials, from which the mean ICER for the base-case was 
calculated. In one-way sensitivity analyses, only the mean value of one selected variable in the 
model was changed, while other variables remained the unchanged. Similar to the base-case 
analysis, we still considered the joint uncertainty across all variables. The statistical analysis 
used in the validation procedure followed that used by other long-term model validations [47-
49]. For internal validity, the results generated from our model were compared with those from 
studies used in creating the model. Specifically, we compared age-specific hip, vertebral and 
wrist fracture annual incidence rates from model outputs against those from the reference 
studies. Goodness-of-fit was evaluated by plotting the model predictions versus observed data 
reported in the reference studies, fitting a linear curve through the points with the intercept of 
zero. The squared linear correlation coefficient (R2), which was an index of the degree to which 
the paired measures co-vary, was provided using linear regression. External validation 
compared the model’s results for key outcomes with available published data that was not used 
in the construction of the model [15], and goodness-of-fit was also evaluated using linear 
regression In this study, we compared the model’s predictions of life expectancy (LE) and 
osteoporosis prevalence rates at specific ages, lifetime osteoporotic hip, clinical vertebral and 
all main (hip, clinical vertebral and wrist fracture combined) osteoporotic fracture risks, and 
10-year fracture risks for all main osteoporotic fractures against the corresponding reported
data [28, 31, 50-53]. All statistical analyses were performed using STATA (STATA 12.1, 
StataCorp LP, College Station, TX, USA). 
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Figure 4.2 Conceptual diagram of the screening model. OP = osteoporosis. The model compares the screening strategy to no screening in postmenopausal 
women. Those subjects who tested positive in “Screening” arm are assumed to be treated with alendronate to prevent fractures. For those who tested negative 
in the last screening, a repeat screening is performed in 5 years. 
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Table 4.2 Age-specific annual fracture rates for total population and calculated annual fracture rates 
attributed from osteoporosis, per 1,000 person-years 
Age (years) Hip fracture a Vertebral fracture b Wrist fracture c 
Annual fracture rates 
for total population 
50-54 0.33 2.19 4.76 
55-59 0.46 3.13 7.32 
60-64 0.54 5.16 11.16 
65-69 0.96 5.64 12.95 
70-74 2.33 8.74 13.17 
75-79 4.08 12.05 13.87 
80-84 6.44 21.19 15.01 
85-89 6.59 26.89 15.10 
  90+ 8.67 27.10 d 13.97 
Calculated annual 
osteoporosis attributed 
fracture rates e 
50-54 7.20 47.76 60.06 
55-59 6.50 44.21 60.43 
60-64 4.08 38.97 49.72 
65-69 4.94 29.01 39.04 
70-74 8.96 33.60 28.83 
75-79 12.68 37.45 23.87 
80-84 16.97 55.84 21.32 
85-89 15.97 65.17 19.41 
  90+ 21.01 65.17 17.96 
a Annual hip fracture rates for total population are derived from Wang et al. (2014) [30].  
b Clinical vertebral fractures. Annual clinical vertebral fracture rates for total population are derived from Bow et 
al. (2012) [31]. 
c Wrist fracture incidences were derived for Caucasians from Lofthus et al (2008) [32], and in the model we were 
adapted the values to Asians by multiplying the relative risk of wrist fractures (0.72, 95% CI: 0.53-1.00) in Asians 
versus Caucasians. 
d Calculated from original data using linear extrapolation. 
e Osteoporosis attributed fracture risks were calculated using Melton’s osteoporosis attributed rates (Melton et al. 
1997 [33]). 
4.4.12 Sensitivity analyses 
One-way sensitivity analyses were performed to identify the influence of input parameters on 
the outcomes. Sensitivity and specificity of DEXA for diagnosing osteoporosis, osteoporosis 
prevalence rate, annual fracture risks, treatment efficacy and HSUVs were varied by ±20% of 
the values used in the base-case analysis. Medication persistence and probability of being 
highly adherent, probability of individuals residing in a nursing home after a hip fracture, 
inpatient costs for hip, vertebral and wrist fractures, annual medication costs and costs of 
screening were varied by ±50% of the values used in the base-case analysis [54]. Additionally, 
we performed one-way sensitivity analyses by assuming different discount rates on cost and 
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effectiveness, treatment duration, no offset time effect after medication discontinuation and 
different screening initiation age. As some variables were defined by a mean and standard error, 
distributions were applied in the model. Probabilistic sensitivity analysis was performed, in 
which sampling of distributions of input parameters was performed to address the uncertainties 
around multiple parameters simultaneously [54]. Cost-effectiveness acceptability curves were 
generated to visually illustrate the probabilities of screening and appropriate treatment being 
cost-effective. 
4.5  Results  
4.5.1 Face validity and internal validation 
The model was designed and constructed by both experienced clinicians (Andrew Palmer, 
Tania Winzenberg) and health economics experts (Lei Si, Andrew Palmer). From a clinical 
perspective, the model structure was determined to correctly represent all important clinical 
facets of osteoporosis screening and fractures [10]. 
We performed a total of 27 internal validations by comparing model predictions of age-specific 
hip, clinical vertebral and wrist fracture incidence rates against those data used in creating our 
model. The results generated by the model closely match the published data from which the 
input probabilities were derived: the regression line slope was 0.996, which was close to 1.00, 
and the R2 was 0.99 which indicated that the model faithfully reproduced the published data. 
The collective results for the internal validation are shown in Appendix 4B.2. 
Table 4.3 summarizes the costs, effectiveness and the incremental cost-effectiveness ratio 
(ICER) of screening with DEXA versus no screening. The mean costs for screening and no 
screening were $1,939 and $1,619 respectively for the base-case analysis, the respective mean 
QALYs were 9.9442 and 9.722. The cost per QALY gained for screening versus no screening 
was $1,440 in the base-case analysis. 
4.5.2 Sensitivity analyses 
Without discounting for costs and effectiveness, the cost per QALY gained decreased to $931. 
The ICER increased to $1,844 when costs and effectiveness were discounted by 5% annually. 
The accuracy of the screening test also impacted on outcomes: lower test sensitivity and 
specificity yielded higher costs but lower effectiveness for the screening strategy while the 
costs and effectiveness of no screening remained unchanged.  
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Medication persistence and adherence both impacted on the ICER: costs per QALY gained 
decreased with lower and increased with higher medication persistence and adherence. Costs 
and effectiveness did not change in the no screening group because no alendronate treatment 
was assumed for individuals in the no screening group. Effectiveness in the screening arm 
changed only slightly compared to that in the base-case analysis, whereas average costs 
changed more substantially especially with varied medication persistence.  
Costs of fracture and screening did not impact on ICER significantly: costs per QALY gained 
were all higher than the WTP threshold and close to that in the base-case analysis. However, 
annual medication cost had a dramatic impact on the cost-effectiveness of DEXA screening: 
with a 50% decrease of annual medication cost, the DEXA screening was cost-saving 
compared with no screening. 
Costs per QALY gained were $3,347, if screening was initiated at the age of 60 DEXA 
screening was cost-saving if the screening was initiated at the age of 70 years. The cost-
effectiveness acceptability curves (CEAC) were provided showing the probabilities of 
screening being cost-effective given a continuous WTP threshold (Figure 4.3). Given the WTP 
of $20,000 per QALY gained, screening initiated from age 65years had a probability of 99% 
of being cost-effective. 
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Table 4.3 Summary of costs, effectiveness, ICER of DEXA screening versus no screening strategy: 
base-case and one-way sensitivity analyses  
Parameters 
Costs a Effectiveness b 
ICER 
DEXA 
No 
screening 
DEXA 
No 
screening 
Base-case 1,939 1,619 9.944 9.722 1,440 
One-way sensitivity analyses 
  Discount rates: 0% 2,922 2,545 12.972 12.567 931 
  Discount rates: 5% 1,542 1,252 8.584 8.427 1,844 
  1.2 times base case annual fracture risks 2,136 1,905 9.881 9.615 870 
  0.8 times base case annual fracture risks 1,724 1,320 10.006 9.832 2,314 
  1.2 times base case treatment efficacy 1,915 1,619 9.950 9.722 1,290 
  0.8 times base case treatment efficacy 1,963 1,619 9.937 9.722 1,598 
  Treatment duration: 2 years 1,818 1,619 9.937 9.722 925 
  Treatment duration: 10 years 1,967 1,619 9.945 9.722 1,566 
  No treatment offset time effect c 1,981 1,619 9.930 9.722 1,736 
  0.8 times base case DEXA sensitivity  2,403 1,619 9.887 9.722 4,751 
  0.8 times base case DEXA specificity 4,524 1,619 9.918 9.722 14,795 
  1.5 times base case medication persistence d 2,179 1,619 9.948 9.722 2,472 
  0.5 times base case medication persistence d 1,689 1,619 9.934 9.722 328 
  1.5 times base case medication adherence e 1,961 1,619 9.947 9.722 1,514 
  0.5 times base case medication adherence e 1,915 1,619 9.939 9.722 1,357 
  1.5 times base case probability of nursing home 1,972 1,670 9.942 9.719 1,355 
  0.5 times base case probability of nursing home 1,906 1,570 9.946 9.724 1,522 
  1.5 times base case fracture inpatient costs 2,401 2,377 9.944 9.722 112 
  0.5 times base case fracture inpatient costs 1,476 862 9.944 9.722 2,768 
  1.5 times base case annual medication costs 2,314 1,619 9.944 9.722 3,133 
  0.5 times base case annual medication costs 1,563 1,619 9.944 9.722 cost-saving 
  1.5 times base case screening cost 2,039 1,619 9.944 9.722 1,892 
  0.5 times base case screening cost 1,839 1,619 9.944 9.722 988 
  1.5 times base case nursing home annual cost 1,969 1,672 9.944 9.722 1,343 
  0.5 times base case nursing home annual cost 1,908 1,567 9.944 9.722 1,537 
  1.2 times base case HSUVs 1,939 1,619 11.954 11.720 1,365 
  0.8 times base case HSUVs 1,939 1,619 7.941 7.744 1,625 
  Screening population aged 60 years 2,245 1,590 11.706 11.510 3,347 
  Screening population aged 70 years 1,603 1,637 8.186 7.932 cost-saving 
ICER = incremental cost-effectiveness ratio, DEXA = dual-energy x-ray absorptiometry, HSUV = Health-state 
utility value 
a Costs are lifetime direct costs and presented in 2013 US dollars. 
b Effectiveness is presented in quality-adjusted life year (QALY). 
c Medication offset time effect refers to the residual effect on fracture risks after the discontinuation of treatment. 
d Medication adherence remains unchanged. 
e Medication persistence remains unchanged. 
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4.5.3 External validation 
The prediction of life expectancy (LE) for 65 year old women without screening was 19.01 
years and 15.74 years for women aged 69 years (average: 17.38 years). Our model prediction 
was similar to the World Health Organization (WHO) audit whereas the mean LE for Chinese 
women aged 65-69 years is 17.15 years [53]. Osteoporosis prevalence rates for ages 60-69, 70-
79 and 80+ years and older were predicted at 14.4%, 26.3% and 39.9% respectively, closely 
matching the respective prevalence rate from the literature of 14.2%, 26.8% and 39.2% [28]. 
Our model predicted the lifetime osteoporotic hip, clinical vertebral and wrist fracture risks for 
Chinese women aged 50 years to be 7.9% (95% CI: 7.2%, 8.6%), 29.8% (95% CI: 27.8%, 
31.9%) and 18.7% (95% CI: 17.2%, 20.1%) respectively. The lifetime risk of all osteoporosis-
related fractures for Chinese women aged 50 years was predicted to be 56.3% (95% CI: 52.1%, 
60.6%). The predictions were comparable to the corresponding values from a Korean study, 
where residual lifetime risk for hip, distal radius and all osteoporotic fractures were reported 
as 12.3%, 21.7% and 59.5% respectively [52]. These predictions were consistent with the 
results of a study on fracture risk across different ethnicities, in which the hip fracture rate for 
Asian women was estimated to be less than half that of Caucasians, but the vertebral fracture 
rate was higher in Asians than Caucasians [31]. The residual lifetime hip, clinical vertebral and 
any common osteoporotic fracture risks in a Caucasian population at age 50 years were 
estimated at 23%, 15% and 46% respectively [50]. By setting the simulation initiation age at 
65 years, the 10-year risk of any major osteoporotic fractures (i.e. hip, clinical vertebral and 
wrist fractures) was predicted to be 13.7% (95% CI: 12.5%, 15.2%), which is comparable to 
the value of 17% observed in a Hong Kong population aged 65 years and older with a total hip 
BMD T-score ≤-2.5 [51]. The regression line slope was 0.952, which was close to 1.00, and 
the R2 was 0.994. The collective results for the external validation are shown in Appendix 4B.2. 
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Figure 4.3 Cost-effectiveness acceptability curves of screening initiated from age 65 years at different 
levels of willingness-to-pay (WTP) per quality-adjusted life year (QALY) gained versus no screening. 
Given the WTP threshold of $20,000 per QALY gained, the probability of screening being cost-
effective versus no screening is 99% if screening is initiated at age 65 years. 
4.6  Discussion 
The application of health technology assessment has increased remarkably over the past 
decades and is expected to grow in the future [10, 11]. A successful health analytic model 
should be acceptable to healthcare providers, health policy decision makers and healthcare 
payers. Moreover, it should be transparent and validated against real-life data [47]. Our 
osteoporosis model was constructed using updated epidemiological and economic data. The 
model structure and functionality has been documented, and the validation analyses revealed 
the accuracy of reproduction of input data. Moreover, our model was constructed 
independently, without bias to any specific medication, intervention, or funding body, avoiding 
the implicit inherent bias potentially associated with external funding. The flexibility and 
adaptability of the model was considered throughout the model construction process. The 
model can be used for evaluating the costs, effectiveness and cost-effectiveness of screening 
for, prevention and medical treatment of osteoporotic fractures. It was designed not only for 
economic evaluations for primary fracture prevention (i.e. prevention of a first osteoporotic 
fracture) but can also be adapted for secondary fracture prevention (i.e. preventions targeted at 
the population who have already sustained a fracture). Further, it was not restricted to a specific 
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country or ethnic population, but can be applied to different populations and countries with 
population- and country-specific data. The model was constructed in TreeAge software which 
is widely used in cost-effectiveness modelling studies. In the future, a user-friendly web-based 
interface will make the model publically available. Finally, the R2 values are all close to 1 for 
the internal and external validations, which indicates our model has good internal and external 
validity: the R2 values are even greater than some validated cost-effectiveness models that have 
been extensively used to assist the submissions of new pharmaceutical products for 
reimbursement around the world such as CORE diabetes model (R2=0.9574 for the internal 
validation and R2=0.9023 for the external validation) [47] and the Archimedes diabetes model 
(R2=0.99 for the external validation) [48]. 
Medication adherence and persistence have consistently been found to impact on medication 
effectiveness and healthcare costs, as well as cost-effectiveness of health interventions [6, 25, 
55, 56]. In our study, we confirmed the previous findings in terms of the substantial impact on 
cost-effectiveness of osteoporosis screening (Table 4.3). However, the change of effectiveness 
in screening strategy was relatively small in one-way sensitivity analyses. The reasons are two-
fold: first, this study incorporated screening of the whole population of both osteoporotic and 
non-osteoporotic people, therefore the changes in medication adherence impacted only to a 
minor degree on effectiveness, as most of the simulated individuals were non-osteoporotic at 
baseline. This differs from the findings reported in a cost-effectiveness study of fracture 
preventions where all simulated patients were osteoporotic [56]. In that Belgian study, 
medication non-adherence decreased the effectiveness (expressed in QALY gained) by 59% 
comparing with the full adherence scenario [56]. In another study of the cost-effectiveness of 
screening a Belgian population, effectiveness of the screening strategy with real-world 
medication adherence only decreased 0.34% from that with full adherence (12.95 QALY 
gained for real-world adherence and 13.00 QALY gained for full adherence compared with no 
screening) [6]. Second, impact of poor medication adherence and persistence was offset by 
residual medication effects after treatment discontinuation. Assuming no offset time effects, 
the effectiveness of screening decreased by 0.014 QALY compared to the base-case analysis 
(Table 4.3). These results further demonstrate the importance of accounting for medication 
adherence and persistence in health economic evaluations of osteoporosis management 
strategies.  
To date, several models have been constructed and used in the field of screening for- and 
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treatment of osteoporosis [7-9, 13, 49, 57-59]. Other than Mueller’s model, all models were 
patient-level (microsimulation) based. Most of models were of good quality and satisfied the 
recommendations from a recent systematic review with regard to the progression of 
osteoporosis models [10]. Nevertheless, limitations existed in these models. For example, 
rescreening intervals for patients diagnosed as non-osteoporotic in the last screening were not 
considered in Mueller’s model [8, 58]; medication adherence and offset time effects were not 
considered in the model from Nshimyumukiza [59]; medication persistence was not included 
in Kingkaew’s model [13]. Medication persistence, adherence and offset time are 
recommended to be incorporated in osteoporosis models due to the demonstrated impact of 
these parameters on the cost-effectiveness of osteoporosis interventions [6, 10]. In the model 
from Hiligsmann [6], medication persistence and adherence was considered in the “screening 
and treating” arm but not in the “no intervention” arm.  
There are a number of major strengths to our modelling approach. First, Bayes’ revision was 
adopted in our model structure, which calculated the posterior probabilities using prior and 
likelihood probabilities. Bayes’ revision has not been adopted in previous screening models for 
osteoporosis but is recommended [6, 7, 9, 13, 60]. Second, the model used patient-level 
(microsimulation) techniques rather than cohort analysis. Microsimulation models using a 
lifetime horizon account for the evolution of patient characteristics over time, such as fracture 
history, time since treatment initiation and time since fracture, and are therefore preferred by 
healthcare decision makers [61]. Third, medication adherence, persistence and offset time 
effect were all thoroughly accounted for in the model.  
There are potential limitations to our model. First, adverse events (i.e. events from the 
medication side effects) were not recorded. Side effects of alendronate such as gastrointestinal 
adverse events and osteonecrosis of the jaw were not included because the health-state utility 
impact of adverse events is unclear, and skeletal side effects occur rarely at the doses used in 
osteoporosis treatment [62-64]. However, medication adverse events should ideally be 
considered in health economic evaluation on medications when good epidemiological data are 
available on such adverse events. Second, our model assumed a fixed rescreening interval for 
those not diagnosed with osteoporosis. Several organizations provided different 
recommendations that varied from at least six months to 5 years [20, 65, 66]. Recent studies 
suggest that the interval of repeat BMD testing should be determined by age, the patient’s 
clinical risk factors as well as baseline bone density [67-69]. With limited prospective data, 
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frequency of bone densitometry is controversial. Our study used a 5-year rescreening interval 
in the base-case analysis and was varied in sensitivity analysis, we expect to adopt a flexible 
rescreening interval in the future when country-specific clinical trial data are available. Third, 
patients in the “no screening” arm who sustained an osteoporotic fracture ideally should be 
prescribed medication to prevent subsequent fractures. However, the current pattern of 
secondary fracture prevention is unknown in China, therefore we only assumed inpatient costs 
one year after fracture in the “no screening” arm. Finally, because of the paucity of data on 
“other fractures” in Chinese studies, we were unable to validate our “other fracture” rates 
generated by the model against published Chinese data. In addition, some of the data we used 
in this study were from Caucasian populations, such as the probability of residing in a nursing 
home after a hip fracture, and treatment efficacy. Future external validation and updates of the 
model are expected when new evidence becomes available. 
Osteoporosis models have been used extensively in cost-effectiveness studies on osteoporosis 
since the first model was published in 1980 [70]. Good cost-effectiveness models are expected 
to be consistent with a coherent theory of the objective health condition [71], so that the 
structure should represent all important disease outcomes and the transition parameters should 
be consistent with the most convincing evidence from clinical trials or meta-analyses. 
Evolution in osteoporosis model structures over time is possibly a reflection of the adoption 
and implementation of good practice in modelling studies. Microsimulation models are 
preferable over cohort based models, which lack comprehensive memory integrity, but they 
require more sophisticated data from clinical trials. Many of the previous models estimated the 
specificity and sensitivity of the screening approach by relying on bone mineral densitometry 
without incorporating other clinical risk factors such as history of fracture, glucocorticoids use 
and smoking. Clinical risk factors were found to contribute substantially to the risk of fracture 
and were included in many fracture risk models such as FRAX [72]. FRAX not only 
incorporated BMD at the femoral neck but other clinical risk factors as an indicator of 
medication intervention threshold. However, the recommended intervention threshold is not 
applicable to the Chinese population [73, 74]. Our model is able to include these assessment 
tools and we would like to define the threshold for the Chinese population from a health 
economic perspective when relevant epidemiological data are available. With multiple 
osteoporosis models developed around the world, and the ongoing evolution of modelling 
techniques, osteoporosis health economics computer modellers should be encouraged to meet 
regularly to compare their models against each other and against data from clinical trials and 
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other high quality studies and to optimize the future development of modelling techniques. 
This approach has been successful in cross-validation and improvement of models in other 
disease areas, e.g.: the Mount Hood Challenge series in diabetes modelling to compare model 
projections with the best available clinical and epidemiological outcomes and to discuss 
avenues of research to improve future models [75-77]. It is recommended that a similar series 
of meetings in the field of osteoporosis health economics modelling should be established. 
A new cost-effectiveness state-transition microsimulation model of screening for and treatment 
of osteoporosis was constructed that implements a unique combination of modern-day 
modelling techniques. It is a flexible model with good internal and external validity that closely 
reproduces clinical input data and epidemiological studies. This new model provides an 
important tool for researchers and policy makers to test the cost-effectiveness of osteoporosis 
screening and treatment strategies. Nevertheless, further external validation and updates of the 
model will constantly be needed as new evidence and more advanced modelling techniques 
become available. 
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Appendix 4B.1: Bayes’ revision in decision trees 
It is recommend to use Bayes’ revision in models that incorporate imperfect tests or forecasts. 
In this study context, bone densitometry may not able to detect all osteoporotic patients 
therefore Bayes’ revision is employed in the decision tree – as DEXA at the femoral neck is 
the gold standard for diagnosing osteoporosis [18], we assumed  sensitivity and specificity of 
100% [19], but carried this assumption in one-way sensitivity analyses. 
The Bayes’ revision allowed the calculation of posterior (or decision) probabilities by the 
following formula: 
P(Posterior)  =
P(Evidence|Hypothesis) × P (Hypothesis)
P (Evidence)
Where P(Hypothesis) is called a prior probability and P(Evidence) is called a marginal 
probability. 
In our sub-decision-tree, there are 4 posterior probabilities incorporated in “On screening” arm: 
P(true positive, i.e. osteoporotic patients who are tested positive), P(false positive, i.e. healthy 
people who are tested positive), P(true negative, i.e. healthy patients who are tested negative), 
P(false negative, i.e. osteoporotic patients who are tested negative). 
The posterior probabilities are calculated from the formulas bellow: 
P(TruePos) =
P(Osteoporosis) × Sensitivity
P(Osteoporosis) × Sensitivity + (1 − P(Osteoporosis)) × (1 − Specificity)
P(FalsePos) =
(1 − P(Osteoporosis)) × (1 − Specificity)
P(Osteoporosis) × Sensitivity + (1 − P(Osteoporosis)) × (1 − Specificity)
P(TrueNeg) =
(1 − P(Osteoporosis)) × Specificity
P(Osteoporosis) × (1 − Sensitivity) + (1 − P(Osteoporosis)) × Specificity
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P(FalseNeg) =
P(Osteoporosis) × (1 − Sensitivity)
P(Osteoporosis) × (1 − Sensitivity) + (1 − P(Osteoporosis)) × Specificity
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Appendix 4B.2: Internal and external validation 
Internal validation 
For internal validity, the results generated by our model were compared with those reported 
from studies used in creating the model. Specifically, we compared age-specific hip, vertebral 
and wrist fracture incidence rates from model outputs against those from the reference studies. 
Goodness of fit was evaluated by plotting the model predictions versus observed data reported 
in the reference studies, fitting a linear curve through the points with the intercept of zero. The 
squared linear correlation coefficient (R2), which is an index of the degree to which the paired 
measures co-vary was provided using linear regression. 
Appendix 4B.2 Table 1. Annual fracture rates, per 10,000 person-years from model reproduction and 
model inputs 
Age (years) 
Annual fracture rates, per 10,000 
person-years from model prediction 
Annual fracture rates, per 10,000 
person-years from literature 
Hip fracture     
  50-54 3.4 3.3 
  55-59 4.6 4.6 
  60-64 5.3 5.4 
  65-69 9.7 9.6 
  70-74 23.2 23.3 
  75-79 42.8 40.8 
  80-84 61 64.4 
  85-89 63.2 65.9 
  90+ 84 86.7 
Clinical vertebral 
fracture 
    
  50-54 23.2 21.9 
  55-59 32.1 31.3 
  60-64 53.3 51.6 
  65-69 58.7 56.4 
  70-74 91.1 87.4 
  75-79 124.9 120.5 
  80-84 218.2 211.9 
  85-89 267.7 268.9 
  90+ 268.2 268.9 
Wrist fracture     
  50-54 34.3 34.272 
  55-59 55.6 52.704 
  60-64 79.55 80.352 
  65-69 93.9 93.24 
  70-74 94.95 94.824 
  75-79 102.05 99.864 
  80-84 107.8 108.072 
  85-89 104.8 108.72 
  90+ 97.15 100.584 
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In total, we performed 27 internal validations by comparing model prediction of age-specific 
hip, clinical vertebral and wrist fracture incidence rate against those used as model inputs 
(Appendix 4B.2 Table 1).  
According to the values in Appendix 4B.2 Table 1, goodness-of-fit test is illustrated in Appendix 
4B.2 Figure 1, by plotting the model predictions versus observed data, the regression line slope 
was 0.996 which was close to 1.00 and the R2 was 0.99 which indicated that the model faithfully 
reproduced the published data.   
Appendix 4B.2 Figure 1. Goodness-of-fit test for model internal validation 
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External validation 
Similar to the internal validation, goodness-of-fit test was performed using linear regression. 
We compared the model’s predictions of life expectancy (LE) and osteoporosis prevalence 
rates at specific ages, lifetime osteoporotic hip, clinical vertebral and all main (hip, clinical 
vertebral and wrist fracture combined) osteoporotic fracture risks, and 10-year fracture risks 
for all main osteoporotic fractures against the corresponding reported data (Appendix 4B.2 
Table 2).  
According to the values in Appendix 4B.2 Table 2, goodness-of-fit test is illustrated in Appendix 
4B.2 Figure 2. The regression line slope was 0.952, which was close to 1.00, and the R2 was 
0.994. 
Appendix 4B.2 Table 2. External validation: comparison of model predictions to the published data 
Parameters Model predictions Data from literature 
Life expectancy for age 65-69, years 17.15 17.38 
Prevalence of osteoporosis ,% 
60-69 years 14.2 14.4 
70-79 years 26.8 26.3 
  80+ years 39.2 39.9 
Lifetime osteoporotic fracture risk at 
age 50 years, % 
  Hip fracture 12.3 7.85 
  Wrist fracture 21.7 18.68 
  Any major fracture (Hip, clinical 
vertebral and wrist fractures) 
59.5 56.31 
10-year risk of any major osteoporotic
fractures (Hip, clinical vertebral and 
wrist fractures), % 
17 13.69 
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Appendix 4B.2 Figure 2. Goodness-of-fit test for model external validation 
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Chapter 5: Residual lifetime and 10-year absolute risks 
of osteoporotic fractures in Chinese men and women 
5.1  Preface 
Residual lifetime risk describes the cumulative risk of developing a disease over the remaining 
lifetime. Assessing residual lifetime fracture risks provides information of absolute risks on the 
population level and potential clinical burden of disease. This chapter documents the first 
application study using our osteoporosis health economic model, residual lifetime and 10-years 
osteoporotic fracture risks for Chinese women and men aged 50 years and above are estimated. 
More than two fifths of Chinese women and around one tenth of Chinese men aged 50 years 
are expected to sustain a first osteoporotic (hip, clinical vertebral or wrist) fracture in their 
remaining lives. While fracture risk estimates are lower in Chinese than Caucasian populations, 
it is clear that osteoporotic fractures will still result in a major burden for the Chinese health 
system and the prevention of osteoporosis is an issue which requires serious attention.  
This chapter has been published in Current Medical Research & Opinion (Appendix 5A). 
Impact factor: 2.65.  
Si L, Winzenberg TM, Chen M, Jiang Q, Palmer AJ. Residual lifetime and 10-year absolute 
risks of osteoporotic fractures in Chinese men and women. Current Medical Research & 
Opinion, June 2015. 31(6):1149-56. 
The published article of this 
chapter appears in an appendix to 
the chapter. It has been removed 
for copyright or proprietary 
reasons.
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5.2  Abstract 
Objective: To determine the residual lifetime and 10-year absolute risks of osteoporotic 
fractures in Chinese men and women. 
Methods: A validated state-transition microsimulation model was used. Microsimulation and 
probabilistic sensitivity analyses were performed to address the uncertainties in the model. All 
parameters including fracture incidence rates and mortality rates were retrieved from published 
literatures. Simulated subjects were run through the model until they died to estimate the 
residual lifetime fracture risks. A 10-year time horizon was used to determine the 10-year 
fracture risks. We estimated the risk of only the first osteoporotic fracture during the simulation 
time horizon. 
Results: The residual lifetime and 10-year risks of having the first osteoporotic (hip, clinical 
vertebral or wrist) fracture for Chinese women aged 50 years were 40.9% (95% CI: 38.3-
44.0%) and 8.2% (95% CI: 6.8-9.3%) respectively. For men, the residual lifetime and 10-year 
fracture risks were 8.7% (95% CI: 7.5-9.8%) and 1.2% (95% CI: 0.8-1.7%) respectively. The 
residual lifetime fracture risks declined with age, whilst the 10-year fracture risks increased 
with age until the short-term mortality risks outstripped the fracture risks. Residual lifetime 
and 10-year clinical vertebral fracture risks were higher than those of hip and wrist fractures in 
both sexes. 
Conclusions: More than one third of the Chinese women and approximately one tenth of the 
Chinese men aged 50 years are expected to sustain a major osteoporotic fracture in their 
remaining lifetimes. Due to increased fracture risks and rapidly ageing population, osteoporosis 
will present a great challenge to the Chinese healthcare system. 
Limitations: While national data was used wherever possible, regional Chinese hip and 
clinical vertebral fracture incidence rates were used, wrist fracture rates were taken from a 
Norwegian study and calibrated to the Chinese population. Other fracture sites like tibia, 
humerus, ribs and pelvis were not included in the analysis, thus these risks are likely to be 
underestimates. Fracture risk factors other than age and sex were not included in the model. 
Point estimates were used for fracture incidence rates, osteoporosis prevalence and mortality 
rates for the general population. 
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5.3  Introduction 
Osteoporotic fractures contribute a substantial disease burden worldwide, resulting in increased 
mortality and quality of life reduction [1, 2], especially in older populations. China has one of 
the most rapidly ageing populations: the proportion of the elderly in China is projected to be a 
quarter of its total population by 2050 [3]. Inevitably, the rising disease and economic burden 
of osteoporotic fractures will challenge the sustainability of the Chinese healthcare system [4]. 
Estimations of residual lifetime and 10-year osteoporotic fracture risks provide important 
information to healthcare policy makers, as they may ration scarce healthcare resources 
according to the future burden of disease. Residual lifetime and 10-year osteoporotic fracture 
risks have been widely reported for Caucasian populations [5-8], but very limited studies have 
been performed in Asian populations [9, 10], and only one [11] in the Chinese population. 
Because life expectancy and fracture rates in the Chinese population have increased in the past 
decade [12, 13], updated estimates of hip fracture are required as well of estimates of risk for 
other important sites begin needed. Moreover, accurate projections of residual lifetime and 10-
year vertebral and wrist fracture risks for the Chinese population will allow international 
comparisons. 
The objective of this study was to determine the residual lifetime and 10-year absolute risks of 
major osteoporotic fractures (hip, clinical vertebral and wrist fractures) in Chinese men and 
women aged 50 years to 90 years. 
5.4  Methods 
5.4.1 Health economics model overview 
A validated state-transition microsimulation was used to estimate residual lifetime and 10-year 
osteoporotic fracture risks [14]. The model structure and validations have been previously 
documented in detail [14]. Briefly, the model simulates the most significant clinical outcomes 
of osteoporosis, i.e. hip, clinical vertebral and wrist fractures [15], using a patient-level 
microsimulation approach. Four basic disease states were constructed: “no history of 
fractures”, “fractured”, “post-fracture” and “death” [14]. The simulated subjects in the model 
are able to transit between the disease states with a 1-year cycle length until they die or until 
the termination of the simulation. Residual lifetime and 10 years were used for the simulation 
time horizons to estimate the lifetime fracture risk and 10-year first fracture risk respectively. 
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Tracker variables were used to record changing patient characteristics over the course of the 
simulation periods, like the evolving history of fracture at various sites. Transition probabilities 
were based on age and sex, osteoporosis prevalence, annual fracture risks and mortality rates, 
and were retrieved from Chinese population-specific sources whenever possible.  
5.4.2 Model parameters 
A summary of the main parameters included in the model is shown in Table 5.1. The initial 
distribution of the simulated patients was based on the prevalence of osteoporosis in the 
Chinese population [16]. We used the World Health Organization (WHO) diagnosis standard 
to define osteoporosis: i.e. hip (femoral neck) bone mineral density (BMD) 2.5 standard 
deviation (SD) or more below the young adult female mean (i.e., T-score≤-2.5) [15]. Non-
osteoporotic subjects in the model could become osteoporotic during the simulation. The 
probability of developing osteoporosis was calculated from the difference in osteoporosis 
prevalence between each 10 year age band plus the mortality rate for that age band [14, 16, 
17]. In summary, the calculated risks of developing osteoporosis were 0.011, 0.014, 0.018 and 
0.033 person-years for women aged 50-59, 60-69, 70-79 and 80+ years respectively. Similarly, 
the calculated risks were 0.004, 0.0036 and 0.009 person-years for men aged 50-59, 60-69 and 
70+ years respectively. We have validated our calculations by comparing the model predicted 
age-specific osteoporosis prevalence against that from the literature using cohort analyses [14].  
Annual fracture incidence rates were obtained from recent Chinese studies wherever available 
[18-20]: annual hip fracture rates were obtained from a study in Hefei, a moderately developed 
city of 1.7 million inhabitants located in central China [20] and annual clinical vertebral 
fracture rates were retrieved from a study in Hong Kong (located in southern China) [19]. As 
there are no Chinese data, annual wrist fracture rates were taken from a Norwegian study and 
calibrated to Asian populations with a fracture relative risk of 0.72 (95% CI: 0.53-1.00) [18]. 
Fracture rates for simulated subjects with and without osteoporosis were applied based on the 
proportion of osteoporosis attributed fractures in those two populations according to well 
accepted methodology [21].  
Age-specific mortality rates for the general population were taken from the China Public Health 
Statistical Yearbook 2012 [17]. No excess mortality was assumed for patients with osteoporosis 
without fractures [22], and increases in mortality were assumed for patients who sustained a 
fracture in the year following that fracture [22]: the standardized mortality ratios (SMRs) for 
men who sustain a hip, vertebral and wrist fracture were 3.51 (95% CI: 2.65-4.66), 2.12 (95% 
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CI: 1.66-2.72) and 1.33 (95% CI: 0.99-1.80) respectively. Similarly, the SMRs for women were 
2.43 (95% CI: 2.02-2.93), 1.82 (95% CI: 1.52-2.17) and 1.42 (95% CI: 1.19-1.70) respectively. 
5.4.3 Analyses 
Microsimulation (or patient-level simulation), in which only one simulated subject transits 
through the model at one time, was used to determine the residual lifetime and 10-year fracture 
risks. Uncertainties, including stochastic (first-order) and parameter (second-order) 
uncertainties, were addressed [23]. First-order uncertainty comes from the probabilistic 
structure of the health economics model, and this random variation can be reduced by 
increasing the number of simulated subjects [24]. Second-order uncertainties relate to the 
uncertainties around the model input parameters and were addressed through probabilistic 
sensitivity analysis (PSA), or the simultaneous sampling of all relevant distributions around 
the input variable values [25].  
A total of 100 samples × 5,000 individual simulations were performed, i.e. distributions were 
sampled 100 times (samples), and after each sample, 5,000 simulated subjects were run through 
the model using the sampled values. Mean and 95% confidence interval (CI) of the residual 
lifetime and 10-year fracture risks were calculated. The health economics model was 
constructed and all the statistical analyses were performed using TreeAge Pro Suite 2014 
(TreeAge Software, Williamstown, Massachusetts).  
5.5  Results 
Absolute residual lifetime and 10-year risks of first osteoporotic hip, clinical vertebral, wrist 
or any of these fractures are shown in Tables 5.2&3 and Figure 5.1. Overall, residual lifetime 
and 10-year risks of the first osteoporotic fracture in women were higher than those projected 
for men at any fracture site across the ages 50 to 90 years. 
At the age of 50 years, 40.9% (95% CI: 38.3-44.0%) of Chinese women were estimated to 
sustain a major (hip, clinical vertebral or wrist) osteoporotic fracture in the remaining life, 
whereas the probability in men was estimated to be 8.7% (95% CI: 7.5-9.8%). Residual lifetime 
risks of the first clinical vertebral fracture were higher than those of hip fracture and wrist 
fracture in both sexes. The pattern of residual lifetime risks with age varied for different fracture 
sites and by sex (Figure 5.1). For hip fracture, residual lifetime risks remained relatively 
constant until the age of 80 years in men and 75 years in women, then decreased with age. For 
clinical vertebral fracture, residual lifetime risks remained constant in men up to the age of 80 
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years whereas the residual lifetime risks decreased progressively with age in women. A similar 
pattern was observed for wrist fractures and any major osteoporotic fractures. 
The absolute 10-year risks of the first major osteoporotic fracture were estimated to be 8.2% 
(95% CI: 6.8-9.3%) for women aged 50 years and 1.2% (95% CI: 0.8-1.7%) for men 
respectively. The pattern of 10-year fracture risks were similar in different fracture sites in 
women and men. Risk increased up to the age of 80 years and then declined and approached 
the residual lifetime fracture risks at the age of 90 years (Figure 5.1). 
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Table 5.1. Key parameters in the model  
Parameter Women Men Distribution 
Prevalence of osteoporosis (%) 
[16] 
3.5 (50-59 years), 14.2 (60-69 
years), 26.8 (70-79 years), 
39.2 (80+  years) 
2.2 (50-59 years), 6.2 (60-69 
years), 9.8 (70-79 years), 18.8 
(80+  years) 
- 
Fracture incidence (annual rate 
per 1,000 person-years) 
   
  Hip [20] 0.33 (50-54 years), 0.46 (55-
59 years), 0.54 (60-64 years), 
0.96 (65-69 years), 2.33 (70-
74 years), 4.08 (75-79 years), 
6.44 (80-84 years), 6.59 (85-
89 years), 8.67 (90+ years) 
0.44 (50-54 years), 0.48 (55-
59 years), 0.46 (60-64 years), 
0.65 (65-69 years), 1.26 (70-
74 years), 2.37 (75-79 years), 
5.19 (80-84 years), 5.71 (85-
89 years), 8.35 (90+ years) 
- 
  Clinical vertebral [19] 2.19 (50-54 years), 3.13 (55-
59 years), 5.16 (60-64 years), 
5.64 (65-69 years), 8.74 (70-
74 years), 12.05 (75-79 years), 
21.19 (80-84 years), 26.89 
(85-89 years), 27.10 (90+ 
years) 
0.50 (50-54 years), 1.11 (55-
59 years), 1.65 (60-64 years), 
0.95 (65-69 years), 2.26 (70-
74 years), 4.50 (75-79 years), 
5.94 (80-84 years), 9.54 (85-
89 years), 10.85 (90+ years) 
- 
  Wrist [18] 4.76 (50-54 years), 7.32 (55-
59 years), 11.16 (60-64 years), 
12.95 (65-69 years), 13.17 
(70-74 years), 13.87 (75-79 
years), 15.01 (80-84 years), 
15.10 (85-89 years), 13.97 
(90+ years) 
1.37 (50-54 years), 1.22 (55-
59 years), 1.42 (60-64 years), 
2.35 (65-69 years), 2.01 (70-
74 years), 2.25 (75-79 years), 
3.42 (80-84 years), 3.44 (85-
89 years), 2.33 (90+ years) 
- 
Mortality rate (per 1,000) for 
general population [17]  
2.12 (50-54 years), 3.48 (55-
59 years), 6.05 (60-64 years), 
10.31 (65-69 years), 20.36 
(70-74 years), 37.84 (75-79 
years), 69.98 (80-84 years), 
136.03 (85+ years) 
5.14 (50-54 years), 7.87 (55-
59 years), 11.66 (60-64 years), 
18.53 (65-69 years), 32.12 
(70-74 years), 55.18 (75-79 
years), 92.94 (80-84 years), 
156.07 (85+ years) 
- 
Relative risks of wrist fractures in 
Asians versus Caucasians [18]  
0.72 (95% CI: 0.53-1.00) 0.72 (95% CI: 0.53-1.00) Beta 
Osteoporosis attribution 
probabilities for hip fractures [21]  
0.75 (Range: 0.20-0.85) for 
50-64 years, 0.85 (Range: 
0.50-0.95) for 65-84 years, 
0.95 (Range: 0.60-0.95) for 
85+  years 
0.55 (Range: 0.10-0.65) for 
50-64 years, 0.75 (Range: 
0.15-0.90) for 65-84 years, 
0.85 (Range: 0.30-0.95) for 
85+  years 
Triangular 
Osteoporosis attribution 
probabilities for clinical vertebral 
fractures [21]  
0.75 (Range: 0.40-0.80) for 
50-64 years, 0.85 (Range: 
0.50-0.95) for 65-84 years, 
0.95 (Range: 0.60-0.95) for 
85+  years 
0.60 (Range: 0.30-0.80) for 
50-64 years, 0.75 (Range: 
0.40-0.90) for 65-84 years, 
0.85 (Range: 0.50-0.95) for 
85+  years 
Triangular 
Osteoporosis attribution 
probabilities for wrist fractures 
[21]   
0.60 (Range: 0.10-0.70) for 
50-64 years, 0.70 (Range: 
0.35-0.80) for 65-84 years, 
0.70 (Range: 0.55-0.90) for 
85+  years 
0.30 (Range: 0.30-0.55) for 
50-64 years, 0.35 (Range: 
0.15-0.50) for 65-84 years, 
0.40 (Range: 0.30-0.50) for 
85+  years 
Triangular 
SMR after a hip fracture [22]   2.43 (95% CI: 2.02-2.93) 3.51 (95% CI: 2.65-4.66) Gamma 
SMR after a clinical vertebral 
fracture [22]  
1.82 (95% CI: 1.52-2.17) 2.12 (95% CI: 1.66-2.72) Gamma 
SMR after a wrist fracture [22]  1.42 (95% CI: 1.19-1.70) 1.33 (95% CI: 0.99-1.80) Gamma 
CI=confidence interval, SMR=standardised mortality ratios. 
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Table 5.2. Residual lifetime risk (%) of the first osteoporotic fracture in men and women by age 
Age 
(years) 
Hip fracture Clinical vertebral fracture Wrist fracture Any of these fractures 
Men Women Men Women Men Women Men Women 
50 2.9 (2.5-3.3) 6.4 (5.8-7.0) 4.2 (3.7-4.6) 19.1 (18.0-20.5) 1.6 (1.3-1.9) 15.4 (14.5-16.5) 8.7 (7.5-9.8) 40.9 (38.3-44.0) 
55 2.9 (2.3-3.3) 5.5 (4.8-6.1) 4.2 (3.7-4.7) 16.4 (15.4-17.5) 1.6 (1.1-1.9) 12.3 (11.3-13.2) 8.7 (7.1-9.9) 34.2 (31.5-36.8) 
60 2.9 (2.6-3.5) 5.4 (4.9-6.0) 4.1 (3.5-4.8) 16.1 (15.0-17.0) 1.5 (1.1-1.8) 11.6 (10.6-12.7) 8.5 (7.2-10.1) 33.1 (30.5-35.7) 
65 3.0 (2.5-3.4) 5.4 (4.8-5.9) 4.1 (3.7-4.6) 15.3 (14.5-16.2) 1.3 (0.9-1.6) 10.1 (9.3-10.9) 8.4 (7.1-9.6) 30.8 (28.6-33.0) 
70 3.1 (2.6-3.7) 5.4 (4.8-5.8) 4.2 (3.7-4.8) 14.9 (14.0-15.8) 1.1 (0.8-1.4) 8.6 (7.7-9.4) 8.4 (6.9-9.8) 28.9 (26.5-31.0) 
75 3.3 (2.9-3.7) 5.2 (4.6-5.8) 4.3 (3.7-4.8) 14.4 (13.6-15.3) 1.0 (0.8-1.2) 7.0 (6.4-7.8) 8.6 (7.4-9.7) 26.6 (24.6-28.9) 
80 3.4 (3.0-3.9) 4.7 (4.3-5.5) 4.3 (3.6-4.8) 13.7 (12.8-14.6) 0.9 (0.6-1.1) 5.4 (4.8-6.0) 8.6 (7.2-9.8) 23.8 (21.9-26.1) 
85 2.9 (2.4-3.3) 3.9 (3.2-4.4) 3.7 (3.2-4.2) 12.4 (11.7-13.3) 0.6 (0.4-0.8) 4.1 (3.5-4.7) 7.2 (6.0-8.3) 20.4 (18.4-22.4) 
90 2.6 (2.2-3.1) 3.3 (2.9-3.8) 2.9 (2.3-3.3) 9.7 (9.0-10.4) 0.3 (0.2-0.5) 2.9 (2.4-3.4) 5.8 (4.7-6.9) 15.9 (14.3-17.6) 
All values are presented with mean and 95% confidence interval. 
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Table 5.3. 10-year risk (%) of the first osteoporotic fracture in men and women by age 
Age 
(years) 
Hip fracture   Clinical vertebral fracture    Wrist fracture   Any of these fractures 
Men Women   Men Women   Men Women   Men Women 
50 0.3 (0.2-0.4) 0.6 (0.3-0.8)  0.6 (0.4-0.8) 3.4 (2.9-3.9)  0.3 (0.2-0.5) 4.2 (3.6-4.6)  1.2 (0.8-1.7) 8.2 (6.8-9.3) 
55 0.3 (0.2-0.5) 0.4 (0.3-0.6)  0.8 (0.6-1.1) 3.0 (2.6-3.4)  0.5 (0.3-0.6) 3.8 (3.3-4.3)  1.6 (1.1-2.1) 7.2 (6.2-8.3) 
60 0.5 (0.3-0.7) 0.7 (0.4-0.9)  0.9 (0.6-1.1) 4.1 (3.4-4.5)  0.6 (0.4-0.8) 5.0 (4.4-5.6)  2.0 (1.3-2.6) 9.8 (8.2-11.0) 
65 0.8 (0.6-1.0) 1.3 (1.1-1.7)  1.4 (1.1-1.7) 5.3 (4.6-5.9)  0.6 (0.4-0.9) 5.4 (4.7-5.9)  2.8 (2.1-3.6) 12.0 (10.4-13.5) 
70 1.5 (1.1-1.8) 2.4 (2.0-2.8)  2.3 (1.8-2.8) 7.3 (6.7-8.1)  0.7 (0.5-0.9) 5.5 (4.8-6.1)  4.5 (3.4-5.5) 15.2 (13.5-17.0) 
75 2.3 (1.9-2.7) 3.5 (3.0-3.9)  3.1 (2.6-3.6) 10.0 (9.2-10.9)  0.8 (0.5-1.0) 5.4 (4.9-6.1)  6.2 (5.0-7.3) 18.9 (17.1-20.9) 
80 2.9 (2.5-3.4) 3.9 (3.5-4.2)  3.8 (3.3-4.4) 12.0 (11.1-12.7)  0.8 (0.6-1.1) 4.7 (4.2-5.2)  7.5 (6.4-8.9) 20.6 (18.8-22.1) 
85 2.7 (2.3-3.1) 3.6 (3.0-4.1)  3.6 (3.1-4.1) 11.8 (11.1-12.7)  0.6 (0.4-0.8) 3.8 (3.3-4.4)  6.9 (5.8-8.0) 19.2 (17.4-21.2) 
90 2.6 (2.1-3.0) 3.2 (2.8-3.7)   2.8 (2.2-3.2) 9.5 (8.8-10.2)   0.3 (0.2-0.5) 2.8 (2.4-3.3)   5.7 (4.5-6.7) 15.5 (14.0-17.2) 
All values are presented with mean and 95% confidence interval. 
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Figure 5.1. Residual lifetime and 10-year risks of the first hip, clinical vertebral, wrist or any of these 
osteoporotic fractures for Chinese men and women by age. 
Chapter 5: Residual lifetime and 10-year absolute risks of osteoporotic fractures in 
Chinese men and women 
211 | P a g e
5.6  Discussion 
Understanding the absolute risks of the first osteoporotic fracture is of value to estimate the 
future burden of osteoporosis to society. To our knowledge, this is the first study to determine 
the residual lifetime and 10-year absolute risks of the first hip, clinical vertebral, wrist or any 
major osteoporotic fracture in Chinese men and women using a health economics model. It is 
estimated that more than one third of Chinese women and approximately one in ten Chinese 
men aged 50 years are expected to sustain a major (hip, clinical vertebral or wrist) osteoporotic 
fracture in their remaining lifetimes. Chinese women are estimated to have much higher 
residual lifetime and 10-year risks of osteoporotic clinical vertebral and wrist fractures, but the 
difference in 10-year risks of hip fractures are relatively small between men and women (Table 
5.3 and Figure 5.1). 
The estimated risks of osteoporotic fractures in the Chinese population from our study are 
consistent with those in previous studies which have been found lower than those in Caucasians 
[7, 8, 26-29] and some other Asian populations [9, 10], but the residual lifetime hip fracture 
risk at age 50 years was noticeably higher than the earlier estimation for the Chinese population 
[11] (Table 5.4). The reasons for the increase are threefold: First, the incidence of hip fractures
has significantly increased in the past decades; this secular trend was not only observed in 
China but in other areas [10, 13, 30, 31]. Second, the proportion of Chinese population aged 
65 years and above has grown with the ageing population [32]. Finally, the life expectancy has 
also increased by approximately 3 years between 2000 and 2010 [33]. Based on the above three 
factors, the residual lifetime hip fracture risk, the result of competing risks between mortality 
and fracture, has increased from 2.4% for women and 1.9% to men in 2002 to 6.4% for women 
and 2.9% for men aged 50 years. 
10-year absolute fracture risks increased with age until annual mortality risks out-competed the
fracture risks. In our study, the turning points for the 10-year fracture risks occur at age 80 
years in both sexes (Figure 5.1), and decrease with age thereafter. The 10-year fracture risks 
approach the residual lifetime fracture risks above age 90 years, as very few people are 
expected to live above the age of 100 years [33]. 
In this study, a validated state-transition microsimulation model was used to estimate the 
residual lifetime and 10-year absolute fracture risks. Health economics models have been 
extensively used in risk predictions not only in osteoporosis but in other diseases [7, 28, 34-
38]. By using this approach, the simulated subjects were analysed for the residual lifetime or a 
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defined time period. More importantly, this health economics model can be used to identify the 
interventions that represent good value for money when it includes costs and effectiveness in 
the model analysis, i.e. cost-effectiveness analysis. Precise estimates of the residual lifetime 
fracture risks for scenarios with and without fracture preventions are of value to the healthcare 
policy maker to leverage scarce resources, therefore future studies are encouraged be 
performed to identify the cost-effective fracture prevention strategies given the increased 
residual lifetime and 10-year fracture risks in the Chinese population. 
Table 5.4. Comparison of residual lifetime osteoporotic fracture risks (%) across countries at age 50 
years 
Country 
Year of 
publication 
Hip fracture Vertebral fracture Wrist fracture 
Men Women Men Women Men Women 
China [11] 2012 1.9 2.4 - - - - 
Current study - 2.9 6.4 4.2 19.1 1.6 15.4 
Australia [27] 2001 2.0 7.0 6.0 8.0 5.0 12.0 
Canada [8] 2012 6.2 7.3 - - - - 
Korea [9] 2011 5.2 12.3 - - 4.9 21.7 
Australia [28] 2001 - 17.0 - 9.6 - - 
Japan [10] 2009 5.6 20.0 - - - - 
Sweden [26] 2000 10.7 22.9 8.3 15.1 4.6 20.8 
Belgium [7] 2008 - 24.8 - 13.9 - 18.1
Norway [29] 2009 18.3 30.4 - - 6.2 32.7
There are potential limitations to our study. First, regional hip and clinical vertebral fracture 
incidence rates were used, which might not be representative of the whole country. Large 
variations in fracture risks within the same country were reported in previous study [27]. It 
would be preferable to use fracture incidences from several regions or country level data if 
these were available, particularly for countries like China whose population has different ethnic 
groups and risks factors. Second, because of the paucity of data on wrist fracture incidence in 
the Chinese population, wrist fracture rates from a Norwegian study were used and calibrated 
to the Asian population using a 0.72 fracture relative risk. Nevertheless, the generalizability of 
the results is a major concern, updated study using data from a country-level survey on different 
fracture sites is required. Third, we only included hip, clinical vertebral and wrist fractures in 
this study, fractures at other sites like tibia, humerus, ribs and pelvis were omitted. Therefore, 
our study potentially underestimated the residual and 10-year risks of all major osteoporotic 
fractures. Fourth, only two risk factors (sex and age) were included in this study. Other risk 
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factors such as smoking, high intake of alcohol and rheumatoid arthritis that might influent the 
fracture risks were not included [39]. In addition, we assumed that the risk of fractures will 
remain stable over simulation time horizon. However, because of the new medications to 
prevent fractures were publically available and the increasing awareness of the significance of 
osteoporosis, recent studies demonstrated that the fracture risks have decreased in some 
countries like Australia [11]. In contrast, in countries like China, Japan, Turkey, hip fracture 
risks kept rising in the past decade [11, 13, 30]. Finally, despite the fact that we only accounted 
for the first fracture in simulated subjects, patients with fracture history might also have been 
included in the original studies. Because fracture risks for patients with prior fractures are 
higher than those who do not have a history of fracture, the probability used may be higher 
than the probability of having a first fracture and in turn the residual lifetime and 10-year risks 
of having a first fracture are potentially overestimated. Due to a lack of published information 
on distributions around fracture incidence rates, osteoporosis prevalence and mortality rates for 
the general population, point estimates only were used for these parameters.  
Nonetheless, the results in this study present the best estimates with currently available data. 
Osteoporosis has been listed as one of the National Health Priorities (NHPs) since 2011, 
because of its substantial disease and financial burden to the Chinese healthcare system. The 
costs of osteoporotic fractures were estimated to double by 2035 due to rapidly ageing Chinese 
population [4], health economics evaluation studies are urgent to be performed to find the 
fracture preventions that present good value for money. To date, several fracture prevention 
drugs in the National Drug List are publically funded. However, no health economics evidence 
was provided for most of these drugs. As a result, cheap drugs such as calcitonin is still 
dominantly used in China [40], while its cost-effectiveness comparing with alendronate is 
inconclusive due to highly sensitive efficacy of calcitonin [41]. Some other drugs, such as 
denosumab, were proved to be cost-effective in the Caucasian population [42], but were not 
reimbursed from the public health insurance. With the baseline fracture risks from the current 
study, future work is urgently needed to identify the cost-effective osteoporosis screening 
strategies and fracture prevention medications using a Chinese country-specific health 
economics evaluation model [14]. 
More than one third of Chinese women and around one tenth Chinese men aged 50 years are 
expected to sustain the first osteoporotic (hip, clinical vertebral or wrist) fracture in the 
remaining life. Risks of fractures have increased in the past decade in Chinese men and women. 
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While fracture risks estimates are lower in Chinese than Caucasian populations, it is clear that 
osteoporotic fractures will still produce a major burden for the Chinese health system and the 
prevention of osteoporosis is an issue which requires serious attention. Without targeted 
interventions, fracture risks may continue to increase in the future which in turn pose a major 
challenge to the healthcare system and also healthcare resources allocation. 
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Chapter 6: Projection of osteoporosis-related fractures 
and costs in China: 2010-2050 
6.1  Preface 
This chapter presents the second application of our osteoporosis health economics model. 
Estimates of current and future number as well as economic burden of osteoporotic fractures 
to the Chinese healthcare system are provided. Around 2.33 million osteoporotic fractures 
occurred in 2010, costing the Chinese healthcare system approximately $9.45 billion. Annual 
number and costs of osteoporosis-related fractures are estimated to double by 2035 and will 
increase to 5.99 million fractures costing $25.43 billion by 2050. Consequently, cost-
effective intervention policies must urgently be identified in an attempt to minimize the 
impact of fractures: a subject of Chapter 7’s investigation. 
This chapter has been published in Osteoporosis International (Appendix 6A). 
Impact factor: 4.17.  
Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ. Projection of Osteoporosis-Related 
Fractures and Costs in China: 2010-2050. Osteoporosis International, July 2015. 26(7): 
1929-37. 
The published article of this chapter 
appears in an appendix to the 
chapter. It has been removed for 
copyright or proprietary reasons.
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6.2  Abstract 
Introduction: The aim of the study was to project the osteoporosis-related fractures and 
costs for the Chinese population aged ≥50 years from 2010 to 2050. 
Methods: A state-transition microsimulation model was used to simulate the annual incident 
fractures and costs. The simulation was performed with a 1-year cycle length and from the 
Chinese healthcare system perspective. Incident fractures and annual costs were estimated 
from 100 unique patient populations for year 2010, by multiplying the age- and sex-specific 
annual fracture risks and costs of fracture by the corresponding population totals in each of 
the 100 categories. Projections for 2011-2050 were performed by multiplying the 2010 risks 
and costs of fracture by the respective annual population estimates. Costs were presented in 
2013 US dollars.  
Results: Approximately 2.33 (95% CI: 2.08, 2.58) million osteoporotic fractures were 
estimated to occur in 2010, costing $9.45 (95% CI: 8.78, 10.11) billion. Females sustained 
approximately 3 times more fractures than males, accounting for 76% of the total costs from 
1.85 (95% CI: 1.68, 2.01) million fractures. Annual number and costs of osteoporosis-related 
fractures were estimated to double by 2035 and will increase to 5.99 (95% CI: 5.44, 6.55) 
million fractures costing $25.43 (95% CI: 23.92, 26.95) billion by 2050.  
Conclusions: Our study demonstrated that osteoporosis-related fractures cause a substantial 
economic burden which will markedly increase over the coming decades. Consequently, 
healthcare resource planning must consider these increasing costs, and cost-effective 
screening and intervention policies must urgently be identified in an attempt to minimize the 
impact of fractures on the health of the burgeoning population as well as the healthcare 
budget. 
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6.3  Introduction 
Osteoporosis and osteoporotic fractures are global concerns both affecting the quality of life 
and incurring a high economic burden to patients and society [1, 2]. The prevalence of 
osteoporosis has been estimated at approximately 13% in the Chinese population, which is 
lower than that seen in Caucasian populations [3]. The risk of fractures increases with age 
[4], so the number of osteoporotic fractures will inevitably increase due to the ageing Chinese 
population [5].  
Worldwide, it was estimated 9 million osteoporotic fractures occurred in 2000, of which 1.6 
million were hip fractures, 1.7 million were wrist fractures and 1.4 million were clinical 
vertebral fractures [6]. The global annual number of hip fracture is predicted to increase to 
2.6 million fractures by 2025 and 4.5 million by 2050 [7]. Similar trends have been projected 
for China, with annual hip fracture number predicted to be 0.69 million in 2006 and to rise to 
1.64 million fractures by 2020 and 5.91 million fractures by 2050 [8]. The annual costs of hip 
fractures in China were estimated at approximately $2.05 billion (in 2013 US dollar) in 2006, 
rising to $27.48 billion and $581.97 billion by 2020 and 2050 respectively. However, there 
are concerns about the accuracy of the Chinese estimation as figures for annual hip fracture 
number were higher than the total global estimation. This is probably because the estimate 
assumed a constant increase in osteoporosis prevalence and there was no thorough 
description of methodology used to project fracture number and costs of osteoporotic 
fractures [8]. 
Due to the increase of proportion of the elderly population, increasing life expectancy and the 
introduction of new drugs and technologies, the total health expenditure in China had risen 
from $180 billion (in 2013 US dollar) in 2000 to $524 billion in 2010 [9]. Although 
osteoporosis has been listed as one of the National Health Priorities since 2011 because of its 
high disease and economic burden, a more robust estimation on number and costs of 
osteoporotic fractures will assist health policy makers to plan healthcare resource allocation 
for prevention and treatment of osteoporotic fractures in the future. Our study aimed to 
provide an updated estimation of number and costs of all major osteoporotic fractures by age 
and gender for the Chinese population aged ≥50 years from 2010 through to 2050. 
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6.4  Methods 
6.4.1 Model overview 
A published, validated state-transition microsimulation model was used to estimate the 
number and costs of osteoporosis-related fractures for the Chinese population aged ≥50 years. 
The model was constructed and validated for the use of health economics evaluations in 
osteoporosis. We have previously described in detail the structure of the model and the model 
parameters [10]. Briefly, four disease states including three types of fracture (hip, wrist and 
vertebral fractures) were incorporated in the model: no history of fracture, fractured, post-
fracture state and death (Figure 6.1). Simulated people were allowed to sustain multiple 
fractures at different sites in their residual lifetime during simulation. The number of fracture 
by age, sex and sites were recorded using tracker variables.  
Figure 6.1. Structure of the Markov model. Simulated patients can transit between Markov 
states following the arrow direction, “Fractured” is a temporary state and denotes patients 
sustaining a hip, vertebral, wrist or other osteoporotic fracture. “Death” is an absorbing state 
that indicates all simulated patients will end in that state. 
6.4.2 Model inputs 
The key parameters in the model are summarized in Table 6.1. Wherever possible, published 
or publicly available Chinese data sources were used in our model. The transition 
probabilities were based on fracture and mortality rates that have been retrieved from 
published studies or from the China Statistical Yearbook (2013) [11-15]. Simulated subjects 
were assumed to have a higher mortality risk after fracture events [16, 17]. Multiple fractures 
at different fracture sites were accounted for in the simulation, with the risk of subsequent 
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fractures by site being elevated compared to that without fracture history [18, 19]. 
The study was performed using a healthcare system perspective, therefore direct costs 
(including direct medical costs and direct non-medical costs) from osteoporosis-related 
fractures were included. Annual costs distributions by fracture sites from a recent study in 
western China were used [20]. Patients were assumed to have a possibility of residing in a 
nursing home after hip fracture [21], and the cost of nursing home was assumed at $4,395 per 
annum [22]. All costs were converted to 2013 US dollars. 
6.4.3 Annual osteoporosis-attributed fracture rates 
Osteoporosis-attributed fractures refer to the fractures that would not have occurred if no 
osteoporosis was present according to the World Health Organization standard, i.e.: hip 
(femoral neck) bone mineral density (BMD) 2.5 standard deviation (SD) or more below the 
young adult mean (i.e. T-score ≤-2.5) [23]. Osteoporosis attribution probabilities by fracture 
site, sex and age were retrieved from the study by Melton et al. [24]. Using these probabilities 
and the annual fracture rates reported in the published literature (Table 6.1) [13-15], the 
annual osteoporotic fracture rates were calculated by fracture site, sex and age.  
6.4.4 Model validation 
By way of internal validation, goodness-of-fit analysis was performed to test whether the 
model could correctly reproduce the input parameters. A linear curve was fitted with the least 
distance between the fitted line and all of the data points [25-27], and the squared linear 
correlation coefficient (R2), which was an index of the degree to which the data variation can 
be explained, was generated from the linear regression model. In this study, we compared the 
hip, clinical vertebral and wrist annual fracture rates by age and sex from model outputs 
against those from the reference studies.  
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Table 6.1. Key parameters in the model  
Parameter Women Men Distribution 
Prevalence of osteoporosis (%) 
[11] 
3.5 (50-59 years), 14.2 (60-69 
years), 26.8 (70-79 years), 
39.2 (80+  years) 
2.2 (50-59 years), 6.2 (60-69 
years), 9.8 (70-79 years), 18.8 
(80+  years) 
- 
Fracture incidence (annual rate 
per 1,000 person-years) 
   
  Hip [15] 0.33 (50-54 years), 0.46 (55-
59 years), 0.54 (60-64 years), 
0.96 (65-69 years), 2.33 (70-
74 years), 4.08 (75-79 years), 
6.44 (80-84 years), 6.59 (85-
89 years), 8.67 (90+ years) 
0.44 (50-54 years), 0.48 (55-
59 years), 0.46 (60-64 years), 
0.65 (65-69 years), 1.26 (70-
74 years), 2.37 (75-79 years), 
5.19 (80-84 years), 5.71 (85-
89 years), 8.35 (90+ years) 
 
  Clinical vertebral [13] 2.19 (50-54 years), 3.13 (55-
59 years), 5.16 (60-64 years), 
5.64 (65-69 years), 8.74 (70-
74 years), 12.05 (75-79 
years), 21.19 (80-84 years), 
26.89 (85-89 years), 27.10 
(90+ years) 
0.50 (50-54 years), 1.11 (55-
59 years), 1.65 (60-64 years), 
0.95 (65-69 years), 2.26 (70-
74 years), 4.50 (75-79 years), 
5.94 (80-84 years), 9.54 (85-
89 years), 10.85 (90+ years) 
 
  Wrist [14] 4.76 (50-54 years), 7.32 (55-
59 years), 11.16 (60-64 
years), 12.95 (65-69 years), 
13.17 (70-74 years), 13.87 
(75-79 years), 15.01 (80-84 
years), 15.10 (85-89 years), 
13.97 (90+ years) 
1.37 (50-54 years), 1.22 (55-
59 years), 1.42 (60-64 years), 
2.35 (65-69 years), 2.01 (70-
74 years), 2.25 (75-79 years), 
3.42 (80-84 years), 3.44 (85-
89 years), 2.33 (90+ years) 
 
    
Mortality rate (per 1,000) for 
general population [12] 
2.12 (50-54 years), 3.48 (55-
59 years), 6.05 (60-64 years), 
10.31 (65-69 years), 20.36 
(70-74 years), 37.84 (75-79 
years), 69.98 (80-84 years), 
136.03 (85+ years) 
5.14 (50-54 years), 7.87 (55-
59 years), 11.66 (60-64 
years), 18.53 (65-69 years), 
32.12 (70-74 years), 55.18 
(75-79 years), 92.94 (80-84 
years), 156.07 (85+ years) 
- 
Relative risks of wrist fractures in 
Asians versus Caucasians [14] 
0.72 (95% CI: 0.53-1.00) 0.72 (95% CI: 0.53-1.00) Beta 
Osteoporosis attribution 
probabilities for hip fractures [24] 
0.75 (Range: 0.20-0.85) for 
50-64 years, 0.85 (Range: 
0.50-0.95) for 65-84 years, 
0.95 (Range: 0.60-0.95) for 
85+  years 
0.55 (Range: 0.10-0.65) for 
50-64 years, 0.75 (Range: 
0.15-0.90) for 65-84 years, 
0.85 (Range: 0.30-0.95) for 
85+  years 
Triangular 
Osteoporosis attribution 
probabilities for clinical vertebral 
fractures [24] 
0.75 (Range: 0.40-0.80) for 
50-64 years, 0.85 (Range: 
0.50-0.95) for 65-84 years, 
0.95 (Range: 0.60-0.95) for 
85+  years 
0.60 (Range: 0.30-0.80) for 
50-64 years, 0.75 (Range: 
0.40-0.90) for 65-84 years, 
0.85 (Range: 0.50-0.95) for 
85+  years 
Triangular 
Osteoporosis attribution 
probabilities for wrist fractures 
[24] 
0.60 (Range: 0.10-0.70) for 
50-64 years, 0.70 (Range: 
0.35-0.80) for 65-84 years, 
0.70 (Range: 0.55-0.90) for 
85+  years 
0.30 (Range: 0.30-0.55) for 
50-64 years, 0.35 (Range: 
0.15-0.50) for 65-84 years, 
0.40 (Range: 0.30-0.50) for 
85+  years 
Triangular 
SMR after a hip fracture [17] 2.43 (95% CI: 2.02-2.93) 3.51 (95% CI: 2.65-4.66) Gamma 
SMR after a clinical vertebral 
fracture [17] 
1.82 (95% CI: 1.52-2.17) 2.12 (95% CI: 1.66-2.72) Gamma 
SMR after a wrist fracture [17] 1.42 (95% CI: 1.19-1.70) 1.33 (95% CI: 0.99-1.80) Gamma 
Costs (2013 US dollar)    
  Annual nursing home [22] 4,395 (Range: 3,767-5,023) 4,395 (Range: 3,767-5,023) Triangular 
  Hip fracture, first year [20] 6,462 (Range: 3,231-9,693) 6,462 (Range: 3,231-9,693) Triangular 
  Vertebral fracture, first year [20] 4,884 (Range: 2,442-7,326) 4,884 (Range: 2,442-7,326) Triangular 
  Wrist fracture, first year [20] 1,980 (Range: 990-2,970) 1,980 (Range: 990-2,970) Triangular 
CI=confidence interval, SMR=standardised mortality ratios. 
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6.4.5 Base year and projection of fractures and annual costs 
Year 2010 was selected as the base year of analysis. Age-, sex- and fracture site-specific 
osteoporotic fracture risks and costs for 2010 were generated from simulations with a one 
year time horizon [28]. A total of ten million simulations (100 sampling × 100,000 trials) 
were performed in each of 100 independent populations (50 age groups × 2 sexes). The total 
Chinese population annual fracture numbers by age and sex in 2010 were estimated by 
multiplying the fracture rates predicted from the model with the corresponding population 
numbers [29]. Total costs of fractures for the base year by age and sex were calculated by 
multiplying the average annual costs predicted from the model by the corresponding 
population totals. Projections for 2011 to 2050 were performed by multiplying base-year 
fracture number by their respective population estimation from the World Bank [29], 
assuming that these fracture rates would not change over the simulated time period. 
6.4.6 Statistical analysis 
The state-transition microsimulation model was constructed and analysed using TreeAge Pro 
Suite 2014 (TreeAge Software, Williamstown, Massachusetts), and the calculation of base-
year and projected fracture number and costs were performed using Microsoft Excel 
(Microsoft Office Professional 2013). Incidence of fractures were reported as the number of 
fractures divided by the population totals aged 50+ years. Uncertainties around the annual 
number and costs of fractures were addressed through probabilistic sensitivity analysis by 
sampling from distributions around the parameters, generating mean and 95% confidence 
intervals (CI) for annual number and costs of fractures. Due to lack of information on 
distributions around vertebral and wrist fracture incidence rates and population projection 
estimates, point estimates only were used for these parameters. 
6.5  Results 
6.5.1 Model validation 
A total of 54 internal validations were performed by comparing model predictions of hip, 
clinical vertebral and wrist fracture rates by age and sex against those data used in creating 
our model (Figure 6.2). The fracture rates generated by the model accurately match the 
published data that had been used in model construction: the regression line slope was 0.992 
and the R2 was 0.997. 
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6.5.2 Base year annual fractures and costs 
Annual fracture number and annual costs for the base year by age group, sex and fracture site 
are given in Table 6.2. In 2010, the model predicted that approximately 2.33 (95% CI: 2.08, 
2.58) million fractures occurred, accounted for approximately 7.15 per 1,000 people aged 50+ 
years, costing about $9.45 billion (95% CI: 8.78, 10.11 billion US dollars) to the Chinese 
healthcare system. Females were estimated to sustain approximately four times the number of 
fractures than males, with total annual incident fractures of 1.85 and 0.48 million 
respectively. Females aged 60-64 years were estimated to sustain highest wrist and total 
fracture events, whereas hip and clinical vertebral fracture number were highest in age group 
75-79 years. The annual costs were highest in age group 75-79 years. Men aged 75-79 years
had the highest total costs and predicted incident hip, clinical vertebral and total fractures. 
Although women sustained around four times the number of fractures, due to the differing 
distribution amongst the site of fractures, the total costs of osteoporotic fracture in women 
was approximately three times than that in men ($7.18 billion versus $2.27 billion). 
6.5.3 Projection of annual fractures and related cost to 2050 
Projection of fractures by sex for each fracture site are given in Figure 6.3 and Appendix 
Table 6B.1. Fracture number and related costs at the included fracture sites were estimated to 
increase through to 2050 in both sexes. Relative to the base year, annual total fracture number 
and costs were predicted to double by year 2035 (4.83 million fractures at a cost of 19.92 
billion US dollars) and were projected to rise to 5.99 (95% CI: 5.44, 6.56) million fractures, 
accounted for approximately 9.84 per 1,000 people aged 50+ years, costing $25.43 billion 
(95% CI: 23.92, 26.95 billion US dollars) by year 2050. 
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Figure 6.2. Goodness-of-fit test for model internal validation 
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Table 6.2. Osteoporotic incident fractures and annual costs by age group, sex and fracture site for the base-year 
Stratum 
Incident osteoporotic fracture number (95% CI) Total annual 
costs b (95% CI) Hip Vertebral a Wrist Total 
Female 
  Age (years) 
50-54 10,713 (7,380, 14,760) 67,944 (58,653, 77,375) 86,496 (73,646, 95,865) 165,153 (139,679, 188,000) 0.57 (0.52, 0.62) 
55-59 14,475 (10,351, 19,223) 101,062 (88,797, 113,779) 134,931 (120,627, 147,087) 250,469 (219,775, 280,089) 0.85 (0.78, 0.93) 
60-64 14,161 (10,578, 18,158) 112,927 (101,204, 124,378) 145,263 (132,612, 158,077) 272,351 (244,394, 300,613) 0.93 (0.86, 1.00) 
65-69 20,987 (17,083, 25,798) 99,431 (91,688, 107,764) 124,621 (114,349, 135,072) 245,040 (223,119, 268,634) 0.87 (0.82, 0.92) 
70-74 37,281 (32,373, 42,547) 121,976 (113,480, 130,969) 104,857 (96,398, 112,538) 264,115 (242,251, 286,054) 1.04 (0.99, 1.11) 
75-79 47,706 (43,340, 52,118) 132,791 (124,785, 141,015) 80,382 (75,045, 85,309) 260,879 (243,170, 278,441) 1.12 (1.07, 1.16) 
80-84 40,377 (37,397, 43,606) 131,734 (125,828, 137,852) 50,954 (46,967, 54,693) 223,065 (210,193, 236,150) 1.01 (0.97, 1.04) 
85-89 20,901 (19,368, 22,407) 77,641 (74,565, 80,779) 23,479 (21,901, 25,127) 122,021 (115,834, 128,313) 0.56 (0.54, 0.58) 
90-94 7,613 (7,132, 8,177) 24,286 (23,314, 25,352) 6,777 (6,282, 7,253) 38,676 (36,728, 40,782) 0.18 (0.18, 0.19) 
    95~ 1,852 (1,730, 1,970) 5,852 (5,625, 6,071) 1,615 (1,498, 1,742) 9,320 (8,853, 9,783) 0.04 (0.04, 0.05) 
    Sub-total 216,066 (186,733, 248,763) 875,646 (807,939, 945,334) 759,375 (689,326, 822,763) 1,851,088 (1,683,998, 2,016,860) 7.18 (6.76, 7.60) 
Male 
  Age (years) 
50-54 11,225 (7,094, 15,857) 19,112 (12,769, 24,119) 16,374 (12,185, 22,033) 46,711 (32,048, 62,009) 0.20 (0.15, 0.24) 
55-59 12,458(8,305, 17,607) 36,633 (29,234, 43,684) 17,067 (12,042, 23,005) 66,158 (49,581, 84,296) 0.29 (0.24, 0.33) 
60-64 11,452 (8,208, 15,355) 27,192 (21,999, 32,497) 16,784 (12,786, 21,329) 55,428 (42,994, 69,181) 0.24 (0.21, 0.27) 
65-69 15,254 (11,647, 18,526) 21,996 (17,431, 25,991) 15,204 (11,764, 18,878) 52,455 (40,843, 63,394) 0.24 (0.20, 0.27) 
70-74 22,882 (19,358, 27,016) 37,663 (33,318, 42,122) 11,717 (9,106, 14,383) 72,262 (61,781, 83,521) 0.36 (0.32, 0.39) 
75-79 32,219 (29,026, 35,470) 40,210 (36,391, 44,147) 10,206 (8,187, 12,124) 82,635 (73,604, 91,740) 0.42 (0.39, 0.45) 
80-84 23,569 (21,651, 25,761) 31,545 (29,358, 33,931) 6,893 (5,775, 8,087) 62,006 (56,784, 67,779) 0.32 (0.30, 0.34) 
85-89 11,855 (10,837, 12,789) 15,491 (14,440, 16,586) 2,276 (1,876, 2,659) 29,622 (27,153, 32,035) 0.16 (0.15, 0.17) 
90-94 3,252 (3,032, 3,514) 3,737 (3,412, 3,988) 435 (358, 518) 7,423 (6,802, 8,020) 0.04 (0.04, 0.04) 
    95~ 720 (670, 780) 829 (753, 883) 96 (81, 114) 1,646 (1,504, 1,777) 0.01 (0.01, 0.01) 
    Sub-total 144,886 (119,829, 172,675) 234,408 (199,105, 267,948) 97,053 (74,160, 123,129) 476,347 (393,093, 563,753) 2.27 (0.02, 2.51) 
Overall total 360,952 (306,561, 421,439) 1,110,055 (1,007,044, 1,213,282) 856,428 (763,486, 945,893) 2,327,435 (2,077,091, 2,580,613) 9.45 (8.78, 10.11) 
a Clinical vertebral fractures. b Costs are presented in 2013 billion US dollars, CI = confidence interval
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Figure 6.3. Estimation of incident osteoporosis-related fractures, i.e., fracture events that would have been avoided if osteoporosis was not presented, and 
costs from 2010 to 2050. Annual fracture costs for year 2010 were predicted to be $9.45 billion to the Chinese healthcare system, it is estimated to double by 
year 2035 ($19.92 billion) and will rise to approximately $25.43 billion by year 2050. All costs are expressed in 2013 US Dollars. 
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6.6  Discussion 
This is the first study using a decision analytic model to estimate the osteoporosis-related 
fracture number and costs for the Chinese population aged ≥50 years from 2010 to 2050. To 
our knowledge, most previous estimates were based on the report “White Paper China 2008, 
Osteoporosis a Summary Statement of China” [8]. In that report, a total of 687,000 hip 
fractures were estimated to occur in China in 2006, with 241,000 in men and 446,000 in 
women over age 50-years. The number of annual hip fractures was projected to rise to 1.64 
million by 2020 and 5.91 million by 2050. However, the estimations were based on the 
overall hip fracture incidence rate for the population aged above 50 years and assumed a 
steady increase of osteoporosis prevalence over the projection period. Vertebral fracture 
number was estimated at 1.08 million per annum, but only vague methodological details on 
how they projected fracture number were described [8]. Our study provided more robust and 
reproducible insight into fracture numbers by age, sex and fracture sites and annual costs over 
an extended time period for the Chinese population compared to previous estimations [8, 30]. 
For the base-year 2010, the total fracture number was estimated to be more than 2.3 million at 
a cost of approximately ten billion US dollars to the Chinese healthcare system. The 
proportion of fracture costs relative to the total health expenditure in 2010 was around 1.8% 
($9.45 billion versus $524 billion) in China, which was much higher than that in the U.S. 
Although the total absolute costs of osteoporotic fractures were estimated at $18.7 billion in 
the U.S., which only took around 0.7% of its total health expenditure [28]. Approximately 
half of the osteoporotic fractures were clinical vertebral fractures, whereas hip and wrist 
fractures (0.36 million and 0.86 million respectively) accounted for the remaining 52% 
fractures. Notably, men contributed approximately 20% of total fracture events, which 
indicated osteoporotic fractures are an important public health issue for men as well as 
women. In particular, the difference in annual hip fracture number (0.07 million) between 
men and women was relatively small compared with that of total fractures (1.37 million). 
This is consistent with the published literature as much lower female to male ratio of hip 
fractures have been reported in the Chinese population [15, 31, 32] than in Caucasians [33, 
34]. Different rates of hip fracture between men and women also explains the fact that 
although the number of all osteoporotic fractures in women is more than 4 times greater than 
that seen in men, the difference in costs between men and women is much smaller, as the 
direct costs of hip fracture are greater than those for vertebral and wrist fractures [20]. 
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Over the 40-year projection period, the estimated number of osteoporosis-related fractures 
and annual costs will increase by approximately 158% and 169% respectively compared to 
2010. The reasons for the increase are two-fold: first, osteoporotic fracture risks increase with 
age, especially after age 50 years when skeletal mass and density reductions are expected [4]. 
With an aging Chinese population, the proportion of population aged ≥50 is estimated to 
double from 24% in 2010 to 48% by 2050 [29]. Second, the population aged 75-79 years in 
2050, where the highest costs were estimated to occur (Table 6.2), almost quadruples 
comparing with year 2010 (increasing by 3.01 times in men and 2.95 times in women).  
State-transition models have been used in the prediction and projection of disease incidences 
and related costs not only in the context of osteoporosis [28, 35-37], but other diseases [38-
40] in the past decades. Using a state-transition model, a variety of epidemiological sources 
affecting osteoporotic fracture risks, such as osteoporosis attribution probabilities for hip, 
vertebral or wrist fractures, are synthesised and analysed simultaneously [28, 36]. More 
importantly, it is possible to record the characteristics of simulated patients to more 
accurately predict long-term observations such as lifetime fracture risks.  
Our study has some limitations. First, the projection results after 2010 were based on sex- and 
age-specific population estimates [29]. Therefore, the accuracy of our estimation is highly 
reliant on the precision of the population projection from the World Bank. Second, our study 
assumed that medical practice and prices in 2010 remained constant over time. In the past, 
new medications became available to prevent fractures [2, 30] and they had impacts on the 
economic burden to the healthcare system. To simplify our projections and in the absence of 
data on which to base assumptions about future medication effectiveness, use and costs, 
incorporation of assumptions about the future interventions to prevent fractures has been 
avoided, and we assumed that the fracture incidence rates will remain constant until 2050. 
Third, the age- and sex-specific incidence rates in our study were retrieved from multiple 
sources in different populations. Hip fracture rates were used from a recent observational 
study from Hefei which is located in the centre of China [15], and it is higher than previous 
reported incidence rates from north-east China ten years ago [31, 41] but similar to another 
study performed in Tangshan [5]. The clinical vertebral fracture rates were retrieved from a 
Southern Chinese population. Due to the lack of Chinese data, the age and gender-specific 
wrist fracture incidence rates were taken from a Caucasian population and calibrated to an 
Asian population [14, 24]. Optimally, better estimations could be achieved based on fracture 
incidence rates derived entirely from Chinese populations when they become available in the 
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future. In addition, the costs of hip, vertebral or wrist fractures were retrieved from the study 
in western China. Due to the differences in healthcare delivery system, demographic and 
socioeconomic variations, the costs of fractures might differ in other regions. Similar to the 
fracture number predictions, projection of fracture costs should be updated using country-
level data in the future. Finally, despite hip, vertebrae and wrist being acknowledged as 
classic osteoporotic fracture sites, it is still hard to define what constitutes an osteoporotic 
fracture [42]. Recent studies have suggested “other” fracture sites like humerus, rib, pelvis, 
tibia and fibular fractures are also common osteoporotic fractures, and the costs and number 
of these “other” fractures were estimated to contribute to a high proportion of total fracture 
costs and incident numbers [28, 43]. However, we excluded “other” fractures in our analyses 
because good estimates of age-specific incidence rates, costs, standardized mortality ratios 
and relative risks of subsequent fractures following a fracture in “other” sites in the Chinese 
population have not yet been reported. Nevertheless, our study potentially underestimates the 
total number and economic impact of osteoporotic fractures.  
Our study demonstrated that osteoporosis-related fractures cause a substantial economic 
burden to the Chinese healthcare system which will markedly increase over the coming 
decades unless action is taken. In 2010, it was estimated over 2.3 million osteoporotic 
fractures led to costs of approximately ten billion US dollars to the Chinese healthcare 
system. Number and costs of osteoporosis-related fracture are predicted to double by year 
2035 and will grow to about 6 million fractures costing $25.4 billion annually by year 2050. 
Consequently, healthcare resource planning must consider these increasing costs, and cost-
effective screening and intervention policies must urgently be identified and implemented in 
an attempt to minimize the impact of fractures on the health of the burgeoning population as 
well as the health care budget. 
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Appendix Table 6B.1 Average annual incident fractures by sex and fracture sites: 2015-2050 
 
2015 2020 2025 2030 2035 2040 2045 2050 
Female 
        
  Hip fracture incidences 245,399 289,892 352,822 422,508 482,220 555,421 626,855 656,745 
  Vertebral fracture incidences a 1,008,193 1,184,410 1,416,285 1,662,843 1,854,752 2,067,428 2,284,375 2,384,460 
  Wrist fracture incidences 889,607 1,055,318 1,232,448 1,385,617 1,509,136 1,610,579 1,673,619 1,698,182 
  All fracture incidences 2,143,199 2,529,620 3,001,555 3,470,968 3,846,107 4,233,428 4,584,849 4,739,387 
  Total costs b 8.27 9.75 11.64 13.59 15.16 16.87 18.52 19.25 
Male 
        
  Hip fracture incidences 165,968 195,752 235,495 280,778 316,203 358,939 286,283 422,255 
  Vertebral fracture incidences a 267,593 313,268 377,356 438,733 481,315 539,336 524,568 620,885 
  Wrist fracture incidences 112,969 133,936 153,611 169,857 183,942 197,253 199,583 211,950 
  All fracture incidences 546,529 642,956 766,462 889,367 981,460 1,095,529 1,010,434 1,255,090 
  Total costs b 2.60 3.06 3.67 4.29 4.76 5.34 5.96 6.18 
Total 
        
  Hip fracture incidences 411,367 485,644 588,317 703,286 798,423 914,360 913,138 1,079,000 
  Vertebral fracture incidences a 1,275,786 1,497,678 1,793,641 2,101,576 2,336,067 2,606,764 2,808,943 3,005,345 
  Wrist fracture incidences 1,002,576 1,189,254 1,386,059 1,555,474 1,693,078 1,807,832 1,873,202 1,910,132 
  All fracture incidences 2,689,728 3,172,576 3,768,017 4,360,335 4,827,567 5,328,957 5,595,283 5,994,477 
  Total costs b 10.87 12.81 15.31 17.88 19.92 22.21 24.48 25.43 
a Clinical vertebral fractures. b Costs are presented in 2013 billion US dollars 
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menopausal women: a health economic modelling study 
7.1  Preface 
This chapter presents the third application of the osteoporosis health economics model. 
Screening for- and appropriate treatment of osteoporosis has been proven to be cost-effective 
in many populations, however, it was not clear in the Chinese population. This study has 
demonstrated that screening for osteoporosis in Chinese women, followed by appropriate 
treatment is cost-effective and may even be cost-saving in Chinese post-menopausal women. 
This chapter has been published in Osteoporosis International (Appendix 7A). 
Impact factor: 4.17. 
Si L, Winzenberg TM, Chen M, Jiang Q, Neil A, Palmer AJ. Screening for osteoporosis 
in Chinese post-menopausal women: a health economic modelling study. Osteoporosis 
International, doi: 10.1007/s00198-016-3502-1 
The published article of this 
chapter appears in an appendix to 
the chapter. It has been removed 
for copyright or proprietary 
reasons.
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7.2  Abstract 
Introduction: This study aimed at determining the cost-effectiveness of osteoporosis 
screening strategies in post-menopausal Chinese women.  
Methods: A validated state-transition microsimulation model with a lifetime horizon was 
used to evaluate the cost-effectiveness of different screening strategies with treatment of 
alendronate compared with current osteoporosis management in China. Osteoporosis 
screening strategies assessed were: 1) universal screening with dual-energy X-ray 
absorptiometry (DXA) alone; 2) Osteoporosis Self-Assessment Tool for Asians (OSTA) + 
DXA; and 3) quantitative ultrasound (QUS) + DXA with rescreening at 2, 5 or 10-year 
intervals for patients screening negative by DXA. The study was performed from the Chinese 
healthcare payer’s perspective. All model inputs were retrieved from publically available 
literature. Uncertainties were addressed by one-way and probabilistic sensitivity analysis.  
Results: Screening strategies all improved clinical outcomes at increased costs, and each 
were cost-effective compared with no-screening in women aged 55 years given the Chinese 
willingness-to-pay threshold of USD 20,000 per QALY gained. Pre-screening with QUS and 
subsequent DXA screening if the QUS T-score≤-0.5 with a 2-year rescreening interval was 
the most cost-effective strategy with the highest probability of being cost-effective across all 
non-dominated strategies. Screening strategies were cost-saving if screenings were initiated 
from age 65-year. One-way sensitivity analyses indicated the results were robust. 
Conclusions: Pre-screening with QUS with subsequent DXA screening if the QUS T-score≤-
0.5 with a 2-year rescreening interval in the Chinese women starting at age 55 is the most 
cost-effective. In addition, screening and treatment strategies are cost saving if the screening 
initiation age is greater than 65-year.  
  
Chapter 7: Screening for osteoporosis in Chinese post-menopausal women: a health 
economic modelling study 
257 | P a g e
7.3  Introduction 
Osteoporosis and osteoporosis-related fracture prevalence increase with age, especially for 
women after menopause [1]. Hip, vertebral and wrist fractures are regarded as major 
osteoporotic fractures, reflecting their relationship with increased mortality, chronic pain, 
disability and diminished quality of life of patients [2-4]. It is estimated that more than 40% 
of the Chinese women aged 50 years will have an osteoporotic fracture in their remaining 
lifetimes [5]. With osteoporosis prevalence among Chinese women aged 50 years and older 
estimated to exceed 40%, 89.2 million women will suffer from osteoporosis in 2025 [1]. 
Evidence has shown that more than 2 million osteoporotic fractures occurred in 2010 for the 
population aged over 50 years at a cost of approximately 9.5 billion US dollars (USD) to the 
Chinese healthcare system [6]. Moreover, the number of fractures and the costs are predicted 
to double by 2035 and will continue to grow in the next decades [6]. 
Despite the fact that osteoporosis has a substantial and increasing financial burden to the 
Chinese healthcare system in the coming decades, bone densitometry and a range of 
osteoporosis drugs are at best partly reimbursed in China [7]. In addition, people have very 
limited access to dual-energy X-ray absorptiometry (DXA) machines particularly in rural 
China. This nascent reimbursement policy and limited access to diagnostic methodologies  
contribute to many osteoporosis patients being undiagnosed [8].  
There are numerous health economics studies on osteoporosis screening [9], many of which 
showed that screening for osteoporosis was cost-effective, especially in Caucasian 
populations [10-12]. Osteoporosis screening was, however, found to be not cost-effective in a 
Thai setting [13].Due to socioeconomic and population diversity, screening strategies must be 
performed in country- and ethnicity-specific analyses [14]. At present, there are no economic 
assessments supporting osteoporosis screening and treatment in China [15]. The objective of 
this study was to analyse the cost-effectiveness of different osteoporosis screening strategies 
followed by alendronate of osteoporosis detected among Chinese post-menopausal women.   
7.4  Methods 
7.4.1 Model description 
A validated individual-level state-transition osteoporosis screening and treatment cost-
effectiveness model was used. The model has been documented and validated in detail 
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elsewhere [16]. A brief description of the model is provided here. The model comprised four 
disease states: “no history of fractures”, “fractured”, “post-fracture” and “death”, with 
potential fractures comprising hip, clinical vertebral and wrist fractures (Figure 7.1) [16]. 
Tracker variables were used to record characteristics of simulated subjects such as “whether 
fractured”, “type of fractures”, “time after last screening” and “time after treatment if 
fractured”. The built-in tracker variables enabled the monitoring of patient history during the 
simulation, and accounted for heterogeneity of the simulated subjects.  
Figure 7.1. Structure of the osteoporosis state-transition model. Figure adapted from Si and 
colleagues [16], permission acquired from Springer. Simulated patients can transit between 
disease states in the direction shown by the arrow. “Fractured” is a temporary state and 
denotes patients with an existing osteoporotic hip, vertebral, or wrist fracture. All patients 
were simulated until “Death”. 
The World Health Organization (WHO) standard was used to define osteoporosis: i.e. hip 
(femoral neck) bone mineral density (BMD) 2.5 standard deviations (SDs) or more below the 
young adult female mean (i.e., T-score≤-2.5) [3]. Three screening techniques with a 
combination of 12 individual screening strategies were included as the interventions, where 
“no screening” was set as the comparator.  
Screening strategies in this study were chosen based on the recommendations from 
Guidelines for the Prevention and Treatment of Primary Osteoporosis [15]. DXA scan is the 
Fractured 
(hip, vertebral or 
wrist fracture) 
No history of 
fracture 
Post-fracture 
Death 
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current gold standard for diagnosing osteoporosis and was therefore incorporated solely or as 
a confirmation test after a pre-screening strategy in the screening arms [3]. Pre-screening 
strategies considered were quantitative ultrasound (QUS) and Osteoporosis Self-Assessment 
Tool for Asians (OSTA), followed by a DXA scan for those who tested positive through 
either strategy.  
Because osteoporosis still remains underdiagnosed in China, patients are often unaware of the 
disease until they have an osteoporotic fracture [17]. As a consequence, osteoporotic patients 
in the “no screening” arm were assumed to receive no pharmaceutical intervention unless 
they had an osteoporotic fracture. The type of medication they were assumed to receive 
reflected the current treatment pattern for osteoporotic fractures in China [18]. Currently 51% 
of fractured osteoporotic patients in China are reported as using calcitonin, 29% 
bisphosphonates [19], and the rest of the patients were assumed to receive only calcium and 
vitamin D supplements.  
Alendronate has been selected as the treatment option in the screening arm as it is the first 
line treatment for osteoporosis in China [7]. Patients who tested positive through DXA across 
the 12 screening alternatives were assumed to receive alendronate combined with calcium 
and vitamin D from the time of screening for a period of five years. Otherwise, individuals 
were assigned to rescreening at 2, 5 or 10-year intervals. In addition, patients that were not 
treated after the last screening but had an osteoporotic fracture were assumed to receive 
alendronate following the same treatment approach in the screening arm.   
We simulated female subjects with a baseline age of 55 years without a history osteoporotic 
hip, vertebral or wrist fractures. The population was assumed to have a mix of both 
osteoporotic and non-osteoporotic subjects – see section following for estimation of 
prevalence. The population in the model was simulated for a lifetime horizon with a one-year 
cycle length. The health economics evaluation was conducted from the Chinese healthcare 
payer’s perspective. All costs were converted from Chinese Yuan to 2015 USD using 
International Monetary Fund purchasing power parity (PPP) values. Costs and effectiveness 
were discounted at 5% annually for the base-case analysis.  
7.4.2 Model parameters 
Wherever possible, model input values were retrieved from publically available Chinese data. 
The selection of model input values was based on recommendations from China Guidelines 
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for Pharmacoeconomic Evaluations, where results from meta-analysis based on large RCTs 
were the highest level, expert opinions and descriptive researches were the lowest level [18]. 
The major parameters included are detailed elsewhere [16], with a summary of model inputs 
given in Table 7.1. 
Osteoporosis prevalence rates for the Chinese population were obtained from a recent meta-
analysis and used to determine the initial probability of the simulated subjects being 
osteoporotic [20]. Sensitivities and specificities for pre-screenings (OSTA and QUS) in the 
Chinese population were determined by different T-score cut-off points [21, 22]. Age-
specific mortality rates for the Chinese women were obtained from the China Public Health 
Statistical Yearbook 2012 [23]. Annual hip and clinical vertebral fracture rates were retrieved 
from epidemiological studies in the Chinese population [24, 25]. Annual wrist fracture rates 
were not available in the Chinese population and data from an Asian population in a 
Norwegian study were used [26]. Annual fracture risks that were attributed to osteoporosis 
were adjusted based on Melton’s osteoporosis attribution rates [27], using the following 
formula: 
Fracture risks (osteoporosis attributed) = Annual fracture rates × AR/P 
Where AR is the Melton’s osteoporosis attribution rates and P denotes osteoporosis 
prevalence rates. 
Poor adherence and persistence with osteoporosis medications is a common problem, 
affecting the efficacy and cost-effectiveness of osteoporosis interventions [28-33]. Both 
reduced adherence and persistence to medications were factored into both no screening and 
screening arms [34-36]. Residual fracture reduction benefits were assumed to decline over 5 
years in a linear manner for those who discontinued medication [12]. Medication persistence 
was built in the model dependent on time after treatment. For those who were on treatment, 
only a proportion of them had high adherence based on medication possession ratios [34, 36]. 
Only direct costs were included in the analyses given a healthcare payer’s perspective. 
Medical costs of the first year following fracture were based on a recent study in western 
China [19]. Annual costs for medication, nursing home residence and costs for screenings 
were retrieved from government recommended prices [37]. Medication costs were assumed 
to be zero for those who discontinued medication and 80% of annual costs for poorly 
adherent patients [29, 38]. Age-specific health state utility values (HSUVs) for the non-
fractured population were obtained from the Chinese National Health Services Survey 2008 
[4, 39]. HSUVs for individuals with a fracture were dependent on the fracture site and time 
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since fracture [4, 16]. 
7.4.3 Analyses and presentation of results 
Monte Carlo probabilistic sensitivity analyses (PSA) was combined with individual-level 
(first-order) simulations to address stochastic and parameter uncertainties in the base-case 
analyses [40]. To ensure the number of simulations was sufficient, we have varied the 
number of samples and trials from 500 to 10,000 until the incremental costs, effectiveness 
and incremental cost-effectiveness ratio (ICER) became stable. Two nested simulation loops 
were run in our base case analyses, where the inner loop evaluated the outcomes across 1,000 
trials for the given parameter values, and the 1,000 outer loop sampled those values to reflect 
parameter uncertainties. Mean costs and effectiveness for each strategy were aggregated, and 
an ICER for each screening strategy compared with no screening calculated. We used the 
willingness-to-pay (WTP) threshold of USD 20,000 per quality-adjusted life year (QALY) 
gained, approximately three times per capita Gross Domestic Product (GDP) in China, to 
determine whether a screening strategy was cost-effective [18]. Cost-effectiveness 
acceptability curves (CEACs) were generated to evaluate the probability of the osteoporosis 
screening strategies being cost-effective given a range of possible WTP thresholds, including 
one time per capita GDP [41]. One-way sensitivity analyses were performed to evaluate the 
robustness of ICER with changes in single parameter values in the model.  
Two approaches were used to present the cost-effectiveness of the osteoporosis screening 
strategies. First, each individual screening strategy was compared with no screening; this 
approach assessed whether a screening strategy was cost-effective given the WTP threshold. 
Second, screening strategies were compared against each other to select the most cost-
effective strategy under the WTP threshold [42]. This process included the initial exclusion of 
dominated strategies (a strategy with higher costs but lower effectiveness than the alternate 
being considered) and strategies subject to extended dominance (a strategy that with a higher 
ICER than the next more effective strategy). 
All analyses were performed using TreeAge Pro Suite 2014 (TreeAge Software, 
Williamstown, Massachusetts). The presentation of the model and study results follow the 
CHEERS guidelines [43]. 
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Table 7.1. Key parameters in the model  
Parameter Value Distribution Reference 
Prevalence of osteoporosis (%)  3.5 (50-59 years), 14.2 (60-69 years), 
26.8 (70-79 years), 39.2 (80+  years) 
- [20] 
Fracture incidence (annual rate per 
1,000 person-years) 
   
  Hip  0.33 (50-54 years), 0.46 (55-59 years), 
0.54 (60-64 years), 0.96 (65-69 years), 
2.33 (70-74 years), 4.08 (75-79 years), 
6.44 (80-84 years), 6.59 (85-89 years), 
8.67 (90+ years) 
- [24] 
  Clinical vertebral 2.19 (50-54 years), 3.13 (55-59 years), 
5.16 (60-64 years), 5.64 (65-69 years), 
8.74 (70-74 years), 12.05 (75-79 years), 
21.19 (80-84 years), 26.89 (85-89 years), 
27.10 (90+ years) 
- [25] 
  Wrist  4.76 (50-54 years), 7.32 (55-59 years), 
11.16 (60-64 years), 12.95 (65-69 years), 
13.17 (70-74 years), 13.87 (75-79 years), 
15.01 (80-84 years), 15.10 (85-89 years), 
13.97 (90+ years) 
- [26] 
    
Mortality rate (per 1,000) for 
general population  
2.12 (50-54 years), 3.48 (55-59 years), 
6.05 (60-64 years), 10.31 (65-69 years), 
20.36 (70-74 years), 37.84 (75-79 years), 
69.98 (80-84 years), 136.03 (85+ years) 
- [23] 
RRs of wrist fractures in Asians 
versus Caucasians  
0.72 (95% CI: 0.53-1.00) Lognormal [26] 
Osteoporosis attribution 
probabilities for hip fractures  
0.75 (Range: 0.20-0.85) for 50-64 years, 
0.85 (Range: 0.50-0.95) for 65-84 years, 
0.95 (Range: 0.60-0.95) for 85+  years 
Lognormal [27] 
Osteoporosis attribution 
probabilities for clinical vertebral 
fractures  
0.75 (Range: 0.40-0.80) for 50-64 years, 
0.85 (Range: 0.50-0.95) for 65-84 years, 
0.95 (Range: 0.60-0.95) for 85+  years 
Lognormal [27] 
Osteoporosis attribution 
probabilities for wrist fractures  
0.60 (Range: 0.10-0.70) for 50-64 years, 
0.70 (Range: 0.35-0.80) for 65-84 years, 
0.70 (Range: 0.55-0.90) for 85+  years 
Lognormal [27] 
SMR after a hip fracture  2.43 (95% CI: 2.02-2.93) Lognormal [2] 
SMR after a clinical vertebral 
fracture  
1.82 (95% CI: 1.52-2.17) Lognormal [2] 
SMR after a wrist fracture  1.42 (95% CI: 1.19-1.70) Lognormal [2] 
RR of osteoporotic fractures with 
treatment 
   
  Alendronate Hip fracture (without prior fractures): 
0.44 (0.31-0.57), Hip fracture (with prior 
fractures): 0.49 (0.34-0.64), Vertebral 
fracture (without prior fractures): 0.50 
(0.35-0.65), Vertebral fracture (with prior 
fractures): 0.53 (0.37-0.69), Wrist 
fracture (without prior fractures): 0.88 
(0.62-1.00), Wrist fracture (with prior 
fractures): 0.52 (0.36-0.68) 
Lognormal [30,31] 
  Calcitonin Vertebral fracture: 0.46 (0.25-0.87), Non-
vertebral fracture: 0.52 (0.22-1.23) 
Lognormal [32] 
  Calcium + vitamin D 0.88 (0.78-0.99) Lognormal [33] 
Medication persistence    
  Alendronate First year: 0.571 (0.29-0.86) - [34] 
  Calcitonin First year: 0.329 (0.16-0.49) - [34] 
  Calcium + vitamin D First year: 0.367 (0.18-0.55) - [35] 
Treatment duration, years 5 (2-10) - [12] 
Probability of being high adherent 
to treatment 
   
  Alendronate First year: 0.619 (0.31-0.93) - [34] 
  Calcitonin First year: 0.364 (0.18-0.55) - [34] 
  Calcium + vitamin D First year: 0.600 (0.30-0.90) - [36] 
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Parameter Value Distribution Reference 
Screening sensitivity 
  DXA at the femoral neck 1 - [3] 
  OSTA (T-score cutoff threshold of 
-1)
0.76 - [21] 
QUS (T-score cutoff threshold of
-1)
0.79 - [22] 
QUS (T-score cutoff threshold of
-0.5)
0.88 - [22] 
Screening specificity
DXA at the femoral neck 1 - [3] 
OSTA (T-score cutoff threshold of
-1)
0.66 - [21] 
QUS (T-score cutoff threshold of
-1)
0.58 - [22] 
QUS (T-score cutoff threshold of
-0.5)
0.39 - [22] 
Average costs (2015 US dollar)
Annual nursing home 4,395 - [37] 
Hip fracture, first year a 6,462 - [19] 
Vertebral fracture, first year a 4,884 - [19] 
Wrist fracture, first year a 1,980 - [19] 
Annual medication costs
    Alendronate 1,100 - [37] 
    Calcitonin 717 - [37] 
    Calcium + vitamin D 90 - [37] 
  DXA scan 69.53 - [37] 
  OSTA assessment 9.3 - [37] 
  QUS scan 1.85 - [37] 
HSUVs 
  Healthy/Osteoporotic population 
without fractures 
0.772 (55-59 years), 0.728 (60-64 years), 
0.702 (65-69 years), 0.685 (70-74 years), 
0.669 (75-79 years), 0.655 (80-84 years), 
0.643 (85+ years) 
- [39] 
  Hip fracture, first year b 0.776 (0.720-0.844) Normal [4] 
  Hip fracture, subsequent years b 0.855 (0.800-0.909) Normal [4] 
  Vertebral fracture, first year b 0.724 (0.667-0.779) Normal [4] 
  Vertebral fracture, subsequent 
years b 
0.868 (0.827-0.922) 
Normal [4] 
  Wrist fracture, first year b 1.000 (0.960-1.000) Normal [4] 
  Wrist fracture, subsequent years b 1.000 (0.930-1.000) Normal [4] 
  Nursing home dwelling 0.400  - [4] 
Annual discount rate 
  Costs 0.05 - [18] 
  Effectiveness 0.05 - [18] 
CI=confidence interval, SMR=standardised mortality ratios, RR=relative risk, DXA=dual-energy X-ray absorptiometry, 
QUS=quantitative ultrasound, OSTA=Osteoporosis Self-Assessment Tool for Asians, HSUV=health-state utility value 
a Direct costs include costs of outpatient consultations, inpatient care, investigations, medication, rehabilitation after fracture 
events, physical therapy, transportation, homecare, preventive care foods and specific equipment. 
b Multipliers for the proportionate effects of fractures on HSUVs, calculated from Si. et al [4]. 
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7.5 Results 
7.5.1 Cost-effectiveness of osteoporosis screening strategies compared with no 
screening 
For the base-case analysis, all screening strategies improved clinical outcomes and increased 
costs, but were cost-effective compared with no screening under the WTP threshold of USD 
20,000/QALY gained (Table 7.2). The mean (SD) lifetime QALY for no screening was 
11.024 (0.074) with mean (SD) lifetime costs of USD 1,440 (USD 98) per person.  
7.5.2 Determination of most cost-effective strategies overall and by age group 
Four strategies were included in the determination of the most cost-effective strategies after 
excluding the dominated and extended dominated strategies (Table 7.3). In general, 
screening strategies with shorter re-screening periods were more expensive but more 
effective. Strategies that only incorporated DXA, rather than combined QUS pre-screening, 
were more costly but more effective, although the differences in QALYs between screening 
strategies were relatively small. 
Given the WTP threshold of USD 20,000 per QALY gained, pre-screening with QUS 
followed by DXA for those with a QUS T-score lower than -0.5 and re-screening those with a 
DXA T-score greater than -2.5 in 2 years had the highest probability (39%) of being the most 
cost-effective screening strategy across the four non-dominated strategies (Figure 7.2). The 
ICER was USD 11,890 per QALY gained compared with the last effective strategy “QUS (-
0.5) + DXA every 5 years”. Besides, the incremental cost for an additional fracture averted 
was USD 5,086 (Table 7.3). 
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Table 7.2. Average costs, effectiveness and incremental cost-effectiveness ratio (ICER) of each screening strategy compared with no screening 
for women aged 55 years 
Strategy 
Average 
lifetime 
costs (2015 
USD) 
Average 
lifetime 
effectiveness 
(QALYs) 
Lifetime fractures per 
1,000 patients 
Incremental 
costs (2015 
USD) 
Incremental 
effectiveness 
(QALYs) 
ICER 
(USD per 
QALY 
gained) 
ICER(USD 
per fracture 
averted) Hip Vertebrae Wrist 
No screening 1,440  11.024 72 269 174 - - -  -  
DXA every 2 years 2,185  11.100 45 179 130 746  0.076   9,812   4,632  
DXA every 5 years 1,895  11.086 51 199 140 455  0.062   7,341   3,641  
DXA every 10 
years 
1,759  11.067 57 225 153 319  0.043   7,423   3,990  
OSTA(-1)+DXA 
every 2 years 
2,009  11.098 47 184 132 569  0.074   7,694   3,746  
OSTA(-1)+DXA 
every 5 years 
1,756  11.082 51 201 142 316  0.058   5,449   2,612  
OSTA(-1)+DXA 
every 10 years 
1,625  11.058 59 231 157 186  0.034   5,464   2,732  
QUS(-0.5)+DXA 
every 2 years 
1,944  11.099 46 180 130 505  0.075   6,691   3,173  
QUS(-0.5)+DXA 
every 5 years 
1,761  11.084 51 200 141 321  0.060   5,357   2,613  
QUS(-0.5)+DXA 
every 10 years 
1,655  11.062 58 228 155 215  0.038   5,669   2,911  
QUS(-1)+DXA 
every 2 years 
2,021  11.099 46 180 131 581  0.075   7,744   3,676  
QUS(-1)+DXA 
every 5 years 
1,746  11.085 51 201 140 306  0.061   5,013   2,486  
QUS(-1)+DXA 
every 10 years 
1,643  11.059 59 231 157 204  0.035   5,819   2,995  
QALY=quality adjusted life year, DXA=dual-energy X-ray absorptiometry, QUS=quantitative ultrasound, OSTA=Osteoporosis Self-
Assessment Tool for Asians, USD=United States dollar 
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Table 7.3. Average costs, effectiveness and incremental cost-effectiveness ratio (ICER) of non-dominated strategies for women aged 55 years  
Strategy 
Average 
lifetime 
costs (2015 
USD) 
Average 
lifetime 
effectiveness 
(QALYs) 
Lifetime fractures per 
1,000 patients 
Incremental 
costs (2015 
USD) 
Incremental 
effectiveness 
(QALYs) 
ICER 
(USD per 
QALY 
gained) 
ICER(USD 
per fracture 
averted) Hip Vertebrae Wrist 
No screening 1,440 11.024 72 269 174 - - - - 
QUS(-0.5)+DXA 
every 5 years 
1,761 11.084 51 200 141 321 0.060 5,357  2,613 
QUS(-0.5)+DXA 
every 2 years 
1,944 11.099 46 180 130 183 0.015 11,890  5,086 
DXA every 2 years 2,185 11.100 45 179 130 241 0.001 402,038  120,612 
QALY=quality adjusted life year, DXA=dual-energy X-ray absorptiometry, QUS=quantitative ultrasound, USD=United States dollar 
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7.5.3 One-way sensitivity analyses 
The results of all one-way sensitivity analyses for the base scenario (screening of women 55 
years of age) are shown in Appendix 7B. Briefly, varying several critical parameter values 
within the model, generally did not alter the most cost-effective screening strategy, although 
the ICERs changed slightly. However, if screening sensitivity and specificity were improved 
by 50%, “QUS (-0.5) + DXA every 5 years” became the most cost-effective strategy. 
Medication adherence, proportion of full medication costs for poorly adherent women and 
treatment duration had little impact on ICERs. 
Choice of the age at screening initiation had a large impact on the assessment of cost-
effectiveness (Table 7.4). From age 65 years, all osteoporosis screening strategies dominated 
no screening giving rise to higher QALYs at lower costs. In a comparison of non-dominated 
strategies “QUS (-0.5) + DXA every 2 years” remained the most cost-effective screening 
strategy given the WTP of USD 20,000 per QALY gained. 
7.5.4 Cost-effectiveness acceptability curve (CEAC) 
The CEAC of all screening strategies is given in Figure 7.2. “No screening” has the highest 
probability (36%) of being cost-effective if the WTP threshold is smaller than USD 7,000 per 
QALY gained. Given three times per capita GDP in China as the WTP threshold (USD 
20,000 per QALY gained), “no screening”, “QUS (-0.5) + DXA every 5 years”, “QUS (-0.5) 
+ DXA every 2 years” and “DXA every 2 years” had probabilities of being cost-effective of 
19%, 37%, 39% and 5% respectively. Given one time per capita GDP as the WTP threshold 
(USD 6,800 per QALY gained), “no screening”, “QUS (-0.5) + DXA every 5 years”, “QUS 
(-0.5) + DXA every 2 years” and “DXA every 2 years” had probabilities of being cost-
effective of 37%, 36%, 27% and 0% respectively. Overall, pre-screen with QUS followed by 
DXA strategies had higher probabilities of being cost-effective compared with DXA alone 
strategy. 
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Table 7.4. Average costs, effectiveness of each screening option by 5-year age increments 
(60-85 years); and incremental cost-effectiveness ratios (ICER) of non-dominated strategies 
compared with the least effective of those strategies by age 
Strategy 
Average 
lifetime costs 
(2015 USD) 
Average lifetime 
effectiveness 
(QALYs) 
ICER 
(USD/QALY 
gained) 
Age 60 years    
  No screening  1,578  9.776 Baseline 
  QUS(-0.5)+DXA every 5 years  1,739  9.865 Dominated 
  QUS(-0.5)+DXA every 2 years  1,633  9.906 421 
  DXA every 2 years  1,831  9.908 98,900 
Age 65 years    
  No screening  1,632  8.458 Dominated 
  QUS(-0.5)+DXA every 5 years  1,570  8.575 Dominated 
  QUS(-0.5)+DXA every 2 years  1,411  8.613 Baseline 
  DXA every 2 years  1,586  8.615 87,645 
Age 70 years    
  No screening  1,700  7.073 Dominated 
  QUS(-0.5)+DXA every 5 years  1,342  7.218 Dominated 
  QUS(-0.5)+DXA every 2 years  1,160  7.257 Baseline 
  DXA every 2 years  1,311  7.259 75,405 
Age 75 years    
  No screening  1,711  5.710 Dominated 
  QUS(-0.5)+DXA every 5 years  1,115  5.878 Dominated 
  QUS(-0.5)+DXA every 2 years  921  5.920 Baseline 
  DXA every 2 years  1,047  5.922 63,174 
Age 80 years    
  No screening  1,642  4.441 Dominated 
  QUS(-0.5)+DXA every 5 years  891  4.630 Dominated 
  QUS(-0.5)+DXA every 2 years  673  4.675 Baseline 
  DXA every 2 years  775  4.677 51,160 
Age 85 years    
  No screening  1,466  3.440 Dominated 
  QUS(-0.5)+DXA every 5 years  649  3.644 Dominated 
  QUS(-0.5)+DXA every 2 years  409  3.694 Baseline 
  DXA every 2 years  494  3.696 42,660 
QALY=quality adjusted life year, DXA=dual-energy X-ray absorptiometry, 
QUS=quantitative ultrasound, OSTA=Osteoporosis Self-Assessment Tool for Asians, 
USD=United States dollar 
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Figure 7.2. Cost-effectiveness acceptability curves of all best screening strategies initiated 
from age 55 years at different levels of willingness-to-pay (WTP) per quality-adjusted life 
year (QALY) gained. “No screening” has the highest probability being cost-effective if the 
WTP threshold is lower than USD 7,000 per QALY gained. Given the WTP threshold of 
USD 20,000 per QALY gained (3 times per capita Gross Domestic Product, GDP, in China), 
“no screening”, “QUS (-0.5) + DXA every 5 years”, “QUS (-0.5) + DXA every 2 years” and 
“DXA every 2 years” have probabilities of being cost-effective of 19%, 37%, 39% and 5% 
respectively. Given one time per capita GDP as the WTP threshold (USD 6,800 per QALY 
gained), “no screening”, “QUS (-0.5) + DXA every 5 years”, “QUS (-0.5) + DXA every 2 
years” and “DXA every 2 years” have probabilities of being cost-effective of 37%, 36%, 27% 
and 0% respectively. 
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7.6  Discussion 
To our knowledge, this is the first health economics study of the cost-effectiveness of 
osteoporosis screening strategies in the Chinese setting. In general, all osteoporosis screening 
strategies are more effective than no screening regardless of screening initiation age in the 
prevention of fractures. In the direct comparison between an individual screening strategy 
and no screening in the base-case analysis (screening of women aged 55 years), screening 
strategies are all cost-effective given the current WTP threshold in China, with “pre-
screening with QUS followed by DXA for those with a QUS T-score lower than -0.5 and re-
screening those with a DXA T-score greater than -2.5 in 2 years” ascertained as having the 
highest probability of being the most cost-effective across all screening strategies. Moreover, 
osteoporosis screening strategies are even cost-saving if the screening initiation age is greater 
than 65 years.  
Screening for osteoporosis has proved cost-effective and has been recommended in many 
populations [10-12, 44]. However, cost-effectiveness of osteoporosis screenings in Asian 
populations is still controversial [13, 45]. In postmenopausal Japanese women, it was 
suggested that DXA screening with hormone replacement therapy (HRT) or alendronate 
treatment for osteoporotic patients might be cost effective [45]. Only hip fractures were 
included in that study, therefore effectiveness of screening strategies has been potentially 
underestimated by the exclusion of other possible fractures [45]. Given the WTP threshold of 
100,000 Thai baht (approximately USD 3,000) per QALY gained, it was suggested that 
osteoporosis screening and treatment strategies were not cost-effective in postmenopausal 
Thai women [13]. In our analysis, we have also demonstrated different WTP thresholds result 
in different choices of the most cost-effective screening strategy. When 3 times per capita 
GDP was used, “QUS (-0.5) + DXA every 2 years” was the most cost-effective strategy with 
an ICER of USD 11,890 per QALY gained. However, the most cost-effective strategy was 
altered to “QUS (-0.5) + DXA every 5 years” if one time per capita GDP was used as the 
WTP threshold. This inconsistency emphasises the importance of conducting country-specific 
health economic evaluations in osteoporosis screening strategies, given the different 
characteristics of populations and WTP thresholds in different countries.  
Currently there are several guidelines for osteoporosis management in China [7], however, no 
health economics evidence was used during their development. Our study demonstrated that 
screening for osteoporosis in postmenopausal Chinese women is cost-effective if the 
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screening initiation age is 55 years. Moreover, pre-screening with QUS with a subsequent 
DXA screening for those who were tested positive and re-screening those with a DXA T-
score greater than -2.5 in 2 or 5 years dominates no screening if the screening initiation age is 
65 years (Table 7.4).  
Measurement of BMD using DXA scan at the femoral neck is currently the gold standard of 
diagnosing osteoporosis, however, due to high costs and lack of access, osteoporosis still 
remains underdiagnosed rather than overdiagnosed in China [17, 46]. QUS and fracture 
assessment tools such as OSTA are less expensive and easier to use in local clinics to identify 
women at risk of osteoporosis, therefore they were used as a prescreening strategy in our 
study. Improvement of accuracy of the prescreening strategy results in identification of more 
women at risk and less misdiagnoses. In our analysis, we have demonstrated that a total of 35 
fractures per 1,000 patients can be averted compared with base case if QUS sensitivity and 
specificity increased by 50%. Consequently, QALYs for “QUS (-0.5)+DXA every 5 years” 
have increased by 0.015 compared with base case (Appendix 7B).  
The recommended time interval between repeated DXA is variable, from 1 year to 15 years 
based on baseline BMDs [47], however no clear evidence of whether a shorter rescreening 
interval was superior to a longer time interval was found in previous health economics studies 
[12]. Our results indicate that in general, shorter a rescreening time interval was associated 
with higher effectiveness and costs, but was most cost-effective at the 2-year time interval.  
Screening initiation age had a high impact on cost-effectiveness. Generally, higher screening 
initiation ages are associated with lower costs per QALY gained because more osteoporosis 
patients are identified and treated [11, 12, 44]. Our study confirmed previous findings that 
screening for osteoporosis is cost-effective from age 55 years, and screenings may be a cost-
saving strategy compared with no screening in older postmenopausal women.  
Previous studies have indicated that medication persistence and adherence greatly impact the 
cost-effectiveness of osteoporosis interventions [29, 48]. However, limitations in these 
previous studies have been identified. Medication persistence and adherence were only 
accounted for in screening/treatment arms, while no treatment was assumed in no screening 
arm, even for those who had an osteoporotic fracture [48]. This assumption contradicts 
several osteoporosis prevention and treatment guidelines, in which treatment is recommended 
for those with bone density loss and a fragility fracture [49, 50]. In our study, we used the 
“current practice” as the comparator (no screening) arm [43]. We have addressed previously 
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identified limitations, as osteoporosis patients who had a fracture in the no screening arm 
were assumed to receive treatment to prevent following fractures, and the choice of the 
treatment was based on current osteoporosis treatment patterns in China [19]. Therefore, we 
incorporated medication persistence and adherence in both no screening and screening arms.  
Interestingly, our study also demonstrated that changes in medication persistence and 
adherence would result in changes in ICERs. Moreover, the changes in ICER were greater for 
changes in medication persistence compared to adherence. This could be explained by the 
assumption that no costs of treatment were incurred by the non-persistent patients, and only a 
20% cost deduction was applied to non-adherent patients while the changes in effectiveness 
were minor. Nevertheless, decision of the most cost-effective screening strategies did not 
alter in one-way sensitivity analyses of medication persistence and adherence (Appendix 7B).  
There are some limitations to our study. First, we did not include fractures such as humerus, 
pelvis, ribs and shoulder fractures in this study [16]. This was due to insufficient Chinese 
epidemiological and economic data on these fractures. Second, the adverse events from 
treatment were not included in the analysis. Despite that, adverse events from oral 
alendronate intake, including gastrointestinal tract, osteonecrosis of the jaw, were considered 
rare at the doses used in the treatment of osteoporosis [51], and thus unlikely to affect the 
cost-effectiveness of osteoporosis screenings. Third, we have not compared the risks of major 
fractures calculated from our model to those from FRAX. Because the epidemiological data 
sources used in our model did not capture all clinical risk factors for osteoporosis, where 
FRAX has incorporated major clinical risk factors for osteoporosis such as smoking, history 
of fracture, glucocorticoid use, rheumatoid arthritis and so on. However, we have previously 
estimated 10-year risks of hip and any major osteoporotic fractures for the Chinese 
population using our model and compared our results with other populations [5]. Last, some 
of our model input parameters such as annual wrist fracture rates and osteoporosis attribution 
rate for annual fracture rates were not available in Chinese population study. Therefore, such 
inputs were retrieved from studies in other Asian populations [26, 27]. In addition, 
standardized mortality ratios after fractures, treatment efficacy and HSUV multipliers were 
not available in the Chinese population, values from Caucasian populations or meta-analysis 
have been used. 
Future research is recommended. First, although bone densitometry was considered as a vital 
component in the diagnosis and management of osteoporosis, fracture risk assessment tools 
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that incorporates other clinical risk factors could provide better estimates of absolute fracture 
risks to inform clinician decision making. FRAX® (http://www.shef.ac.uk/FRAX) has been 
developed by the WHO and is increasingly used in China, however, concerns have arisen that 
the intervention threshold for therapeutic interventions was poorly defined in the Chinese 
population [52]. Future research is encouraged to determine the FRAX intervention threshold 
for the Chinese population, taking into account both health and economic consequences. 
Finally, we have identified for healthcare policy makers in China which osteoporosis 
screening strategy is of best value for money. However, we have not attempted to address 
issues of affordability (i.e. budget impact) in this analysis, but acknowledge that this would 
be an area of important future research, given the fact that DXA is not commonly available in 
China, especially in small-scale cities and rural area. 
In conclusion, this study determined the cost-effectiveness of different osteoporosis screening 
strategies using a validated model in the Chinese setting. Given the WTP threshold of USD 
20,000 per QALY gained, pre-screening with QUS followed by DXA for those with a QUS 
T-score lower than -0.5 and re-screen those with a DXA T-score greater than -2.5 in 2 years, 
is recommended for Chinese postmenopausal women aged 55 years. If the health payer is not 
willing to pay extra money for additional effectiveness from the intervention, i.e. with a WTP 
threshold of USD 0 per QALY gained, screening for osteoporosis from age 65 years is 
recommended.  
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Appendix 7B: One-way sensitivity analyses for all non-dominated strategies 
One-way sensitivity analysis for all best screening strategies: 0% discount rates for costs and effectiveness 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted 
Hip Vertebrae Wrist 
No screening 3,918 19.026 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
4,301 19.254 51 200 141 383 0.228 1,678 3,110 
QUS(-0.5)+DXA every 2 
years 
4,551 19.318 46 180 130 250 0.064 3,913 6,956 
DXA every 2 years 4,972 19.319 45 179 130 421 0.001 421,087 210,544 
One-way sensitivity analysis for all best screening strategies: 8% discount rates for costs and effectiveness 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted 
Hip Vertebrae Wrist 
No screening 911 8.724 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,180 8.757 51 200 141 268 0.033 8,127 2,180 
QUS(-0.5)+DXA every 2 
years 
1,331 8.765 46 180 130 151 0.008 18,898 4,200 
DXA every 2 years 1,521 8.766 45 179 130 190 0.000 634,204 95,131 
One-way sensitivity analysis for all best screening strategies: 0.5 times QUS sensitivity and specificity 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted 
Hip Vertebrae Wrist 
No screening 1,440 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,687 11.080 51 202 143 247 0.056 4,415 2,078 
QUS(-0.5)+DXA every 2 
years 
1,876 11.098 46 181 131 189 0.018 10,476 4,963 
DXA every 2 years 2,185 11.100 45 179 130 310 0.002 154,957 77,479 
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One-way sensitivity analysis for all best screening strategies: 1.5 times QUS sensitivity and specificity 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,440 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,619 11.099 45 180 132 180 0.075 2,395 1,137 
QUS(-0.5)+DXA every 2 
years 
1,998 11.100 45 179 130 379 0.001 379,002 126,334 
DXA every 2 years 2,185 11.100 45 179 130 - - Dominated Dominated 
 
        
 
 
        
 One-way sensitivity analysis for all best screening strategies: 0.8 times base-case annual fracture rates 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,199 11.101 59 222 142 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,556 11.150 42 165 115 357 0.049 7,290 3,537 
QUS(-0.5)+DXA every 2 
years 
1,744 11.161 38 149 107 188 0.011 17,050 6,698 
DXA every 2 years 1,984 11.162 38 148 106 240 0.001 240,262 120,131 
          
          One-way sensitivity analysis for all best screening strategies: 1.2 times base-case annual fracture rates 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,660 10.950 83 313 205 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,952 11.021 59 233 166 292 0.071 4,115 2,043 
QUS(-0.5)+DXA every 2 
years 
2,129 11.039 52 209 154 177 0.018 9,824 4,113 
DXA every 2 years 2,369 11.040 52 208 153 241 0.001 240,504 120,252 
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One-way sensitivity analysis for all best screening strategies: 0.5 times base-case medication persistence 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,258 11.014 73 276 179 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,475 11.077 51 203 148 216 0.063 3,431 1,715 
QUS(-0.5)+DXA every 2 
years 
1,622 11.092 46 184 139 147 0.015 9,804 4,457 
DXA every 2 years 1,855 11.093 46 183 138 234 0.001 233,582 116,791 
          
          One-way sensitivity analysis for all best screening strategies: 1.5 times base-case medication persistence 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,614 11.034 69 259 169 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
2,040 11.092 49 196 134 426 0.058 7,342 3,609 
QUS(-0.5)+DXA every 2 
years 
2,261 11.108 44 176 123 221 0.016 13,815 6,140 
DXA every 2 years 2,510 11.109 44 175 122 249 0.001 248,786 124,393 
          
          One-way sensitivity analysis for all best screening strategies: 0.5 times base-case medication adherence 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,426 11.021 72 272 176 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,735 11.080 52 203 143 310 0.059 5,246 2,537 
QUS(-0.5)+DXA every 2 
years 
1,914 11.095 47 183 133 179 0.015 11,932 5,114 
DXA every 2 years 2,155 11.096 47 182 132 241 0.001 240,557 120,279 
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One-way sensitivity analysis for all best screening strategies: 1.5 times base-case medication adherence 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,455 11.027 71 266 173 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,787 11.088 49 196 138 333 0.061 5,455 2,620 
QUS(-0.5)+DXA every 2 
years 
1,974 11.105 44 176 128 186 0.017 10,965 5,326 
DXA every 2 years 2,216 11.106 44 175 127 242 0.001 241,845 120,923 
          
          One-way sensitivity analysis for all best screening strategies: no medication offset time effect 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,452 11.019 73 273 196 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,807 11.072 55 214 143 355 0.053 6,700 2,731 
QUS(-0.5)+DXA every 2 
years 
1,997 11.086 50 195 133 190 0.014 13,545 5,578 
DXA every 2 years 2,239 11.087 50 194 132 242 0.001 242,076 121,038 
          
          
          One-way sensitivity analysis for all best screening strategies: treatment for 2 years 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,437 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,674 11.082 21 201 144 237 0.058 4,080 1,588 
QUS(-0.5)+DXA every 2 
years 
1,850 11.097 46 181 133 176 0.015 11,720 29,301 
DXA every 2 years 2,089 11.098 45 181 133 239 0.001 239,245 239,245 
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One-way sensitivity analysis for all best screening strategies: treatment for 10 years 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,440 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,827 11.087 50 198 138 387 0.063 6,145 3,001 
QUS(-0.5)+DXA every 2 
years 
2,021 11.103 45 178 127 194 0.016 12,104 5,379 
DXA every 2 years 2,263 11.104 45 177 127 243 0.001 242,835 242,835 
          
          
          One-way sensitivity analysis for all best screening strategies: 0.5 times base-case annual medication costs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,227 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,361 11.084 51 200 141 134 0.060 2,234 1,090 
QUS(-0.5)+DXA every 2 
years 
1,495 11.099 46 180 130 134 0.015 8,919 3,716 
DXA every 2 years 1,726 11.100 45 179 130 231 0.001 231,241 115,621 
 
         
          One-way sensitivity analysis for all best screening strategies: 1.5 times base-case annual medication costs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,652 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
2,161 11.084 51 200 141 509 0.060 8,480 4,137 
QUS(-0.5)+DXA every 2 
years 
2,394 11.099 46 180 130 232 0.015 15,495 6,456 
DXA every 2 years 2,645 11.100 45 179 130 251 0.001 251,204 125,602 
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One-way sensitivity analysis for all best screening strategies: 50% of full medication costs for poorly adherent women  
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,363 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,680 11.084 51 200 141 317 0.060 5,288 2,580 
QUS(-0.5)+DXA every 2 
years 
1,853 11.099 46 180 130 173 0.015 11,503 4,793 
DXA every 2 years 2,092 11.100 45 179 130 239 0.001 239,080 119,540 
 
         
 
         
One-way sensitivity analysis for all best screening strategies: full medication costs for poorly adherent women  
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,491 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,815 11.084 51 200 141 324 0.060 5,403 2,635 
QUS(-0.5)+DXA every 2 
years 
2,005 11.099 46 180 130 190 0.015 12,676 5,282 
DXA every 2 years 2,248 11.100 45 179 130 243 0.001 242,652 121,326 
 
         
          
          One-way sensitivity analysis for all best screening strategies: 0.5 times base-case annual inpatient costs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 957 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,361 11.084 51 200 141 404 0.060 6,741 3,288 
QUS(-0.5)+DXA every 2 
years 
1,570 11.099 46 180 130 209 0.015 13,931 5,804 
DXA every 2 years 1,813 11.100 45 179 130 243 0.001 242,845 121,423 
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One-way sensitivity analysis for all best screening strategies: 1.5 times base-case annual inpatient costs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,923 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
2,161 11.084 51 200 141 238 0.060 3,973 1,938 
QUS(-0.5)+DXA every 2 
years 
2,318 11.099 46 180 130 157 0.015 10,484 4,368 
DXA every 2 years 2,558 11.100 45 179 130 240 0.001 239,601 119,801 
          
          One-way sensitivity analysis for all best screening strategies: 0.5 times base-case screening cost 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,440 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,700 11.084 51 200 141 260 0.060 4,331 2,113 
QUS(-0.5)+DXA every 2 
years 
1,813 11.099 46 180 130 114 0.015 7,587 3,161 
DXA every 2 years 1,942 11.100 45 179 130 129 0.001 129,125 64,563 
          
          
          One-way sensitivity analysis for all best screening strategies: 1.5 times base-case screening cost 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,440 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,823 11.084 51 200 141 383 0.060 6,383 3,114 
QUS(-0.5)+DXA every 2 
years 
2,075 11.099 46 180 130 252 0.015 16,828 7,012 
DXA every 2 years 2,428 11.100 45 179 130 353 0.001 353,321 176,661 
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One-way sensitivity analysis for all best screening strategies: 0.5 times base-case annual nursing home costs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,416 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,742 11.084 51 200 141 327 0.060 5,444 2,656 
QUS(-0.5)+DXA every 2 
years 
1,926 11.099 46 180 130 184 0.015 12,289 5,120 
DXA every 2 years 2,168 11.100 45 179 130 241 0.001 241,069 120,535 
          
          One-way sensitivity analysis for all best screening strategies: 1.5 times base-case annual nursing home costs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,464 11.024 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,780 11.084 51 200 141 316 0.060 5,270 2,571 
QUS(-0.5)+DXA every 2 
years 
1,962 11.099 46 180 130 182 0.015 12,126 5,052 
DXA every 2 years 2,203 11.100 45 179 130 241 0.001 241,377 120,689 
          
          One-way sensitivity analysis for all best screening strategies: 0.8 times base-case HSUVs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,440 8.791 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,761 8.848 51 200 141 321 0.057 5,639 2,613 
QUS(-0.5)+DXA every 2 
years 
1,944 8.861 46 180 130 183 0.013 14,085 5,086 
DXA every 2 years 2,185 8.862 45 179 130 241 0.001 241,223 120,612 
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One-way sensitivity analysis for all best screening strategies:  1.2 times base-case HSUVs 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,440 13.274 72 269 174 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,761 13.333 51 200 141 321 0.059 5,448 2,613 
QUS(-0.5)+DXA every 2 
years 
1,944 13.350 46 180 130 183 0.017 10,771 5,086 
DXA every 2 years 2,185 13.351 45 179 130 241 0.001 241,223 120,612 
          One-way sensitivity analysis for all best screening strategies: 0.8 times treatment efficacy 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,498 11.000 78 291 186 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,828 11.069 54 205 155 329 0.069 4,775 2,337 
QUS(-0.5)+DXA every 2 
years 
2,020 11.081 49 185 145 192 0.012 16,020 5,492 
DXA every 2 years 2,263 11.082 49 184 144 243 0.001 243,405 121,703 
          One-way sensitivity analysis for all best screening strategies:  1.2 times treatment efficacy 
 
Strategy 
Lifetime 
costs 
Lifetime 
effectiveness 
Lifetime fractures per 1,000 
patients 
Incremental 
costs, 2015 
USD 
Incremental 
effectiveness, 
QALY 
ICER, USD 
per QALY 
gained 
ICER, USD per 
fracture averted  
Hip Vertebrae Wrist 
No screening 1,417 11.033 70 260 170 - - Baseline Baseline 
QUS(-0.5)+DXA every 5 
years 
1,757 11.088 49 192 144 341 0.055 6,191 2,961 
QUS(-0.5)+DXA every 2 
years 
1,941 11.104 44 171 134 184 0.016 11,492 5,108 
DXA every 2 years 2,182 11.105 43 171 134 241 0.001 241,203 241,203 
QALY=quality adjusted life year, DXA=dual-energy X-ray absorptiometry, QUS=quantitative ultrasound, USD=United States dollar 
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Chapter 8: Summary and future directions 
8.1  Summary of the thesis 
In Chapter 1, an introduction to osteoporosis and health economics was provided. Osteoporosis 
and osteoporotic fractures contribute a substantial and growing disease and economic burden 
worldwide [1, 2]. What is worse, the general public normally lacks awareness of osteoporosis 
and its risks [3, 4] and sometimes even the experts provide “misleading and nihilistic” 
recommendations on fracture prevention [5, 6]. Failure to recommend an appropriate 
prevention strategy to those who are at risk of fracture results in high incidence of fracture 
events. When recommending a fracture prevention strategy, it should be provided with the 
clinical and economic merits having been considered. Health economic evaluation is a key 
means to assist decision makers to ration limited healthcare resource in an attempt to achieve 
the highest wellbeing at minimal costs. Modelling is an important method in health economic 
evaluation. It is an “unavoidable fact of life” because economic valuations solely based on 
clinical trials are limited to intermediate endpoints or have short-term follow-up periods [7]. In 
addition, health economic modelling enables the synthesis of the best available data from 
different sources. My work on health economic evaluations of osteoporosis interventions was 
conducted using a modelling approach.  
Prior to the development of my own model, a systematic review of previous osteoporosis 
models was performed and detailed in Chapter 2. The characteristics and evolution of models 
were summarised and, more importantly, recommendations for the development of future 
models in this field were provided. A good economic modelling study should follow the well-
accepted recommendations [8] and critical appraisals, such as the British Medical Journal (BMJ) 
checklist [9] and the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) statement [10]. A Markov cohort modelling approach was not recommended in 
osteoporosis due to its memoryless nature [11], because the “memory” of simulated patients 
such as fracture history is critical to assigning appropriate transition probabilities, utilities and 
costs in the model. Preferably, a lifetime simulation horizon was recommend to capture all 
relevant costs and effectiveness. Medication persistence and adherence have huge impacts on 
cost-effectiveness of osteoporosis interventions, therefore they should be included in the model.  
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Health state utility values (HSUVs) are used in calculating quality-adjusted life years 
(QALYs), therefore they are key to cost-effectiveness and cost-utility analysis. For those 
countries with limited data on HSUVs for osteoporosis-related fractures, data from meta-
analysis are preferred. There are two meta-analyses of HSUVs for osteoporosis that were 
conducted before our study [12, 13], while the HSUVs for conditions after hip and vertebral 
fractures provided in the later meta-analysis was considerably lower than the previous study. 
In addition, neither study provided HSUVs for subsequent years after vertebral and wrist 
fractures due to paucity of data. An updated meta-analysis of HSUVs for osteoporosis-related 
conditions was conducted; this study was presented in Chapter 3. The pooled HSUVs for pre-
fracture, post-hip fracture, post-vertebral fracture and post-wrist fracture were 0.76 (95% CI: 
0.75, 0.77), 0.57 (95% CI: 0.52, 0.63), 0.59 (95% CI: 0.55, 0.62), and 0.72 (95% CI: 0.67, 0.78) 
respectively. Time after fracture contributed to the heterogeneity: HSUVs improved with time 
after fracture events but remain relatively low compared with those for pre-fracture. In addition, 
a formula for future modellers to calculate HSUVs in their population of interest has been 
provided. 
With the recommendations for future osteoporosis models from the systematic review and a 
standard set of HSUVs for osteoporosis-related conditions, a new osteoporosis health economic 
model has been developed. The construction and validation of the new model was presented in 
Chapter 4. This new osteoporosis health economic model is a state-transition microsimulation 
model incorporating major clinical outcomes of osteoporosis. It has been validated in the 
Chinese population but is flexible to be adapted to other populations. The model was proved 
to have good face, internal and external validities and can therefore be used with confidence in 
future economic evaluations of osteoporosis intervention strategies. 
Chapters 5-7 presented 3 examples of applications of the osteoporosis health economics model. 
Disease and economic burden is key to decision makers to understanding the magnitude of the 
problem incurred by the disease. However, such evidence is lacking in the Chinese population 
and hence health economic studies are called for by the Chinese guidelines for osteoporosis 
[14]. Using the osteoporosis health economics model, the lifetime risk of the first osteoporotic 
fracture in Chinese women and men aged 50 years was estimated to be 40.9% (95% CI: 38.3-
44.0%) and 8.2% (95% CI: 6.8-9.3%) respectively. Chinese women were estimated to have 
similar risks of any osteoporotic fracture compared with the world average. However, the risks 
of vertebral fracture were higher compared with some other populations such as the Australian, 
Swedish and Belgian populations. Chinese men were estimated to have lower risks across 
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different fractures. Approximately 2.33 (95% CI: 2.08, 2.58) million osteoporotic fractures 
occurred in 2010, costing around USD 9.45 (95% CI: 8.78, 10.11) billion to the Chinese 
healthcare system. The number and costs of fractures will double by 2035 if no action is taken. 
These two studies have provided the best evidence of the magnitude of osteoporosis disease 
and financial burden in China. Moreover, the most cost-effective osteoporosis screening 
strategy has been identified in an attempt to reduce the impact of osteoporosis. It was found 
that pre-screening with quantitative ultrasound (QUS) with subsequent dual-energy X-ray 
absorptiometry (DXA) screening if the QUS T-score≤-0.5 with a 2-year rescreening interval in 
the Chinese women starting at age 55 is the most cost-effective among 12 screening strategies. 
Approximately 159 osteoporotic fractures were estimated to be averted per 1,000 people with 
an additional cost of USD 505, the incremental cost-effectiveness ration (ICER) of the most 
cost-effective screening strategy is USD 3,137 per QALY gained compared with no screening. 
In summary, the model has been thoroughly documented and proven to be valid, and has been 
successfully used in economic evaluations of fracture prevention.  
8.2  Future directions 
8.3.1 Collection of country-specific data on costs and HSUVs 
Country-specific data on costs and HSUVs related to osteoporosis and osteoporotic fractures 
is limited to date. Ideally, health economic evaluations should be conducted in country- and 
population-specific settings using country-specific input data for costs, utilities and 
probabilities, because using data from other populations reduces the validity and transferability 
of the health economic evaluation (insert a reference for this). In 2007, the “International Costs 
and Utilities Related to Osteoporotic Fractures Study (ICUROS)” was launched to estimate 
costs and quality of life related to fractures in 11 countries worldwide [15]. However, no Asian 
country has been included in the ICUROS. The Asian countries have the largest and most 
rapidly ageing population, and it has been estimated that half of all the world’s hip fractures 
will occur in Asia by 2050 [16]. As a consequence, Asian countries are in the most need to deal 
with the disease and financial burden caused by osteoporosis.  
Our new osteoporosis health economics model was validated in the Chinese population [17], 
and numerous application studies were conducted [2, 18]. The limitation was acknowledged 
that some data inputs in our model, such as HSUV multipliers, were based on other populations 
due to the paucity of such data in the Chinese population. Based on preliminary work in this 
field, I have received a grant funded by the National Natural Science Foundation of China 
(CIA, Grant number: 71503007) to collect costs and HSUV data in the Chinese population and 
this study has been included in the ICUROS study as the Chinese arm. This study will 
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contribute greatly to the current literature in this field and improve the validity of our model in 
its use in the Chinese population. 
8.3.2 Cost-effectiveness of osteoporosis treatments for the Chinese population 
Calcium and vitamin D supplements, calcitonin, raloxifene, alphacalcidol, alendronate and 
zoledronic acid are listed as first-line osteoporosis drugs in China and they are fully or partly 
reimbursed by social health insurance [19]. However, economic evidence to support the drug 
reimbursement policy in China has been lacking to date and no study has been conducted to 
systematically evaluate the cost-effectiveness of these first-line drugs. For example, 
alphacalcidol, calcitonin and raloxifene was found to be not cost-effective to treat established 
osteoporosis but they are still reimbursed as first-line drugs in China [20]. By contrast, there 
are some drugs which were proven to be cost-effective in the Caucasian population, however, 
they are not reimbursed in the Chinese population. For example, denosumab is a novel agent 
for the treatment of osteoporosis in postmenopausal women with increased risk of fractures 
and it is generally cost-effective compared with other first- and second-line osteoporosis drugs 
[21]. However, no economic evaluation of denosumab has been conducted in the Chinese 
population and it is still not reimbursed in China.  
An economic evaluation study of all osteoporosis medications that are currently available in 
the Chinese market will be conducted to identify those that represent good value for money in 
the Chinese population. This study will assist policy makers to update the essential drug list in 
osteoporosis as well as to provide clinicians with economic evidence to underpin their clinical 
practice.  
8.3.3 Determination of intervention thresholds for fracture risk assessment tools 
It is well acknowledged that fracture risk assessment is not solely based on bone mineral 
densities (BMDs), but other clinical risk factors. Several fracture risk assessment tools have 
been developed incorporating clinical risks factors with or without BMD, such as FRAX 
(http://www.shef.ac.uk/FRAX/) and the Garvan Bone Fracture Risk Calculator 
(http://www.garvan.org.au/bone-fracture-risk). Clinicians make treatment decisions based on 
absolute risks of future fractures, such as 5- or 10-year fracture risks, generated from these risk 
assessment tools. For example, in the United States a patient with low BMD is recommended 
to be treated when the 10-year probability of any major osteoporotic fracture is 20% or above 
or when the 10-year hip fracture risks exceeds 3% [22]. These intervention thresholds may only 
be relevant to the US population and the generalisability to other populations should remain be 
determined because of different fracture risks in different populations with varying levels of 
socioeconomic development, treatment patterns and other health economic consideration. 
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However, they have been used in osteoporosis guidelines in other countries including China 
without justification [14, 23]. Future study is encouraged to define the treatment thresholds for 
the Chinese taking into consideration both health and economic consequences in this specific 
population.  
8.3.4 Patients’ preference in osteoporosis treatments 
Numerous studies have shown medication adherence and persistence impact on costs, 
effectiveness and cost-effectiveness of therapeutic interventions [24-26]. Medication efficacy 
is reduced by poor adherence and persistence, therefore improvement in medication adherence 
and persistence is another important issue to be addressed in the real world setting. 
Understanding patients’ preferences for different treatments is important to improve 
medication adherence and persistence. A Belgian study found that osteoporotic patients 
preferred 6-month subcutaneous injection and oral monthly tablets compared with weekly oral 
tables, 3-month subcutaneous injections, 3 month and yearly intravenous injections [27]. The 
evidence of patients’ preferences for osteoporosis treatments is still limited in most other 
countries. Given differences in medication patterns, out-of-pocket payments, socioeconomic 
status and preference for medication administration route, future studies investigating patients’ 
preference for osteoporosis drugs are encouraged in other countries including China. 
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Appendix 4: Curriculum Vitae 
 
317 | P a g e  
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1. Si, Lei. Pharmacoeconomics [in Chinese]. In Qicheng Jiang ed. Health Economics. Beijing: 
People's Medical Publishing House. (coming soon)  
2. Si, Lei, Palmer, Andrew. Prevention of T2DM: health economics [internet]. 2014 [cited 2014 
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CONFERENCE ABSTRACTS （PRESENTING AUTHOR）  
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Si, L, T.M. Winzenberg, and A.J. Palmer, Universal screening for osteoporosis in Chinese 
post-menopausal women? 
2. Oral presentation: ASMR (Australian Society for Medical Research) Medical Research Week, 
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Appendix 4: Curriculum Vitae 
 
318 | P a g e  
8. Poster presentation: ISPOR (International Society for Pharmacoeconomics and Outcomes 
Research) 6th Asia Pacific Conference. Beijing, China 
Si, L., T.M. Winzenberg, L. Wang, A.J. Palmer, Cost-effectiveness analyses of screening and 
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TEACHING EXPERIENCE  
1. Practical Methods for Health Economic Evaluation, 26-28 Nov. 2014 Hobart, Australia  
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